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ABSTRACT 
Various members of the insulin-like growth factor (IGF) family of growth factors are 
highly expressed in bone tissue and are vitally important for the normal development 
and function of bone. Recent studies have shown that IGF-I can associate with the 
extra-cellular matrix proteins vitronectin (VN) and fibronectin (FN) via IGF binding 
protein-5 (IGFBP-5). Furthermore, when these complexes are pre-bound to a tissue 
culture surface they can stimulate enhanced responses in epithelial cell types in vitro. 
More recently, transforming growth factor-beta 1 (TGF-β1), epidermal growth factor 
(EGF) and basic fibroblast growth factor (bFGF) have also been shown to interact 
with VN and to elicit functional responses in various cell types. Taken together, 
these findings indicate that exploitation of the adhesive properties of these ECM 
proteins might allow immobilisation of various growth factors at the culture surface. 
This may provide a novel means of coating engineered biomaterial constructs with 
agents which can elicit specific functional effects in therapeutically important cells, 
such as those used in cell-based therapeutics for the replacement and / or 
regeneration of damaged bone tissue.  
 
Since both VN and FN are also important matrix components of bone, this study 
sought to investigate the hypothesis that select pre-bound combinations of these 
matrix proteins and growth factors could also stimulate functional responses in bone 
cells and the therapeutically important so called mesenchymal stem cells. Thus it is 
reported here that pre-bound combinations of VN, IGFBP-5 and IGF-I or FN 
IGFBP-5 and IGF-I significantly stimulate cell migration in the osteoblast-like 
SaOS-2 cells. While, VN, IGFBP-5 and IGF-I stimulated cell proliferation over 72 
hr, FN, IGFBP-5 and IGF-I did not. Moreover, I found that VN, IGFBP-5 and IGF-I 
could facilitate alkaline phosphatase (ALP) expression in SaOS-2 cells. VN, FN and 
EGF on the other hand could sustain SaOS-2 cells for up to 12 days in culture, but 
could not sustain ALP expression; hence it is possible that these cells may have 
entered a state of quiescence in response to this treatment.  
 
Extending these studies to cells derived from clinical samples, pre-bound 
combinations of VN / IGFBP-5 / IGF-I were not able to support initiation of human 
mesenchymal stem cell (hMSC) cultures. Nevertheless, VN alone in serum free 
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media stimulated substantial metabolic activity and protein synthesis in hMSCs once 
the cultures were established. Moreover, the addition of IGFBP-3 or -5 together with 
IGF-I can enhance the response to levels equivalent to that observed with 10% FCS. 
I also report that the responses to VN and TGF-β1 are synergistic and stimulate 
greater hMSC metabolic activity than 10% FCS.  
 
Interestingly, hMSCs cultured in IGF-I or TGF-β1 and low concentrations of VN 
aggregated, an effect that was not observed when higher concentrations of VN were 
used. I hypothesise that this aggregation effect was due to endogenous protease 
activity, and therefore examined MMP-2 and 9 activity in hMSC conditioned media. 
Both pro-MMP-2 and pro-MMP-9 were constitutively expressed by hMSCs but 
there was no evidence of the active forms in the conditioned media, indicating that 
neither IGF-I nor TGF-β1 affect MMP-2 or -9 expression or activation in serum-free 
media. However, hMSC conditioned media could degrade IGFBP-5, suggesting that 
there is proteolytic activity within the conditioned media which may impact on the 
function of ECM / growth factor components in serum-free media settings. Thus, 
while ECM and growth factors may stimulate desirable responses in therapeutically 
important cells in serum-free culture, the role that endogenously expressed proteases 
have on the efficacy of such media supplements needs to be examined closely.  
 
Taken together, the studies reported in this thesis provide proof of principle data 
indicating that select combinations of ECM proteins and growth factors could be 
utilised in bone tissue engineering applications. This may be achieved for example, 
as a biomaterial coating, or could form the basis of a viable alternative media 
supplement for the serum-free culture of hMSCs.   
 
 
 
 
 
 
 vii 
TABLE OF CONTENTS  
                                                                                                                  
Statement of Originality                                                                                         …..ii  
Acknowledgements                                                                                                .....iii 
Abstract                                                                                                                  .......v  
Table of contents                                                                                                    …vii 
List of Figures                                                                                                        ...xiii 
List of Tables                                                                                                         …xvi 
List of Abbreviations                                                                                             ...xvii 
List of Publications and Presentations                                                                   ...xix 
 
CHAPTER 1: LITERATURE REVIEW 
1.1  Introduction.                                                                                                ….2 
1.2  Bone Structure and Function: Overview                                                     .....4 
1.2.1 Bone remodelling: Overview                                                          .....5 
1.2.2  Osteoclasts                                                                                      …..6 
1.2.3  Osteoblasts                                                                                       .....8 
1.2.4  Human Mesenchymal Stem Cells                                                  …..9 
1.2.5  Osteoblast-like SaOS-2 cells                                                           ...11 
1.3   Integrins                                                                                                      …12 
  1.3.1  Integrins present in bone                                                                 ...13 
1.4  Vitronectin and Fibronectin                                                                        …14 
  1.4.1 Vitronectin                                                                                      …14 
  1.4.2 Fibronectin                                                                                      …18 
1.5  Insulin Like Growth Factors                                                                       …19 
1.5.1  Insulin like growth factors and hMSCs                                          …20 
1.5.2 Insulin like growth factors: Localisation and role in bone  
remodelling                                                                                      ...21                                                          
1.6  Insulin Like Growth Factor Binding Protein-5                                           ...22 
1.6.1 Insulin like growth factor binding protein-5 and hMSCs               …24 
1.6.2 Insulin like growth factor binding protein-5: Localisation in bone…25 
1.6.3 Insulin like growth factor binding protein-5: Role in bone  
Remodelling                                                                                   …25 
 viii 
1.7  Transforming Growth Factor-β1                                                                 …27 
1.7.1 Transforming growth factor-β1 and hMSCs                                   …29 
1.7.2 Transforming growth factor-β1: Localisation in bone                    …30 
1.7.3 Transforming growth factor-β1: Role in bone remodelling            …31 
1.8   Matrix Metalloproteinases                                                                          …32 
1.9   Bone Tissue Engineering                                                                            …34 
1.10 Conclusion                                                                                                  …37 
1.11  Outline of Project                                                                                       …38 
  1.11.1 Hypothesis                                                                                      …38 
  1.11.2 Aims                                                                                               …38 
 
CHAPTER 2:  MATERIALS AND METHODS 
2.1 Materials                                                                                                     …40 
2.1.1 Proteins                                                                                           …40 
2.1.2 Tissue Culture                                                                                 …40 
2.1.3 Experimental and General Reagents                                              …40 
2.2 Cells and Culture Conditions                                                                      …41 
  2.2.1 SaOS-2 cells                                                                                   …41 
  2.2.2 Human Bone Marrow Derived Mesenchymal Stem Cells  
(hMSCs)                                                                                         …42   
2.3 Pre-Binding of Vitronectin, Fibronectin, IGFBP-5 and IGF-I to Tissue 
Culture Wells                                                                                              …42 
2.4 Pre-Binding of Vitronectin, Fibronectin, IGFBP-5 and IGF-I to  
Transwells™                                                                                               …43 
2.5 Preparation of Solution Phase VN and Growth Factors for hMSC           
Studies                                                                                                        …44 
2.6 Migration Assays                                                                                        …44 
2.7 Attachment Assays                                                                                     …45 
2.8 CyQuant® Cell Proliferation Assay                                                            …46 
2.9 Metabolic Activity Assay                                                                           …47 
2.10 Colony Forming Unit-Fibroblastic Assay                                                  …48 
2.11 Total Protein Assay                                                                                    …48 
2.12 Morphological Analysis                                                                             …49 
2.13 Gelatin Zymography                                                                                   …49 
 ix
2.14 IGFBP-5 Degradation Assay                                                                      …50 
2.15 Solution Phase Culture of SaOS-2 Cells                                                    …51 
2.16 Differentiation Assay Cultures                                                                   …51 
2.17 Real Time PCR Analysis                                                                            …52 
2.18 Statistical Analysis                                                                                     …54 
 
CHAPTER 3:  EFFECTS OF PRE-BOUND VITRONECTIN, IGFBP-5 
AND IGF-I ON OSTEOBLAST LIKE SAOS-2 CELL 
MIGRATION, ATTACHMENT, METABOLIC 
ACTIVITY AND PROLIFERATION 
3.1 Introduction                                                                                                …56 
3.2 Experimental Procedures                                                                            …58 
3.2.1 Materials                                                                                         …58 
3.2.2 Pre-Binding of Proteins                                                                  …59 
3.2.3  Transwell™ Migration Assay                                                        …59 
3.2.4 Attachment Assay                                                                             …60 
3.2.5 Proliferation Assay                                                                            …60 
3.2.6 Metabolic Activity Assay                                                                  …61 
3.3  Results                                                                                                        …61 
3.3.1 Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell 
migration                                                                                         …61 
3.3.2 Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell 
attachment                                                                                       …64 
3.3.3 Effect of various doses of pre-bound VN on SaOS-2 cell   
proliferation                                                                                    …66 
3.3.4 Effect of various doses of pre-bound IGFBP-5 and IGF-I on        
SaOS-2 cell proliferation                                                                …70 
3.3.5 Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell 
metabolic activity                                                                           …72 
3.3.6 Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell 
proliferation                                                                                    …74 
3.4 Discussion                                                                                                   …78 
 
 x
CHAPTER 4:  EFFECTS OF SOLUTION PHASE VITRONECTIN, 
IGFBP-3 OR -5 AND IGF-I OR TGF-β1 ON hMSC 
METABOLIC ACTIVITY, TOTAL PROTEIN, 
CULTURE MORPHOLOGY AND GELATINASE 
EXPRESSION. 
4.1 Introduction                                                                                                 ...88 
4.2 Experimental Procedures                                                                            …90 
4.2.1 Materials                                                                                         …90 
4.2.2 Isolation and culture of hMSC from donor bone marrow samples…91 
4.2.3 Colony Forming Unit-Fibroblastic Assay                                      …91 
4.2.4 Preparation of tissue culture plates with VN and growth factors for 
metabolic activity and total protein assays                                     …92 
4.2.5 Metabolic Activity Assay                                                               …92 
4.2.6 Total Protein assay                                                                         …93 
4.2.7 Morphological analysis                                                                  …93 
4.2.8 Gelatin Zymography                                                                      …93 
4.2.9 Western blot of IGFBP-5 degradation by hMSC conditioned        
media                                                                                             …94 
4.3 Results                                                                                                       …94 
4.3.1 Effect of pre-bound or solution phase VN, IGFBPs and IGF-I on bone 
marrow derived fibroblastic cell attachment                                 …94 
4.3.2 Effect of solution phase VN, IGFBP-5 and IGF-I on hMSC  
metabolic activity                                                                          …98 
4.3.3 Effect of solution phase VN, IGFBP-3 and IGF-I on hMSC  
metabolic activity                                                                         …103 
4.3.4 Effect of solution phase VN and TGF-β1 on hMSC                 
metabolic activity                                                                         …106 
4.3.5 Effect of solution phase VN, IGFBP-5 and IGF-I on hMSC           
total protein                                                                                  …110 
4.3.6 Effect of solution phase VN, IGFBP-3 and IGF-I on hMSC           
total protein                                                                                 …115 
4.3.7 Effect of solution phase VN and TGF-β1 on hMSC                         
total protein                                                                                 …119 
 xi
4.3.8 Time dependent effect of IGF-I and TGF-β1 on hMSC culture 
morphology                                                                                   …122 
4.3.9 Effect of VN concentration on IGF-I and TGF-β1 mediated         
hMSC culture aggregation                                                            …123 
4.3.10 Donor effect on IGF-I and TGF-β1 mediated hMSC culture 
aggregation                                                                                   …123 
4.3.11 Effect of solution phase VN, IGFBP-3 or -5 and IGF-I or              
TGF-β1 on expression of MMP-2 and MMP-9 by hMSCs          …135 
4.3.12 Degradation of IGFBP-5 by hMSC conditioned media               …140 
4.4 Discussion                                                                                               ...142 
 
CHAPTER 5: MULTI-PROTEIN COMPLEXES DETERMINE SaOS-2 
CELL FUNCTIONAL RESPONSES 
5.1 Introduction                                                                                              …154 
5.2 Experimental Procedures                                                                         …156 
5.2.1 Materials                                                                                      …156 
5.2.2 Pre-binding of Proteins                                                                …157 
5.2.3 Transwell™ Migration Assay                                                      …158 
5.2.4 Proliferation Assay                                                                       …158 
5.2.5 Solution Phase Culture                                                                 …159 
5.2.6 Differentiation Assay                                                                   …159 
5.2.7 Real Time PCR Analysis                                                             …159 
5.3 Results                                                                                                      …161 
5.3.1 Effect of pre-bound FN, IGFBP-5 and IGF-I on SaOS-2 cell 
migration                                                                                      …161 
5.3.2 Effect of various doses of pre-bound FN on SaOS-2 cell             
proliferation                                                                                 …164 
5.3.3 Effect of various doses of pre-bound FN and VN on SaOS-2 cell 
proliferation                                                                                 …168 
5.3.4 Effect of pre-bound FN, IGFBP-5 and IGF-I on SaOS-2 cell 
proliferation                                                                                 …172 
5.3.5 Effect of solution phase VN and FN with or without EGF                   
or bFGF on SaOS-2 cell culture morphology                             …177 
 xii
5.3.6 Effect of VN, VN/IGFBP-5/IGF-I, VN/TGF-β1 or                 
VN/FN/EGF on SaOS-2 cell morphology, compared                          
to osteoblastic differentiation media                                            …180 
5.3.7 Effect of VN, VN/IGFBP-5/IGF-I, VN/TGF-β1 or VN/FN/EGF on 
osteoblast differentiation marker expression in SaOS-2 cells      …186 
5.4 Discussion                                                                                                 …192 
 
CHAPTER 6: GENERAL DISCUSSION                                              
6.1 Discussion                                                                                                       …206 
CHAPTER 7: APPENDIX 
 Buffer Recipes 
7.1 Functional Assays                                                                                     …222 
7.2 Gelatin Zymography                                                                                 …222 
7.3 SDS-PAGE and Western Blot                                                                  …223 
 
REFERENCES:                                                                                                  …225 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiii 
LIST OF FIGURES 
1.1 Schematic diagram of the gross and microscopic structure of long bones   …5 
1.2 Schematic diagram of osteoclast structure and microenvironment              …7 
1.3 Specific osteoblast lineage markers                                                             ...10 
1.4 The major biological functions in which vitronectin is involved                ...14 
1.5 Schematic representation of the domain structure of vitronectin               …15 
1.6 Schematic representation of the insulin like growth factor binding         
protein 5 (IGFBP-5) domain structure                                                       …23 
1.7 Model of IGF independent action of IGFBP-5 in osteoblasts                    …27 
3.1 Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell migration  …63 
3.2 Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell            
attachment                                                                                                   …65 
3.3 Effect of various doses of pre-bound VN on SaOS-2 cell proliferation     …69 
3.4 Effect of various doses of pre-bound IGFBP-5 and IGF-I on SaOS-2 cell 
proliferation                                                                                                …71 
3.5 Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell metabolic 
activity                                                                                                        …73 
3.6 Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell         
proliferation                                                                                                …77 
4.1 Effect of pre-bound or solution phase VN, IGFBPs and IGF-I on bone 
marrow derived fibroblastic cell attachment                                              …97 
4.2 Effect of solution phase VN, IGFBP-5 and IGF-I on hMSC metabolic 
activity                                                                                                      …101 
4.3 Effect of solution phase VN, IGFBP-3 and IGF-I on hMSC metabolic 
activity                                                                                                      …105 
4.4 Effect of solution phase VN and TGF-β1 on hMSC metabolic activity   …109 
4.5 Effect of solution phase VN, IGFBP-5 and IGF-I on hMSC total                  
protein                                                                                                       …113 
4.6 Effect of solution phase VN, IGFBP-3 and IGF-I on hMSC total            
protein                                                                                                       …117 
4.7 Effect of solution phase VN and TGF-β1 on hMSC total protein            …121 
 xiv
4.8 a)Effect of IGF-I and TGF-β1 on hMSC culture morphology after 24 hr…125                                                                    
b)Effect of IGF-I and TGF-β1 on hMSC culture morphology after 48 hr…127 
c)Effect of IGF-I and TGF-β1 on hMSC culture morphology after 72 hr…129 
4.9 Effect of VN concentration on IGF-I and TGF-β1 mediated hMSC         
culture aggregation                                                                                   …131 
4.10 Donor effect on IGF-I and TGF-β1 mediated hMSC culture              
aggregation                                                                                               …133  
4.11 Effect of solution phase VN, IGFBP-3 or -5 and IGF-I or TGF-β1 on 
expression of MMP-2 and MMP-9 by hMSCs                                        …137 
4.12 Time dependent expression of MMP-2 and –9                                        …139 
4.13 IGFBP-5 degradation by hMSC conditioned media                                …141 
5.1 Effect of pre-bound FN, IGFBP-5 and IGF-I on SaOS-2 cell migration …163 
5.2 Effect of various doses of pre-bound FN on SaOS-2 cell proliferation   …167 
5.3 Effect of various doses of pre-bound FN and VN on SaOS-2 cell  
proliferation                                                                                              …171 
5.4 Effect of pre-bound FN, IGFBP-5 and IGF-I on SaOS-2 cell            
proliferation                                                                                              …175 
5.5 Effect of solution phase VN and FN with or without EGF or                          
bFGF on SaOS-2 cell culture morphology                                               …179 
5.6 a)Effect of VN, VN / IGFBP-5 / IGF-I, VN / TGF-β1 or VN / FN / EGF          
on SaOS-2 cell morphology after 48 hr                                                    …183 
b)Effect of VN, VN / IGFBP-5 / IGF-I, VN / TGF-β1 or VN / FN / EGF          
on SaOS-2 cell morphology after 7 days                                                  …185 
5.7 Effect of VN, VN/IGFBP-5/IGF-I, VN/TGF-β1 or VN/FN/EGF                    
on osteoblast differentiation marker expression in SaOS-2 cells                  
after 48 hr                                                                                                 …189  
5.8 Effect of VN, VN/IGFBP-5/IGF-I, VN/TGF-β1 or VN/FN/EGF                           
on osteoblast differentiation marker expression in SaOS-2 cells                       
after 7 days                                                                                               …191 
5.9 Effect of VN, alone or in combination with IGFBP-5/IGF-I or                  
TGF-β1, on ALP activity per 105 SaOS-2 cells                                        …199 
5.10 Effect of VN, alone or in combination with IGFBP-5/IGF-I or                  
TGF-β1, on the ratio of [3H]-Pro and [3H]-Leu in newly synthesised     
proteins in SaOS-2 cells                                                                           …201  
 xv
6.1 Comparison of protein from media with 10% FCS and media with VN, 
IGFBP and IGF-I                                                                                      …210 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvi
LIST OF TABLES 
2.1 Real time-PCR Primer Sequences                                                              …54 
4.2.1 Summary of statistical analysis for Figure 4.2b                                       …100 
4.3.1  Summary of statistical analysis for Figure 4.3b                                       …104 
4.4.1 Summary of statistical analysis for Figure 4.4b                                       …108 
4.5.1 Summary of statistical analysis for Figure 4.5b                                       …112 
4.6.1 Summary of statistical analysis for Figure 4.6b                                       …116 
4.7.1 Summary of statistical analysis for Figure 4.7b                                       …120  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvii
LIST OF ABREVIATIONS 
αMEM   Minimal Essential Medium-alpha formulation 
ALS   Acid labile subunit 
AMV    Avian myeloblastosis virus 
APS   Ammonium persulphate 
bFGF   Basic fibroblast growth factor 
BSA   Bovine serum albumin 
cDNA   Complementary Deoxyribonucleic acid  
CIMPR  Cation independent mannose-6-phosphate receptor 
DEPC    Diethylpyrocarbonate 
DNA   Deoxyribonucleic acid  
dNTPs   deoxynucleotide triphosphates  
DMEM  Dulbecco’s modified Eagles medium 
ECM   Extracellular matrix  
EDTA   Ethylenediamine tetraacetic acid  
EGF   Epidermal growth factor 
ERK   Extracellular signal-regulated kinase 
FAK   Focal adhesion kinase 
FCS   Foetal calf (bovine) serum 
FN   Fibronectin 
HBB   HEPES binding buffer 
HBSS   Hank’s balanced salt solution 
HEPES  4-2(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IGF-I   Insulin like growth factor-I 
IGF-II   Insulin like growth factor-II 
IGF-IR  IGF-I Receptor 
IGFBP   Insulin like growth factor-binding protein 
JNK   Jun N-terminal kinase 
KCl   Potassium chloride 
kDa   Kilodalton 
MAPK   Mitogen-activated protein kinase 
MgCL2  Magnesium chloride 
mRNA   Messenger ribonucleic acid 
 xviii 
MW   Molecular weight  
o/n   Overnight 
PAI-I    Plasminogen activator inhibitor-1 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PDGF   Platelet derived growth factor 
RGD   Arginine-Glycine-Aspartate 
RNA   Ribonucleic acid  
RT   Room temperature 
SDS   Sodium dodecyl sulphate 
SDS-PAGE  SDS-Poly acrylamide gel electrophoresis 
SEM   Standard error of the mean 
TBE    Tris borate EDTA buffer 
TE    Tris EDTA buffer 
TEMED  N,N,N', N'-tetramethylethylenediamine 
TGF-β1  Transforming growth factor-beta 1 
Tris   Tris[hydroxymethyl] amino methane 
Triton-X100  Iso-octylphenoxypolyethoxyethanol 
Tween 20  Polyethylene 20-sorbitan monolaurate 
uPAR   Urokinase plasminogen activator receptor 
uPA   Urokinase plasminogen activator 
UV   Ultra violet 
VN   Vitronectin 
 
 
 
 
 
 
 
 
 
 
 xix
LIST OF PUBLICATIONS AND PRESENTATIONS 
 
1. Schleicher I, Parker A, Leavesley D, Crawford R, Upton Z, Xiao Y: Surface 
modification by complexes of vitronectin and growth factors for serum-free 
culture of human osteoblasts. Tissue Engineering. 11(11/12): 1688-1698 
(2005). (Publication) 
 
2. Parker T, Leavesley D, Upton Z: Vitrogro Complexes in Bone Tissue 
Engineering. QUT Orthopaedic Showcase 2 Dec (2003) (Oral presentation) 
 
3. Schleicher I, Parker T, Leavesley D, Crawford R, Upton Z, Xiao Y: Surface 
modification by complexes of vitronectin and growth factors for human 
osteoblast culture. Fifth Combined Meeting of the Orthopaedic Research 
Societies, Sydney, Australia, 29 Oct (2004). (Oral presentation)  
 
4. Parker T, Upton Z, Leavesley D: Combinations of Vitronectin, Insulin-like 
Growth Factor Binding Protein-3 or-5 and Insulin like Growth Factor-I or 
Transforming Growth Factor-beta 1 Stimulate Proliferative Responses in 
SaOS-2 cells and Human Mesenchymal Stem Cells in Serum Free 
Conditions. Eighth annual Tissue Engineering Society International Meeting, 
Shanghai, China, 22-26 Oct (2005). (Oral presentation)  
 
5. Parker T, Upton Z Leavesley D: The Functional Effects of Various 
Combinations of Vitronectin, IGFBP-3 or -5 and IGF-I or TGF-β1 on SaOS-2 
cells and Human Mesenchymal Stem Cells in Serum Free Conditions. Third 
International Congress of the Growth hormone Research Society and the 
Insulin-Like Growth Factor Society, Kobe, Japan, Nov (2006). (Oral 
presentation) 
 
6. Parker T, Whiteside E, Yameen Y, Upton Z, Leavesley D: Complexes of IGFs, 
IGFBPs and Vitronectin Stimulate Proliferation and MMP Secretion by 
Osteoblast-Like SaOS-2 Cells. Second International GH-IGF Symposium, 
Cairns, Australia, 18-22 Apr (2004). (Poster presentation) 
 xx
 
7. Parker T, Whiteside E, Yameen Z, Upton Z, Leavesley D: Complexes of IGFs, 
IGFBPs and Vitronectin Stimulate Proliferation and MMP Secretion by 
Osteoblast-Like SaOS-2 Cells. Australian Society of Medical Research Student 
Conference, Wesley Hospital, Brisbane, Australia, Jun (2004). (Poster 
presentation) 
 
8. Parker T, Yameen Z, Upton Z, Leavesley D: Combinations of Vitronectin, 
Insulin like Growth Factor Binding Protein 3 or 5 and Insulin like Growth 
Factor-I stimulates initial proliferative responses in SaOS-2 cells and hMSCs 
in serum free conditions. Australian Society of Medical Research Student 
Conference, Wesley Hospital, Brisbane, Australia, Jun (2005). (Poster 
presentation) 
 
9. Parker T, Upton Z Leavesley D: The Functional Effects of Various 
Combinations of Vitronectin, IGFBP-3 or -5 and IGF-I or TGF-β1 on SaOS-2 
cells and Human Mesenchymal Stem Cells in Serum Free Conditions. 
Australian Society of Medical Research Student Conference, Wesley Hospital, 
Brisbane, Australia, Jun (2006). (Abstract) 
 
10. Parker T, Upton Z, Leavesley D: The Functional Effects of Vitronectin or 
Fibronectin, IGFBP-5 and IGF-I Complexes on SaOS-2 cell Migration and 
Proliferation in Serum Free Conditions. IGF’s Down Under-Bound Up All 
Over, Brisbane, Sept 29 (2006). (Poster presentation) 
 
11. Parker T, Upton Z, Leavesley D: The Functional Effects of Vitronectin or 
Fibronectin, IGFBP-5 and IGF-I Complexes on SaOS-2 cell Migration and 
Proliferation in Serum Free Conditions. Combio 2006 Brisbane Sept 24-28 
(2006). (Poster presentation) 
 
 
 
 
 1 
 
 
 
 
CHAPTER 1: 
  
LITERATURE REVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
1.1 INTRODUCTION 
The term ‘tissue engineering’ was coined by members of a panel representing the 
National Science Foundation (NSF), Bioengineering and Research to Aid the 
Handicapped (BRAH) and Biotechnology (BIOTECH) who gathered to discuss 
future directions in bioengineering in the United States. While, BIOTECH desired 
novel methods for homologous cell culture, BRAH sought the development of whole 
organ replacement systems. The two research areas appeared to overlap, and in order 
to consolidate their efforts the term ‘tissue engineering’ was developed. The term 
was formally defined at a workshop to identify appropriate areas for engineering 
research in the new emerging technology of tissue engineering, held at Lake Tahoe, 
California on February 26-29, 1988. The first research proposals were received and 
funded in 1988. Over recent decades tissue engineering has become a major global 
research area in biotechnology (Patrick et al. 1998).  
 
Broadly defined ‘tissue engineering’ is the use of living cells together with either 
natural or synthetic extra-cellular components in vitro, for the development of 
implantable parts or devices for the restoration or replacement of tissue or organ 
function (Patrick et al. 1998).  In order to regenerate living tissue in vitro, cells must 
be organised and behave as if they are part of the original tissue in vivo. In layman’s 
terms this means that the cells must ‘sense’ they are in their natural environment. 
Cells must be able to proliferate, differentiate and/or migrate and this then implies 
they must receive, from their new environment, the appropriate cues, which facilitate 
and direct these processes. A critical component of appropriately organising cells 
and their functions into tissues, is their association with the extra-cellular matrix 
(ECM) (Ross 1998). The ECM is a structural material made by the cells which acts 
as a scaffold within which the cells reside and is largely composed of tissue specific 
mixtures of glycoproteins and proteoglycans. Cells interact directly with the ECM 
via specific cell surface receptors, which are often associated with intra-cellular 
signalling networks; thus cell / ECM interactions can induce signalling events within 
the cells and thereby modify cell function. Local variation in the composition of the 
ECM can result in temporal and spatial variation in cellular responses and thus tissue 
structure and function. A volumous literature has been produced over the last decade 
describing the association of growth factors and cytokines with various ECM 
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components and mediation of cell function through cell / ECM interactions (Jones et 
al. 1993; Slater et al. 1995; Taipale et al. 1998; Nam et al. 2000; Conover and 
Khosla 2003; Hutchings et al. 2003; Russo et al. 2005). Significant among these are 
the discoveries that many of the components of the insulin-like growth factor (IGF) 
family of growth factors and associated proteins are observed to associate with 
vitronectin (VN)(Upton et al. 1999; Nam et al. 2002; Kricker et al. 2003), a 
ubiquitous 75 kDa ECM glycoprotein (Schvartz et al. 1999). Since this initial 
observation epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) 
and transforming growth factor-β (TGF-β) have also been shown to associate with 
VN (Schoppet et al. 2002; Hollier et al. 2005). Notwithstanding, VN is also known 
to facilitate integrin and urokinase system mediated cell attachment (Ruoslahti and 
Pierschbacher 1987; Leavesley et al. 1992; Felding-Habermann and Cheresh 1993; 
Kanse et al. 1996).   
 
One of the most active areas of research within tissue engineering is the field of 
‘Bone tissue engineering’. Investigators from the traditional disciplines of 
biomedical and chemical engineering, polymer chemistry, biochemistry, cell and 
molecular biology, genomics and physiology conduct research in this field. Likely 
due to this cross disciplinary approach to research, a huge volume of literature has 
been generated in the last decade regarding the incorporation and convergence of 
ideas between these disciplines for the purposes of developing better bone 
therapeutics for the treatment of musculoskeletal pathologies. For example, 
production of biomaterials such as hydroxyapatite by materials chemists and 
engineers are now being investigated by cell and molecular biologists for their 
effects on cell behaviour. Furthermore, incorporation of various ECM components 
with these biomaterials is also being investigated to modify cell behaviour through 
their combined effects.  
 
The last decade has also seen the emergence of methodologies enabling isolation and 
culture of human mesenchymal stem cells (hMSC). hMSCs have a demonstrated 
potential to generate multiple tissue types including bone and cartilage. Many 
modern strategies for the development of advanced connective tissue therapeutics are 
focusing on implantable constructs consisting of a biomaterial scaffold, 
incorporating some form of ECM and / or ex vivo expanded, undifferentiated 
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hMSCs. The underlying concept is to deliver a large number of precursor cells, 
which subsequently differentiate into appropriate mature tissue types through 
guiding interactions with both the accompanying scaffold / ECM and the 
surrounding host tissue.  
 
Interactions between the ECM and components of the IGF system and other 
biologically active factors such as TGF-β are believed to have wide ranging effects 
on bone tissue growth and turnover, thus facilitating increased interest in the 
potential use of these compounds in the development of novel therapeutics for 
treatment of a variety of bone diseases. Likewise there is increasing interest in the 
incorporation of hMSCs into novel tissue engineered therapeutics. With this 
background in mind, in addition to providing a brief background on bone, bone 
remodelling and discussion of the current literature on hMSCs, this review will 
concentrate on discussion of the components of the IGF system, TGF-β1 and VN. In 
particular the review will be focussed on their interactions and effects on hMSCs, 
localisation in bone and role in bone remodelling.  
 
1.2 BONE STRUCTURE AND FUNCTION: OVERVIEW 
Bone is a specialised form of connective tissue in which its extra-cellular 
components are mineralised, conferring both strength and a degree of elasticity with 
a minimum of bony mass. In addition to structural support for the body as a whole, 
bone also provides protection to soft organs such as brain, heart and lungs etc and 
facilitates movement due to the particular arrangement of bones, joints, ligaments, 
tendons and skeletal muscle tissue. Bone, playing a vital role in calcium 
homeostasis, serves as a repository for calcium and other inorganic ions and provides 
the site of hematopoiesis within the marrow cavity of some bones (Heaney 2003; 
Aguila and Rowe 2005).   
 
Macroscopically compact bone appears solid and dense. However, microscopically 
compact bone contains a mass of canals that serve as conduits for blood vessels, 
lymphatic vessels and nerves. The basic structural unit of compact bone is called an 
osteon, which consists of concentric rings of bone matrix lamellae, arranged around 
a central conduit named the Haversian canal (Burkitt et al. 1993). Type 1 collagen is 
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the major fibrous constituent of bone and is arranged in a common direction in each 
lamella but in opposing directions in adjacent lamellae (Burkitt et al. 1993; 
Sommerfeldt and Rubin 2001; Locke 2004). The central cavity of bone consists of a 
meshwork of porus bone called cancellous or trabecular bone. Thus, bone is both 
lightweight and strong due to the combination of the strength characteristics of the 
haversian system and lamellar bone and the support characteristics of cancellous 
bone (Figure 1.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic diagram of the gross and microscopic structure of long 
bones. (www.botany.uwc.ac.za/sci_ed/ grade10/mammal/bone.htm) 
 
1.2.1 Bone remodelling: Overview 
Bone remodelling is performed by osteoclasts and osteoblasts; together these cells 
form a functional unit called the bone metabolic unit (BMU), also sometimes called 
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the basic multi-cellular unit (Sommerfeldt and Rubin 2001). The BMU is responsible 
for the maintenance of calcium and phosphate homeostasis in addition to bone 
growth and maintenance of bone integrity. This is achieved through constant bone 
resorption and synthesis of new bone. Osteoclasts resorb bone while osteoblasts 
synthesise new bone matrix (osteoid) and provide the enzymes that facilitate the 
process of matrix mineralisation with calcium and phosphate ions to form 
hydroxyapatite (HA) (Ca10(PO4)6).  
 
1.2.2 Osteoclasts 
Osteoclasts are large multinucleated cells that are derived from hematopoietic stem 
cells and are responsible for bone resorption (Suda et al. 1992). The sequence of 
cellular events involved in bone resorption is referred to as the resorption cycle. The 
osteoclast-mediated resorption cycle includes: migration of the osteoclast to the 
resorption site; attachment of the osteoclast to the bone surface; polarisation and 
formation of new osteoclast plasma membrane domains; dissolution of 
hydroxyapatite, degradation of the organic matrix; removal of degradation products 
from the resorption lacuna; and finally, either return to a non-resorbing phenotype or 
the osteoclast undergoes apoptosis (Vaananen et al. 2000). Morphologically, the 
most characteristic feature of osteoclasts is the presence of a ‘ruffled border’, a 
highly convoluted region of the plasma membrane adjacent to the bone surface. The 
adjacent cytoplasm contains a large number of lysosomes, which are involved in the 
degradation of resorbed bone matrix (Figure 1.2). Surrounding the ruffled border is a 
region known as ‘the sealing zone’, where the plasma membrane is relatively 
uniform. Actin filaments are concentrated within the cytoplasm of the sealing zone 
and are surrounded by a ring of cytoskeletal and adhesion molecules such as vinculin 
and talin. Interestingly, some authors have suggested that the sealing zone membrane 
contains numerous VN receptors (αvβ3 integrins) and that osteoclast attachment is 
mediated by sealing zone αvβ3 integrins binding to a variety of ECM proteins 
including VN (Davies et al. 1989) and osteopontin (Reinholt et al. 1990). More 
recently, however, others have failed to demonstrate αvβ3 localisation in the sealing 
zone (Lakkakorpi et al. 1991; Masarachia et al. 1998; Duong et al. 2000) although it 
was found to be important for proper osteoclast function.  Still others have suggested 
some members of the cadherin family are important for the tight attachment of the 
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sealing zone to the bone surface (Ilvesaro et al. 1998). Thus, the specific molecules 
responsible for mediating osteoclast sealing zone attachment to the bone surface 
remain to be identified unequivocally. The resorption area under the ruffled border, 
called the Howship’s lacuna, is acidic, which favours dissolution of bone mineral 
(Baron et al. 1985). This is due to vacuolar type H+-ATPase proton pump, located in 
the plasma membrane of the ruffled border, which transport protons into the 
resorption lacuna, thereby decreasing the pH of the microenvironment (Vaananen et 
al. 1990) (Figure 1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Schematic diagram of osteoclast structure and microenvironment. 
Osteoclasts are giant multinucleate cells of the hematopoietic lineage that are 
responsible for the resorption of bone. Resorption of the mineral component of bone 
(hydroxyapatite) is facilitated by the production of an acidic microenvironment 
beneath the osteoclast via the action of vacuolar type H+-ATPase proton pumps 
located in the osteoclast ruffled border. Cell attachment molecules such as integrins 
and / or cadherins mediate osteoclast attachment to the bone surface through 
interactions with select bone ECM proteins and to the intracellular actin cytoskeleton 
through cytoskeletal adhesion complexes such as vinculin and talin. 
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1.2.3 Osteoblasts 
Osteoblasts are mononucleate cells of mesenchymal origin, which produce bone 
ECM and enzymes that facilitate the matrix mineralisation processes. Both hormonal 
and non-hormonal molecules stimulate proliferation and differentiation processes in 
osteoblasts. These include, but are not limited to, thyroid hormone (TH) (Pepene et 
al. 2001), parathyroid hormone (PTH) (McCarthy et al. 1989b), growth hormone 
(GH), prostaglandins (Hakeda et al. 1991), oestradiol (Ernst et al. 1989; Westley and 
May 1994), TGF-β, IGF-I and IGF-II (Hock et al. 1988; McCarthy et al. 1989a; 
Yakar et al. 2002). The differentiation process of the osteoblast lineage is well 
defined and is characterised by coordinated progressive changes in cell morphology 
accomplished by transient expression of various bone specific and bone non-specific 
proteins, bone matrix formation and matrix mineralisation. Terminally differentiated 
osteoblasts undergo apoptosis, become bone-lining cells (senescent osteoblasts), or 
become embedded in the matrix and become osteocytes, which survive in small 
spaces between the lamellar bone known as lacunae. Osteocytes are thought to form 
a continuous syncytium that can sense mechanical loads acting on bone and monitor 
bone integrity and allow communication with the bone lining cells. Thus this large 
network of interconnected cells has the potential to orchestrate the spatial and 
temporal recruitment of cells of the BMU (Sommerfeldt and Rubin 2001). This is 
achieved through cell / cell interactions between osteocytes via specialised 
cytoplasmic processes, which exist in small channels called canaliculi and link 
individual lacunae to each other and to the central haversian canal system.  
 
Transient expression of ECM proteins by osteoblasts results in the formation of new 
bone matrix into which secreted growth factors such as the IGFs, IGF-binding 
proteins (IGFBPs), and TGF-βs (which include the bone morphogenetic proteins 
(BMPs)) become incorporated. These are stored in the matrix and upon release 
during bone turnover / remodelling events can alter the behaviour of subsequent 
generations of osteoblasts in a paracrine manner (Mundy et al. 1995). This further 
suggests that an age-related down regulation of these genes, and subsequent reduced 
concentration of the corresponding proteins, may partially explain the reduced 
osteoblast activity observed in pathological conditions such as osteoporosis (Mohan 
et al. 1995a).  
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1.2.4 Human Mesenchymal Stem Cells 
Human osteoblasts arise from human mesenchymal stem cells (hMSCs) which most 
commonly reside within the bone marrow. hMSCs are thought to be the cells which 
facilitate bone remodelling and repair processes (Bruder et al. 1998a; Richards et al. 
1999). hMSCs are characterised as being multipotential, that is they are able to 
differentiate variously into cartilaginous tissue (Johnstone et al. 1998; Pittenger et al. 
1999; Majumdar et al. 2000), bone tissue (Bruder et al. 1997b; Jaiswal et al. 1997; 
Pittenger et al. 1999; Lennon et al. 2000), tendinous tissue (Young et al. 1998), 
muscle tissue (Wakitani et al. 1995), adipose tissue (Pittenger et al. 1999) and 
stromal tissue which supports haematopoiesis (Majumdar et al. 1998), while also 
being capable of self renewal (Caplan 1994) (Figure 1.3). Cultured hMSCs have a 
demonstrated ability to be passaged and expanded up to 25 times without significant 
changes in morphology, growth pattern or immunophenotype. This translates into an 
approximate 550 million fold increase in cell number (Conget and Minguell 1999). 
These authors also demonstrated that hMSCs cultured and expanded in the absence 
of differentiation stimuli express cell surface antigens associated with mesenchymal, 
endothelial and epithelial cell lineages (Conget and Minguell 1999). 
 
MSC differentiation into a given tissue type, for example bone, is regulated by 
specific growth factors, cytokines, vitamins and microenvironment / ECM to which 
the hMSC is exposed (Bruder et al. 1997b; Jaiswal et al. 1997; Pittenger et al. 1999; 
Coelho et al. 2000; Coelho and Fernandes 2000; Lennon et al. 2000; Bennett et al. 
2001a). hMSCs have also been shown to be involved in osteoclastogenesis in vitro. 
Experimental co-cultures of human haematopoietic stem cells (hHSCs) and human 
MSCs (hMSCs) indicated that terminal differentiation of hHSCs into osteoclasts 
(Ocls) is dependent on cell-to-cell contact and the provision by hMSCs of 
osteoclastogenic factors to the hHSCs (Mbalaviele et al. 1999). Interestingly, these 
data further suggested that hHSCs induce hMSCs to produce cytokines that regulate 
osteoclastogenesis. These findings also suggest that while hMSCs constitute the 
source of new tissue for purposes such as wound repair, they are also important 
regulators of homeostatic mechanisms such as integration and control of the BMU.   
 
In vitro, expanded MSCs have been shown to synthesise bone when seeded onto 
biodegradable collagen scaffolds and implanted into large segmental bone defects in  
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Figure 1.3. Specific osteoblast lineage markers. SH-2, SB-10, SB-2. SB-3, SB-5 
and STRO-1 are monoclonal antibodies that recognise specific cell surface antigens 
on the respective cells of the osteoblast lineage. Also shown are the temporal 
expression profiles of Transforming Growth Factor-β (TGF-β), Fibroblast Growth 
Factor (FGF), Platelet Derived Growth Factor (PDGF), Alkaline Phosphatase 
(ALP), Osteonectin, Osteopontin, Type 1 Collagen (Col-1), 1,25-dihydroxyvitamin 
D3 (Vitamin D), Bone Sialoprotein and Osteocalcin mRNA.  Adapted from (Bruder 
et al. 1997a). 
 
mice (Turgeman et al. 2001). MSCs seeded onto hydroxyapatite / β-tricalcium 
phosphate scaffolds can support the regeneration of bone when implanted into a 
significant clinical defect in the femurs of rats. The newly synthesised bone tissue 
exhibits superior biomechanical and histomorphometrical properties to the implanted 
hydroxyapatite / β-tricalcium phosphate scaffolds alone (Bruder et al. 1998b). Thus 
hMSC-seeded scaffolds have a demonstrated ability to repair bone defects in animal 
models and this strongly suggests that this technology offers an equivalent potential 
in human patients. Importantly, the proliferative capacity and population of hMSCs 
are similar in osteoporotic patients to healthy individuals, irrespective of age 
(Stenderup et al. 2001).  These data support our view that hMSCs harvested from 
patients own bone marrow, expanded in culture and seeded onto orthopaedic 
implants coated with osteoinductive matrix / growth factors will enhance 
osseointegration of the implant. 
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Of the various cell lineages into which hMSCs are capable of differentiating, the 
osteoblastic lineage is the most thoroughly understood.  hMSC osteoblastic 
differentiation has been characterised (Figure 1.3) using various antibodies to 
specific cell surface antigens, enzyme activity assays, mRNA expression and 
mineralisation (Haynesworth et al. 1992a; Haynesworth et al. 1992b; Bruder et al. 
1997a; Jaiswal et al. 1997; Oreffo et al. 1999; Yamaguchi et al. 2000; Bennett et al. 
2001a; Kawaguchi et al. 2001; Papergerakis et al. 2002). Transiently expressed 
proteins have been used extensively to define various intermediate stages of cells 
differentiating along the osteoblast lineage. Thus, determination of the protein / 
antigen expression profile of cells cultured on a particular biomaterial or ECM / 
growth factor complex is indicative of the potential of the substrate for the support of 
differentiation of cells along the osteoblastic lineage. The capacity of cells to 
differentiate appropriately while attached to a surface is an important consideration 
for both ex vivo and in vivo bone healing and regeneration processes. I envisage that 
this will help facilitate osseointegration of biomaterials with existing bone tissues.   
 
1.2.5 Osteoblast-like SaOS-2 Cells 
Although, originally isolated from an osteosarcoma from an 11 year old female in 
1977 and thus having potential for abnormal gene expression, SaOS-2 cells have 
become a popular cell line model for developmental studies of osteoblast responses 
to various treatments. This popularity is partly due to their clonal expansion ability 
which provides large homogeneous populations of osteoblast-like cells (Murray et 
al. 1987; Farley et al. 1991; Farley et al. 1993; Okumura et al. 2001; Kilpadi et al. 
2004). The osteoblast-like properties of SaOS-2 cells were initially described by 
Rodan and co-workers in 1987 (Rodan et al. 1987). These properties include: 
production of a mineralised matrix; parathyroid hormone-sensitive adenylate cyclase 
activity; osteonectin production and secretion; presence of 1,25-dihydroxyvitamin D3 
receptors; and significantly, cell density dependent-alkaline phosphatase activity, 
(Rodan et al. 1987). Of importance to the research described in this thesis, SaOS-2 
cells express αvβ3 and α5β1 integrins, classical cell surface receptors for VN and FN 
respectively (Koistinen et al. 1999; Postiglione et al. 2003; Kilpadi et al. 2004). 
SaOS-2 cells also express IGF-I receptors and are responsive to IGF-I (Bilbe et al. 
1996; Nasu et al. 2000; Grey et al. 2003; MacEwen et al. 2004). In addition, they 
have been shown to express epidermal growth factor receptor (EGFR), fibroblast 
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growth factor-I receptor (FGF-IR) and type I, type II and III (betaglycan) TGF-β 
receptors (Takeuchi et al. 1995; Bilbe et al. 1996). Thus SaOS-2 cells are a useful 
model cell line model for evaluating osteoblastic responsiveness to matrix proteins 
such as VN and FN and to growth factors such as IGF-I, EGF, and TGF-β1.   
 
1.3 INTEGRINS  
Integrins are cell surface transmembrane glycoproteins of a heterodimeric structure 
of non-covalently bound α and β subunits and mediate cellular attachment to the 
ECM (Pierschbacher and Ruoslahti 1984). Various combinations of the 16 known α 
and 8 β subunits form 22 distinct heterodimers, with each determining ligand-
binding specificity.  Integrins, including those expressed by bone cells (osteoclasts 
and osteoblasts), consist of a large extra cellular domain, a single hydrophobic 
transmembrane domain and a short cytoplasmic domain. The extra-cellular domain 
has been shown to be responsible for binding / interacting with ECM proteins 
through highly specific peptide recognition motifs such as the Gly-Glu-Arg (GER) 
sequence of type 1 collagen (Knight et al. 1998), recognised by α2β1 and the Arg-
Gly-Asp (RGD) sequence present in many ECM proteins, including fibronectin 
(Pierschbacher and Ruoslahti 1984), osteopontin (Reinholt et al. 1990), bone 
sialoprotein (Byzova et al. 2000) and of particular interest to this author, VN (Pytela 
et al. 1985) and recognised by αvβ3 integrins.  
 
In addition to cell adhesion, ligation of integrin receptors stimulates intracellular 
signalling events such as tyrosine phosphorylation (Schwartz et al. 1995) and 
activation of focal adhesion kinase (FAK), as well as mitogen-activated protein 
(MAP) kinases (Chen et al. 1994) such as extra-cellular signal-related kinase (ERK). 
Interestingly, integrin ligand occupancy and aggregation have been shown to induce 
EGF, PDGF and bFGF receptor accumulation at sites of integrin aggregation, 
resulting in enhanced growth factor receptor tyrosine phosphorylation and enhanced 
downstream ERK activity (Miyamoto et al. 1996). Lai et al (2001), demonstrated 
that expression of ERK1 dominant negative protein in the human osteoblast cell line 
HOB inhibited ERK / MAPK activity, resulting in decreased proliferation and 
differentiation but interestingly, inhibited adhesion, spreading and migration. The 
later was partly explained by the finding that β1, αvβ3 and αvβ5 integrin expression 
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was also inhibited by the expression of the dominant negative ERK1 protein. These 
findings suggest that integrin expression and hence cell attachment, spreading and 
migration, are modulated by signal transduction elements that are demonstrated 
downstream effectors of integrin / ECM complexes and / or growth factor / growth 
factor receptor complexes (Lai et al. 2001).  It is through these intracellular 
signalling pathways that processes including cellular proliferation, differentiation 
and migration have been linked with distinct integrins and their interactions with 
specific ligands (Leavesley et al. 1992; Leavesley et al. 1993; Miyamoto et al. 1996; 
Cowles et al. 2000; Gronthos et al. 2001; Lai et al. 2001; Maile et al. 2001). 
 
1.3.1 Integrins present in bone 
FCS contains multiple, diverse adhesive proteins such as fibronectin and VN. These 
ECM proteins adhere to culture substratum and mediate cellular attachment through 
interactions with integrins expressed on the cell surface. Osteoblasts express a 
diverse range of integrins including α5β1, α2β1, αvβ1 and αvβ3, although particular 
patterns of integrin expression is thought to be dependent on the particular stage of 
osteoblast differentiation (Bennett et al. 2001a; Bennett et al. 2001b). Gronthos et 
al., (2001) recently suggested that the β1-integrin subfamily may be involved in 
regulating the differentiation of bone marrow stromal precursor cells into mature, 
functional osteoblasts (Gronthos et al. 2001). While the αv subunit is expressed in 
both osteoblasts and osteoclasts, the β1 subunit appears to have the major functional 
role in osteoblasts whereas the β3 subunit is predominant in osteoclasts. Indeed, the 
highest level of in vivo expression of αvβ3 integrins is in osteoclasts (Horton 1997; 
Duong et al. 2000; Bennett et al. 2001a). Schneller et al., (1997) showed that 
mitogenicity was increased and activated PDGF receptor co-immunoprecipitated 
with αvβ3 integrin complexes when 3T3 fibroblasts were plated onto VN compared 
to collagen (Schneller et al. 1997). The αvβ3–VN relationship has been widely 
studied, especially in regards to its association with growth factor mediated cell 
function in various cell types. 
 
In common with primary osteoblasts, SaOS-2 cell adhesion is mediated through the 
actions of integrin heterodimers involving αv and β1 subunits that bind with ECM 
proteins containing RGD sequences. These events are important for the attachment, 
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spreading, proliferation and differentiation of these cells on titanium and polystyrene 
surfaces (Degasne et al. 1999; Bennett et al. 2001b). 
 
hMSCs have been shown to express α1 (Bruder et al. 1998a)  α4, α5 and β1 
(Gronthos et al. 2001) integrin subunits and of particular interest to this author, the 
αvβ3 and αvβ5 heterodimer complexes (Conget and Minguell 1999). The αvβ3 and 
αvβ5 integrins have been shown to bind VN via the RGD sequence thus mediating 
cellular attachment, reducing microvascular endothelial cells apoptosis (Isik et al. 
1998) and, in the case of αvβ3, promoting IGF-I stimulated cell migration (Leavesley 
et al. 1992; Leavesley et al. 1993).  
 
1.4 VITRONECTIN AND FIBRONECTIN 
1.4.1 Vitronectin 
Vitronectin (VN) is a 75 kDa multifunctional glycoprotein localised to the ECM and 
plasma. VN is involved in a wide variety of biological activities including promotion 
of cell adhesion, spreading, proliferation and migration. It is also involved in 
immune defence through interactions with complement complexes, and haemostasis 
through interactions with heparin. These functions are summarised in Figure 1.4 and 
have been reviewed by (Schvartz et al. 1999).  
 
 
Figure 1.4. The major biological functions in which vitronectin is involved. 
Adapted from Schvartz et al., (1999). 
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The open reading frame (ORF) of VN, deduced from a human cDNA library, 
encodes for a 459 amino acid protein with a 19 amino acid signal peptide (Figure 
1.5) (Schvartz et al. 1999). 
 
 
 
 
Figure 1.5. Schematic representation of the domain structure of vitronectin. The 
domain structure and localisation of the ligand binding domains on VN for; 
Plasminogen activator inhibitor-1 (PAI-1), urokinase plasminogen activator receptor 
(uPAR), integrins, TGF- β, thrombin-antithrombin III complex, plasminogen and 
heparin. Localisation of the cystine residues responsible for maintenance of 
multimeric quaternary structure via disulphide bond formation. Adapted from 
Schvartz et al (1999).  
 
Plasma VN is largely synthesised in the liver and secreted into the circulation in a 
non-adhesive, monomeric ‘native’ conformation (Seiffert and Smith 1997). Native 
VN is structurally altered through interactions with a number of plasma proteins to 
form ‘denatured’ VN.  Denatured VN can form multimers following endogenous 
cleavage of the 75 kDA native protein into 10 kDa and 65 kDa fragments, linked by 
a disulfide bond (Cys274- Cys453) (Figure1.5).  
 
VN exists in the ECM in the multimeric form (Gibson and Peterson 2001).  The 
amino terminal domain (residues 1-44), also known as the somatomedin B domain, 
has been shown to bind plasminogen activator inhibitor-1 (PAI-1) (Seiffert et al. 
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1994; Okumura et al. 2002) and urokinase plasminogen activator receptor (uPAR) 
(Wei et al. 1994; Okumura et al. 2002). PAI-1 competitively inhibits the VN / uPAR 
and VN / integrin interactions (Deng et al. 1996; Deng et al. 2001) and there is 
evidence to suggest it may also inhibit cell migration (Kanse et al. 1996). Directly 
adjacent to residues 1-44, is the Arg-Gly-Asp (RGD) integrin recognition sequence 
(aa 45-47) through which integrin dependent cellular attachment and spreading is 
mediated (Schvartz et al. 1999) (Figure 1.5). Cell attachment to VN occurs through 
integrin binding via the RGD motif and / or via VN-uPAR-uPA ± αv integrin 
complex formation (Kjoller 2002). While PAI-1 competitively disrupts uPAR and 
integrin binding of VN, recent evidence suggests that PAI-1 can induce cell 
detachment from VN by interacting with active uPA bound to uPAR in a VN-
independent process. In addition, this process is found to result in the inactivation 
and internalisation of uPAR-uPA-αv integrin complexes (Czekay et al. 2003). These 
data demonstrate VN is able to facilitate cellular responses to specific ligands 
through co-localisation of the relevant receptors. 
 
As discussed above, the RGD sequence facilitates the binding of a range of integrins 
to VN, including those expressed by bone cells such as αvβ3, αvβ5, α5β1, α2β1 
(Bruder et al. 1998a; Conget and Minguell 1999; Gronthos et al. 2001). Of particular 
significance, TGF-β1, a growth factor highly expressed in bone tissue, has been 
shown to bind to a region of VN between residues 43 and 62 (Figure 1.5). This is of 
particular importance because this interaction was also shown to inhibit both uPAR 
and integrin mediated cell adhesion (Schoppet et al. 2002). In addition, VN / TGF-β1 
complex formation did not interfere with TGF-β mediated signal transduction 
indicating a functional TGF-β / TGF-β receptor interaction (Schoppet et al. 2002). 
These data suggests a mechanism by which TGF-β initiated intracellular signalling 
could be mediated without interference from either uPAR or integrin intracellular 
signalling pathways. Interestingly, this interaction also provides a mechanism for the 
accumulation and storage of TGF-β in the ECM. 
 
A region of acidic amino acids between residues 53 and 64 in VN is involved in 
binding the thrombin-antithrombin III complex and collagen (Figure 1.5). This 
region is also known as the polyanionic segment and is thought to associate with the 
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so-called polycationic segment (residues 348-376) via ionic interactions; this in turn 
stabilises the VN molecule as the folded monomer conformation found in plasma 
(Schvartz et al. 1999).  The remainder of VN consists of six hemopexin repeats, 
which contain a plasminogen-binding site (residues 332-348), a heparin binding site 
(residues 348-361) and additional PAI-1 binding site (residues 348-370) (Kost et al. 
1992) (Figure 1.5).  
 
Francois et al, (1999) suggested that removal of multimeric VN complexes from the 
circulation was mediated by VN binding to endothelial cell surface 
glycosaminoglycans via VN’s single functional heparin binding domain (residues 
348-361) (Figure 1.5). Whether or not the bound multimeric VN is subsequently 
transported to underlying ECM or internalised and degraded remains unclear 
(Francois et al. 1999).  
 
Another important family of proteins able to bind VN are the IGFs. Of particular 
interest to this author, VN has also been found to bind IGF-II but not IGF-1 (Upton 
et al. 1999). Moreover, it has been suggested that the binding interaction between 
IGF-II and VN may involve residues other than those involved in IGF-II binding to 
IGFBPs. This was indicated by the finding that des(1-6)-IGF-II, an IGF-II analogue 
with a much reduced affinity for IGFBPs, retained the ability to bind VN (Upton et 
al. 1999). This work, for the first time, demonstrated an interaction between VN and 
an important biologically active growth factor (Upton et al. 1999). Since then, as 
discussed above, TGF-β1 has also been shown to bind VN (Schoppet et al. 2002). 
Inspired by the work by Upton and co-workers, Kricker et al., (2003) recently 
provided evidence that the IGFBPs could bind to VN and, in the case of IGFBP-5, 
enhance IGF-I stimulated biological effects, such as IGF-I mediated cell migration 
(Kricker et al. 2003). From the same laboratory Noble et al., (2003) demonstrated 
IGF-II pre-bound to VN enhanced IGF1R mediated MCF-7 breast cancer cell 
migration (Noble et al. 2003). The sites on VN of IGF-II and the IGFBPs binding 
remains to be elucidated, however, Kricker et al., (2003) demonstrated that the 
heparin binding domain of IGFBP-3 was critical for binding to VN (Kricker et al. 
2003). Similarly, the heparin binding domain of IGFBP-5 is also critical for binding 
to VN (Nam et al. 2002). PAI-1 has also been shown to bind to VN and IGFBP-5, 
and VN is able to compete with PAI-1 for binding to IGFBP-5, suggesting a close 
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spatial relationship between the PAI-1 and IGFBP-5 binding sites on VN  (Nam et 
al. 1997). Functionally, IGF-I / IGFBP-5 / VN complex formation has been shown to 
potentiate IGF-I mediated cell migration and DNA synthesis (Nam et al. 2002).   
 
Interestingly, variation in the biological activity of VN bound to tissue culture plastic 
(TCP) has been shown to vary between TCP manufacturers which strongly suggests 
VN conformation is important (Underwood et al. 1993). The saturation limit for VN 
molecules attached to TCP substrates in a “side on” arrangement (as opposed to “end 
on) has been estimated at 210 ng/cm2 (Pitt et al. 1987; Pitt et al. 1989). However, the 
amount of VN bound per cm2 can be increased by exposing the TCP to higher 
concentrations of VN but this results in multilayering or reorientation of the 
molecules, ie. to “end on”, demonstrated by interrogation of pre-bound VN with 
domain specific monoclonal antibodies. In the case of VN the conformation 
appeared not to change despite multilayering or reorientation (Underwood et al. 
1993). 
 
1.4.2 Fibronectin 
Like VN, Fibronectin (FN) is a multifunctional glycoprotein present in plasma and 
tissue ECM. FN typically exists as a homo-dimer of two ~250 kDa disulfide linked 
subunits. However, the molecular weight (MW) of FN can vary depending on 
alternative splice variations (Tamkun et al. 1984). FN derived from plasma typically 
has a lower MW than cellular FN, is largely synthesised by hepatocytes in the liver 
and is present in plasma at ~300 µg/mL (Yamada and Kennedy 1979). A number of 
different integrins are capable of binding to FN and significant among these are the 
RGD binding integrins α5β1 and αvβ3 (Ruoslahti 1988; Pankov and Yamada 2002). 
FN is also capable of binding a number of other ECM components including type I 
and type IV collagen, fibrin, heparin and heparan / condroitin / dermatan sulphate 
proteoglycans (Ruoslahti 1988; Romberger 1997). More recently FN has been shown 
to bind both IGFBP-3 and -5 (Gui and Murphy 2001). The interaction between 
IGFBP-5 and FN has been recently demonstrated to negatively modulate IGFBP-5’s 
IGF-I dependent activity in mouse embryonic cell migration by enhancing 
proteolytic degradation of IGFBP-5. However, the identity of the particular protease 
or proteases mediating this phenomenon remains unresolved (Xu et al. 2004).  
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Additionally, FN has been shown to prevent apoptosis of mature osteoblasts and this 
effect was further enhanced by the addition of TGF-β1. The authors found that FN 
and TGF-β1 cooperated to regulate the survival of mature osteoblasts in vitro 
(Globus et al. 1998). Similar to VN, monolayers of FN molecules bound to tissue 
culture plastic have a saturation limit of 0.36 µg/cm2 (Pitt et al. 1989). However, 
interrogation of high concentrations of pre-bound FN with monoclonal antibodies 
revealed that multilayering of the FN molecules was possibly occurring, although it 
remained unclear whether this result was an artefact caused by steric hindrance of 
antibody binding to FN molecules (Underwood et al. 1993).  
 
1.5 INSULIN-LIKE GROWTH FACTORS 
The IGFs, IGF-I and IGF-II, are growth-promoting polypeptides which have both 
anabolic and mitogenic effects on cells and have essential roles in growth and 
development. IGF-I and II are both single chain polypeptides, similar in amino acid 
sequence (62%) and structure and bear substantial homology (40%) with proinsulin 
(Yu and Berkel 1999). IGF-I and IGF-II are synthesised as pre-proteins and circulate 
as 70 and 67 amino acid mature peptides, respectively. IGF-I is 7.6 kDa basic 
peptide while IGF-II is slightly acidic and has a molecular weight of 7.5 kDa. The 
biological actions of the IGFs are mediated through 2 IGF receptors. These are the 
type 1 IGF receptor (IGF1R) and the type 2 IGF receptor (IGF2R). The type II 
receptor is also known as the cation-independent mannose-6 phosphate receptor 
(CIMPR). Both IGF-I and IGF-II bind to the IGF1R with similar high affinity, 
whereas only IGF-II binds with high affinity to the CIMPR (Kiess et al. 1994). 
Interestingly, as discussed above, IGF-II has been shown to directly interact with VN 
(Upton et al. 1999), as has TGF-β1 (Schoppet et al. 2002). Both IGF-II and TGF-β1 
interact with the IGF2R / CIMPR (Dennis and Rifkin 1991; Kiess et al. 1994; Ghosh 
et al. 2003). Additionally, the CIMPR has been shown to mediate the activation of 
latent TGF-β1 by forming complexes with plasminogen and uPAR (Godar et al. 
1999) the latter of which is also known to interact with VN (Wei et al. 1994; 
Okumura et al. 2002). However, no studies have yet looked at possible trimeric, 
IGF-II / VN / TGF-β1 complex formation, nor the possible functional consequences 
of such an interaction.  
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IGF action is also regulated by the 6 so-called IGF binding proteins (IGFBP 1-6). 
IGFBPs facilitate the availability and action of the IGFs by extending IGF half life, 
transporting the IGFs in serum, mediating IGF binding to their receptors and 
importantly, localising IGFs in tissues. Due to differences in structure, post-
translational modifications, and expression patterns, each of the IGFBPs are 
associated with unique functions (Wood 1995). 
 
1.5.1 Insulin like growth factors and hMSCs 
The expression of IGF-I mRNA in hMSCs has been shown to increase in response to 
stimulation by TGF-β1 (Kveiborg et al. 2001a). However, no changes in IGF-II 
mRNA could be detected following identical treatment. Regulation of IGF-I 
synthesis by TGF-β1 on the other hand has been demonstrated at the transcriptional 
level (Kveiborg et al. 2001a). These findings support the hypothesis that TGF-β1 has 
a stimulatory effect on hMSC cell proliferation by inducing a localised increase in 
IGF-I levels, which act in a paracrine fashion. However, mature human osteoblasts 
obtained from trabecular bone explants were found to consistently express both IGF-
I and -II mRNA transcripts, while transformed osteoblast cell lines were found to 
express neither IGF-I nor IGF-II mRNA transcripts (Okazaki et al. 1995).   
 
Glucocoticoids, such as dexamethasone (Dex), are well known to stimulate rodent 
and human osteoprogenitor cell differentiation (Cheng et al. 1994; Haynesworth et 
al. 1996; Bruder et al. 1997b; Jaiswal et al. 1997). Jia and Heersche (2002) have 
investigated which components of the IGF system, ie IGF-I and II, IGFBPs and 
IGFRs, are involved in Dex-induced in vitro rat osteoprogenitor differentiation. 
Significantly, they found that IGF-I transcripts were down-regulated in cultures 
treated with Dex, suggesting that IGF-I down-regulation is a consequence of the 
differentiation process, or that differentiation is triggered by a reduction of local 
IGF-I concentration and therefore reduced IGF-mediated cell proliferation (Jia and 
Heersche 2002). This supports the earlier findings of (Delany and Canalis 1995) and 
similar findings in human marrow stromal cells (Cheng et al. 1998), but seemingly 
contradicts an earlier report from the same authors that IGF-I and -II stimulated 
osteoprogenitor proliferation and differentiation (Jia and Heersche 2000). However, 
the later study also revealed that IGFBP-4, which is known to be inhibitory to IGF-I 
induced osteoblastic cell proliferation (Grellier et al. 1996; Gustafsson et al. 1999), 
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was not highly transcribed in immature, actively growing osteoprogenitor colonies. 
In contrast, IGFBP-4 was highly transcribed in older, differentiating cultures in 
which osteoid was accumulating. Furthermore, transcription of IGFBP-3, which is 
known to have stimulatory effects on IGF mediated cell proliferation (Conover and 
Kiefer 1993; Ramagnolo et al. 1994), was upregulated in immature, proliferating 
cultures but was found to be down-regulated as cultures differentiated and aged. 
Taken together these findings suggest that IGFBP-3 may mediate storage of IGF-I in 
immature cultures and as synthesis of IGF-I and IGFBP-3 decreases, synthesis of 
IGFBP-4 coincidentally increases, thus competing for remaining IGF-I and reducing 
its availability and mitogenic activity. Recently, Walsh et al., (2003) found that 
exogenous IGF-I did not support hMSC proliferation, nor did it induce osteoblast 
marker expression. However, in the assay systems used in this study the authors 
added the IGF-I to the hMSCs in solution and in the presence of 15% FCS. Thus, 
any effect of exogeneous IGF-I may have been masked by responses to the many 
growth factors and mitogens in the FCS (Walsh et al. 2003). 
 
1.5.2 Insulin like growth factors: Localisation and role in bone remodelling 
IGF-I and -II are among the most abundant growth factors synthesised by osteoblasts 
and are largely present in bone matrix as part of a larger protein complex with the 
IGF binding proteins (Bautista et al. 1990; Bautista et al. 1991; Mohan and Baylink 
1991). Localisation of the IGFs in bone tissue is primarily due to the ECM binding 
capabilities of the IGFBPs, particularly IGFBP-5. IGFBP-5 has been shown to 
accumulate in bone ECM and is capable of binding hydroxyapatite, the mineral 
component of bone (Bautista et al. 1991). Many studies, however, have investigated 
the effect of various cytokines and hormones on the expression of the IGFs by 
osteoblasts. For example triiodothyronine (T3) has been shown to have little effect 
on IGF-I expression, but stimulated a doubling of the number IGF1Rs available for 
the binding of IGF-I on the surface of cultured human osteoblasts (Pepene et al. 
2001). Similarly, the stimulatory effect of prostaglandin F2α (PGF2α) on the 
proliferation of murine MC3T3-E1 cells was found to be due to increased expression 
of the IGF1R at the cell surface in the absence of any increase in IGF-I (Hakeda et 
al. 1991). Interestingly, Dex induced osteoblast differentiation of human bone 
marrow stromal cells resulted in a decrease of IGF-I, IGFBP-3, IGFBP-5 and 
IGFBP-6 synthesis and secretion, and an increase in IGF-II and IGFBP-2 levels 
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(Cheng et al. 1998). This is consistent with the observed reduction in proliferation of 
osteoblast precursors exposed to Dex, since IGF-I, IGFBP-3 and IGFBP-5 are 
known to have mitogenic effects on cells (Jones et al. 1993; Ramagnolo et al. 1994). 
However, the increase in IGF-II, along with the decrease in IGFBP-6 levels observed 
in response to Dex treatment, is interesting because both IGF-I and IGF-II have been 
associated with enhancement of osteoblast differentiation processes (McCarthy et al. 
1989c; a; Jia and Heersche 2000). IGFBP-6 has been shown recently to have a much 
higher affinity for IGF-II than for IGF-I (Kricker et al. 2003) and therefore down-
regulation of IGFBP-6 would also increase the availability of IGF-II in the local 
microenvironment. However, few studies have investigated the spatial expression of 
the IGFs in relation to cells of the BMU. 
 
1.6 INSULIN LIKE GROWTH FACTOR BINDING PROTEIN-5  
IGFBP-5 was first isolated from human bone tissue in 1991 by Bautista and co-
workers (Bautista et al. 1991). Cleavage of a 20 amino acid signal peptide yields a 
29 kDa mature IGFBP-5 peptide of 252 amino acids, which is secreted from the cell 
(Figure 1.6). IGFBP-5, like the other IGFBPs, has three distinct domains, each of 
similar size: an N-terminal domain, which contains the primary binding site for IGFs 
I and II; a mid-region, in which each IGFBP has an almost unique sequence and 
where most post-translational modifications of the protein occur; and a C-terminal 
domain which contains regions responsible for binding the ECM, the 85 kDA 
leucine rich glycoprotein known as the acid labile subunit (ALS) (Baxter et al. 1989) 
and cell membrane proteins (Figure 1.6). It is thought that the unique sequence 
within the mid-region confers each IGFBP with unique functions, although this still 
requires definitive proof.  Most of the proteolytic sites identified thus far are located 
in this region, as are 4 O-glcosylation sites (Thr103, Thr104, Thr111 and Thr152) 
(Conover and Kiefer 1993) and 12 phosphorylation sites (Coverley and Baxter 1997) 
(Figure 1.6). IGFBP-5 susceptibility to proteolytic degradation is potentially altered 
due to the proximity of many of these post-translational modifications to known 
proteolytic sites (Bach 1999) (Figure 1.6). IGFBP-5 binds to ECM proteins such as 
thrombospondin, osteopontin (Nam et al. 2000) and VN (Nam et al. 2002) with high 
affinity. It is thought that IGFBP-5 binding to the ECM is mediated by ionic 
interactions (Jones et al. 1993) with 2 regions that contain several basic amino acid 
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clusters; Arg201-Arg218 and Ala131-Thr141. Of these regions, residues 201-218 exhibit 
~ 4-fold more potent ECM binding than residues 131-141 (Parker et al. 1996). 
Recently, residues 77-81 in the amino terminus and residues 217 and 223 in the 
carboxy terminus of IGFBP-3 were identified as critical residues involved in high 
affinity binding of IGF-I (Yan et al. 2004). Similarly, residues 203 and 209 in the 
carboxy terminus of IGFBP-5 have been confirmed to be critical for the IGFBP-5 / 
IGF-I interaction (Allan et al. 2006).  Amino acids 201-218 have also been shown to 
regulate IGFBP-5 binding to hydroxyapatite (the mineral component of bone) 
(Campbell and Andress 1997) and the ALS (Figure 1.6).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Schematic representation of the insulin like growth factor binding 
protein 5 (IGFBP-5) domain structure. Adapted from (Schneider et al. 2002) 
 
The ALS is known to participate in the formation of a high molecular weight (150 
kDa) ternary complex with either of the IGFs and IGFBP-3, and is thought to i) 
protect IGFBP / IGF complexes from proteolytic degradation and to ii) regulate 
passage of IGFBP-3 / IGF-I complexes from the circulation into target tissues. More 
recently IGFBP-5 has also been shown to be capable of participating in ternary 
complex (130 kDa) formation with the IGFs and the ALS (critical residues Lys211, 
Arg214, Lys217 and Arg218) (Twigg and Baxter 1998; Twigg et al. 1998; Firth et al. 
2001). This can be explained by close sequence similarity between the carboxyl 
domains of IGFBP-3 and IGFBP-5. The ALS is primarily produced by the liver and 
is found mainly in serum. Significantly, thus far just 1 study has looked for 
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expression and production of ALS by bone cells (Kanzaki et al. 1995). The authors 
found that ALS was not released into the conditioned media by either normal human 
osteoblasts, or the osteoblast-like, SaOS-2 osteosarcoma cell line. Curiously, studies 
examining the presence of the ALS have yet to be performed on natural bone, or 
osteoblast-derived ECM, major reservoirs of both IGFBP-5 and IGFs (Bautista et al. 
1990; Bautista et al. 1991; Hakeda et al. 1996; Campbell and Andress 1997; Govoni 
et al. 2005). Since the ALS in the circulation is involved in regulating the availability 
of IGFBP / IGF complex to the tissues, a similar mechanism could exist in bone. For 
example the ALS might protect bone matrix bound IGFBP-5 / IGF complex from 
proteolytic degradation until osteoclast resorption creates an acidic environment that 
can degrade the ALS and in turn allow specific proteases access to the IGFBP-5 / 
IGF complex and release IGF into the local microenvironment.   
 
IGFBP-5 also has been shown to interact with the protease inhibitor, plasminogen 
activator inhibitor-1 (PAI-1) (Nam et al. 1997). Jones et al., (1993) found that the 
growth stimulatory effect of IGF-I on fibroblasts was potentiated when IGFBP-5 was 
present in cell culture substrata. However, no effect on IGF-I stimulated growth was 
observed when IGFBP-5 alone was present in the medium. Rather, it was degraded 
to a 22 kDa fragment, thus suggesting that IGFBP-5 bound to ECM is protected from 
proteolytic degradation and is able to localise IGF-I to the ECM where it may 
mediate cellular growth responses (Jones et al. 1993). 
 
1.6.1 Insulin like growth factor binding protein-5 and hMSCs 
While many studies have examined the interactions and effects of IGFBP-5 in 
osteoblasts, few studies have addressed the interactions or effects of IGFBP-5 in 
hMSCs. Nonetheless, it has been shown that hMSCs do express both IGFBP-5 
mRNA and protein and that this expression can be negatively regulated by treatment 
of hMSC cultures with dexamethasone. Indeed, IGF-I expression is down-regulated 
in hMSCs treated with dexamethasone (Cheng et al. 1998). Thus, considering that 
together IGFBP-5 and IGF-I are known to have mitogenic effects on osteoblast cell 
proliferation (Cheng et al. 1998) a possible mechanism for the negative effect on 
hMSC proliferation by dexamethasone is suggested. In addition, IGFBP-5 has 
recently been shown to enhance IGF-I mediated hMSC chemotactic migration 
(Fiedler et al. 2006).    
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1.6.2 Insulin like growth factor binding protein-5: Localisation in bone 
IGFBP-5 was originally isolated from human bone by Bautista et al (1991) using a 
HA affinity matrix, leading to the hypothesis that IGFBP-5 association with HA was 
a potential mechanism of localisation in mineralised tissue. However, IGFBP-5 has 
also been shown to bind type III and type IV collagens, laminin (Jones et al. 1993), 
fibronectin and VN (Nam et al. 2002). In vitro studies in human fibroblast 
monolayer cultures have shown that glycosaminoglycans such as heparin, heparan 
sulphate and dermatan sulphate can protect IGFBP-5 from proteolytic degradation 
(Arai et al. 1994). These data suggest the potential mechanism of regulation of 
IGFBP-5 function and / or accumulation of IGFBP-5 in bone tissue may be complex 
and manifold.  
 
PTH and prostaglandin E2 occupy key roles in bone remodelling and hence have also 
been examined for specific effects on IGFBP-5 degradation. These hormones induce 
the  breakdown of IGFBP-5 from the bone ECM of cultured mouse calvariae, 
resulting in the accumulation of 21 kDa immunoreactive fragments in conditioned 
media (Hakeda et al. 1996). As IGF-I and -II have also been shown to accumulate in 
bone matrix, the demonstrated presence of IGFBP-5 suggests a possible mechanism 
for localising the IGFs in bone tissue until required by cells.  
  
1.6.3 Insulin like growth factor binding protein-5: Role in bone remodelling  
The presence of IGFBP-5 in bone matrix suggests that IGFBP-5 has a role in normal 
bone physiology through direct, or indirect, stimulation of osteoblast behaviour. As 
discussed above, IGFBP-5 associates with the bone mineral (HA) matrix which may 
function to sequester and localise IGF-I and -II in bone tissue for potential release in 
bone remodelling (Bautista et al. 1991). Of the 6 IGFBPs, IGFBP-5 binds the IGFs 
with the highest affinity. Interestingly, IGFBP-5 binds IGFs with a 50 fold greater 
affinity than the IGF1R (Cohick and Clemmons 1993). Recently, our laboratory 
demonstrated that IGF-I mediated cellular migration is significantly enhanced 
through the formation of a trimeric complex of IGF-I, IGFBP-5 and VN (Kricker et 
al. 2003). These data suggest IGF-I mediated cell activity may be regulated in bone 
through an additional mechanism since VN, a ubiquitous ECM protein of all 
connective tissue, is co-localised with IGFBP-5 and IGF-I present in high 
concentration in bone tissue (Bautista et al. 1991); (Andress and Birnbaum 1992; 
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Hakeda et al. 1996; Franchimont et al. 1997a; Franchimont et al. 1997b). However, 
whether this trimeric complex naturally occurs in bone tissue remains to be verified.  
 
In addition to facilitating IGF mediated cell-signalling pathways, IGFBP-5 mediates 
IGF independent cell responses. A 23 kDa fragment and a carboxytruncated form of 
IGFBP-5 have been shown to have mitogenic effects independent of IGF-I in 
neonatal mouse (Andress and Birnbaum 1992) and human (Mohan et al. 1995b) 
osteoblast-like cells. In addition, IGFBP-5 stimulated proliferation of osteoblasts 
derived from IGF-I knockout mice, even in the presence of IGFBP-4, a potent 
inhibitor of IGF actions in osteoblasts, further demonstrating that IGFBP-5 has 
independent biological activity (Miyakoshi et al. 2001). Andress (1995) found that 
IGFBP-5 binds and is internalised with a 420 kDA membrane protein in mouse 
osteoblasts. This “ligand-induced internalisation” appears to require the basic region 
at 201-218 in IGFBP-5 (Andress 1995). A subsequent study revealed that intact 
IGFBP-5 and the IGFBP-5 fragments 1-169 and 201-218 stimulated phosphorylation 
of serine residues present in this 420 kDA membrane protein and this putative ‘BP-5 
receptor’ has demonstrated protein kinase capability; phosphorylating casein in vitro 
(Andress 1998). This indicates that at least in osteoblasts, IGFBP-5 acts in an IGF 
independent manner, possibly with its own signal transduction pathway (Andress 
1998). However, the physiological role of this interaction remains to be elucidated. 
While the identity of this putative IGFBP-5 receptor is unknown, the authors 
discussed the existence of only one other 400 kDa membrane protein with serine / 
threonine kinase activity, the type V TGF-β receptor (O'Grady et al. 1992). 
However, treatment with TGF-β was not able to stimulate IGFBP-5 receptor 
phosphorylation, indicating that while the putative IGFBP-5 receptor and the type V 
TGF-β receptor are functionally similar (phosphorylate casein on serine residues), 
they have distinct ligand binding characteristics (Andress 1998). In addition, co-
immunoprecipitation and immunofluorescence studies further demonstrate that i) 
IGFBP-5 interacts with a nuclear transcription modulator protein known as ‘Four 
and a Half LIM Protein 2’ (FHL2) and that ii) both FHL2 and IGFBP-5 localise to 
the nucleus in human bone cells (Amaar et al. 2002). While the functional 
significance of the above observations is unclear, experimental data reported by 
others clearly indicate that IGFBP-5 acts as a growth factor that translocates to the 
nucleus via a signal-dependent β importin-mediated pathway (Schedlich et al. 1998; 
 27 
Schedlich et al. 2000). Moreover, the androgen receptor is co-activated by FHL2 
(Muller et al. 2000), This further suggests that the FHL2 / IGFBP-5 interaction may 
play a role in the modulation of osteoblast proliferation or differentiation processes 
(Figure 1.7). In fact recently, FHL-2, IGFBP-5 and a disintegrin and 
metalloprotease-9 (ADAM-9) (a known IGFBP-5 protease) were found to be co-
ordinately regulated during osteoblast differentiation in response to either 
dexamethasone, TGF-β1 or bone morphogenetic protein-7 (BMP-7) (Govoni et al. 
2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Model of IGF independent action of IGFBP-5 in osteoblasts. In the 
proposed IGF-independent mechanism, IGFBP-5 from the cytoplasm, or an 
extracellular source, enters the nucleus via its nuclear localisation sequence and the 
nuclear transporter, importin-β. IGFBP-5 may bind to FHL2, a transcription 
modulator, in the cytoplasm and shuttle FHL2 into the nucleus or bind FHL2 in the 
nucleus to stimulate transcription of target genes. Adapted from (Mohan and Baylink 
2002). 
 
1.7 TRANSFORMING GROWTH FACTOR-β1 
 TGF-β1 is the prototypical member of the TGF-β superfamily, which currently 
consists of over 30 members. These have been further characterised into the inhibin / 
activin family, the mullerian inhibitory substance (MIS) family, the bone 
morphogenic protein family and the TGF-β family (Bonewald 1999). All TGF-β 
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family members are potent stimuli of cell functions including proliferation and 
differentiation.  In mammals there are 3 isoforms of TGF-β, TGF-β1, TGF-β2 and 
TGF-β3, which exist predominantly as homodimers. However, heterodimers of TGF-
β2 / 3 and TGF-β1 / 3 have also been isolated (Bonewald 1999). Dramatic differences 
are evident in the tissue distribution of the various TGF-β isoforms. For example, the 
TGF-β2 isoform represents about 50% of total TGF-β present in the kidney (Marra et 
al. 1996), while in the prostate there is a 20-30 fold over-expression of the TGF-β2 
isoform relative to the TGF-β1 isoform. In contrast, 80 to 90% of TGF-β in bone is 
the TGF-β1 isoform (Bonewald 1999).  
 
The TGF-β family members mediate diverse biological effects through binding with 
the Type I, II or III TGF-β receptors. Each isoform of TGF-β binds with different 
affinities to each of the TGF-β receptors suggesting diverse combinations of TGF-β 
isoforms and TGF-β receptor provide potential for varied biological effects 
(Bonewald 1999). For example, the Type-I TGF-β receptor binds TGF-β2 with much 
higher affinity than either TGF-β1 or TGF-β3 (Cheifetz et al. 1986), while the Type 
II TGF-β receptor bind TGF-β1 and TGF-β3 with a 100 fold higher affinity than 
TGF-β2 (Lin et al. 1992). Most cells in the body express receptors for TGF-β, 
suggesting responses to TGF-β must be tightly regulated. Further, most cells secrete 
TGF-β in its latent, or inactive form (Hyytiainen et al. 2004). However, the 
predominant reservoirs of TGF-β in the body are platelets, bone and serum (Seyedin 
et al. 1985; O'Connor-McCourt and Wakefield 1987; Wakefield et al. 1988), 
although TGF-β within these reservoirs exists in the latent or inactive form.   
 
Like the IGFs, TGF-β1 exists in bone primarily as part of a functionally inactive 
larger protein complex. This complex consists of a 25 kDa TGF-β homodimer, 
which following proteolytic cleavage remains non-covalently associated with a 75 
kDa propeptide homodimer, referred to as the latency-associated peptide (LAP). 
Three known isoforms of LAP correspond to each mature TGF-β isoform to which it 
is complexed ie. LAP-β1, LAP-β2 or LAP-β3. This complex, termed the small latent 
complex, represents approximately 50% of the latent TGF-β produced by 
osteoblasts. However, the small latent complex is also produced by other cell types 
and as such may serve a unique function as a free circulating, more activatable form 
(Bonewald et al. 1991; Bonewald 1999). Interestingly, LAP-β1 and LAP-β3 have 
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been shown to contain an RGD sequence and potentially bind to all of the αv 
integrins, including αvβ1, αvβ5 (Munger et al. 1998), αvβ3 (Ludbrook et al. 2003), 
αvβ6 (Munger et al. 1999) and αvβ8 (Mu et al. 2002). In LAP-β2 the arginine is 
substituted with a serine residue (SGD) and is not a ligand for any of these integrins 
(Ludbrook et al. 2003). While the function of these interactions is not currently 
understood, it is possibile that i) αv integrins localise TGF-β at the cell surface to be 
activated by specific proteases such as MMP-1 (Mu et al. 2002) or MMP-2 (Brooks 
et al. 1996) or ii) LAP / integrin ligation initiates αv integrin specific intracellular 
signalling events. The propeptide, LAP, disulfide linked to the 190 kDa “latent 
transforming growth factor-β-binding protein 1” (LTBP1) (Kanzaki et al. 1990; 
Dallas et al. 1995), is a member of a large family of ECM proteins which include 
fibrillins 1 and 2 and LTBPs 1-4 (Sinha et al. 1998). 
 
1.7.1 Transforming growth factor β1 and hMSC’s 
TGF-β1 is a potent mitogen of hMSCs in vitro through the induction of IGF-I 
(Kveiborg et al. 2001b) and has also been found to stimulate the proliferation of 
mature osteoblasts. However, in the presence of calcitrol, TGF-β1 stimulates the 
production of bone matrix associated proteins such as alkaline phosphatase and type 
1 collagen and inhibits the expression of osteocalcin, required for matrix 
mineralisation and terminal differentiation of mature osteoblasts (Kassem et al. 
2000). Similarly, TGF-β1 has also been shown to inhibit bone morphogenetic protein 
2 (BMP-2) mediated osteoblast precursor differentiation (Spinella-Jaegle et al. 
2001). Thus the effects of TGF-β1 on hMSCs are complex and unclear.  
 
Intriguingly, activated TGF-β1 is also capable of binding to VN at a site in close 
proximity to VN’s RGD motif, inhibiting both uPAR and αv-integrin dependent cell 
attachment (Schoppet et al. 2002). Thus TGF-β1 may also effect uPAR and integrin 
mediated signal transduction pathways. This finding is of particular interest because 
it suggests TGF-β1 may be immobilised on various substrates as part of an ECM / 
growth factor complex. Interestingly, this and the findings of Kricker and co-workers 
that IGF-I could bind VN via select IGFBPs (Kricker et al. 2003), highlights the 
prospect of incorporating both TGF-β1 and IGF-I into pre-bound substrate coatings 
for bone tissue engineered therapeutics. While it is widely held that TGF-β1 induces 
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differentiation of osteoblasts, in 2001 Kveiborg and co-workers reported that TGF-β1 
induced hMSCs to express IGFBP-3 and IGF-I thus inducing hMSC proliferation 
(Kveiborg et al. 2001a). TGF-β1 and IGF-I were combined in a recent study of 
periosteal hMSCs in an in vitro organ culture model of chondrogenisis, and it was 
found that the combination of TGF-β1 and IGF-I stimulated an enhanced 
proliferative response in early chondrogenesis and over 6 weeks resulted in greater 
cartilage growth compared to the responses to either of the individual growth factors 
alone (Fukumoto et al. 2003). While the above was an agarose suspension periosteal 
organ culture system designed to induce chondrogenesis, no other investigations 
have examined the response of bone marrow derived hMSCs with combined TGF-β1 
and IGF-I in a pre-bound format with VN.  
 
1.7.2 Transforming growth factor β1: Localisation in bone 
Dallas and co-workers (2002) recently demonstrated that osteoclast-mediated 
proteolysis of the LTBP1 complex released latent TGF-β1 from cultured primary 
osteoblast-derived ECM, in vitro. In addition, purified forms of the serine proteases, 
elastase and plasmin, and the matrix metalloproteinases (MMP) MMP2 and MMP9 
were shown to cleave LTBP1, releasing latent TGF-β1 from the ECM (Dallas et al. 
2002). Earlier studies demonstrated that active TGF-β1 is dissociated from the LTBP-
1 complex at low pH suggesting that the acidic microenvironment produced within 
the resorption zone of active osteoclasts may be another mechanism through which 
active TGF-β1 can be liberated (Pfeilschifter and Mundy 1987; Pfeilschifter et al. 
1990; Hosoi et al. 1996). Indeed, activated TGF-β1 has been immuno-localised to 
osteoclast resorption lacunae and adjacent ECM in mice calvariae. TGF-β1 has been 
shown, in vitro, to induce mature osteoblasts to express both itself and the LTBP1, 
which are then assembled inside the cell and secreted into newly formed bone matrix 
(Miyazono et al. 1991), presumably to await release and activation at a later point by 
resorbing osteoclasts. However, to the best of this author’s knowledge the 
distribution or spatial relationship of the small latent complex and the large latent 
binding protein complex is entirely uncharacterised. Furthermore the fate, or 
function, of osteoclast activated TGF-β1 in vivo is also unknown. Does osteoclast 
activated TGF-β1 bind cell surface receptors on osteoclasts, osteoblasts, or the 
precursors of these cell types? Which receptors do they interact with? In vivo co-
localisation and in vitro cell signalling studies may help to answer these questions 
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and assist the elucidation of the role of TGF-β1 in the sequence of events between 
bone resorption by osteoclasts and subsequent bone formation by osteoblasts.  
 
1.7.3 Transforming growth factor β1: Role in bone remodelling 
The largest source of TGF-β1 in the body is bone tissue, although it exists largely as 
an inactive latent complex. Release of activated TGF-β1 occurs in actively resorbing 
bone and this activation has been shown to occur by a number of mechanisms, 
(discussed above). Local release of TGF-β1 from bone matrix by osteoclasts during 
bone resorption may be an important regulatory mechanism of bone cell activity 
(Bonewald and Mundy 1990).  TGF-β1 has been shown to inhibit osteoclastogenesis 
through the stimulation of marrow stromal and osteoblastic cells to produce 
osteoprotegerin (OPG). This in turn binds to receptor activator of NF-κβ ligand 
RANK-L, preventing activation of RANK on the surface of osteoclastic cells (Lacey 
et al. 1998). However, others have demonstrated that osteoclast differentiation 
processes and RANK expression in the murine monocytic cell line RAW 264.7 is 
increased when exposed to TGF-β1 (Yan et al. 2001). Thus the net effect of exposure 
to TGF-β1 on bone resorption may be regulated by balanced responses between 
marrow stromal / osteoblastic cells on the one hand, and pre-osteoclasts / osteoclasts 
on the other.  
 
Karsdal et al., (2001) reported that osteoblasts cultured on the surface of bone slices, 
mimicking the osteoblastic ‘bone lining cells’ found in vivo, underwent a 
morphological change from cuboidal, or cobblestone appearance, to a highly 
elongated shape when exposed to TGF-β1. This shape change exposed the 
underlying bone surface, allowing co-cultured osteoclasts access to the substratum, 
which in turn facilitated resorption pit formation. In addition, the authors found that 
TGF-β1 induced osteoblast elongation was dependent on p38 MAP kinase activity 
and MMP 13 (collagenase 3) expression. Although up regulation of MMP 13 
expression by TGF-β1 induced signal transduction pathways was independent of the 
p38 MAP kinase pathway, TGF-β1 regulation of osteoblast morphology is affected 
by multiple intra-cellular signalling pathways (Karsdal et al. 2001). As discussed 
above, the latent TGF-β complex may be released from the ECM and subsequently 
activated by either specific proteolytic cleavage, or exposure to extremes in pH.  
Activated TGF-β itself can regulate the activation of the latent complex by 
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stimulating protease inhibitor production, such as PAI-1 and tissue inhibitor 
metalloproteases (metalloprotease inhibitors) (Laiho et al. 1986; Bonewald and 
Mundy 1990) and inhibition of plasminogen activator (Laiho et al. 1987), urokinase 
and collagenase (Bonewald and Mundy 1990).  
  
TGF-β1 also stimulates ascorbate transport in osteoblasts by increasing the rate of 
synthesis of either Na+ ascorbate co-transporters or proteins that interact with and 
regulate existing transporters in the cell membrane to increase ascorbate uptake 
(Dixon and Wilson 1992). Because ascorbate (Vitamin C) is well known as an 
essential requirement for osteoblastic differentiation and collagen synthesis (Murad 
et al. 1981; Jaiswal et al. 1997; Coelho and Fernandes 2000) this may be a 
mechanism through which TGF-β1 enhances matrix synthesis by osteoblastic cells. 
 
1.8 MATRIX METALLOPROTEINASES 
A potential problem facing the successful culture of primary bone cells on pre-bound 
protein complexes is the possible degradation of the matrix protein / growth factor 
substrate by cellular expression of various proteases. It is well known that actively 
migrating cells produce a range of proteases in order to facilitate migration through 
the ECM; this is particularly evident in pathogenic processes such as facilitation of 
metastatic tumour dissemination (Sternlicht and Werb 2001) and in normal processes 
such as bone remodelling. In the normal, healthy in vivo context protease expression 
is highly regulated, whereas, in the in vitro, context especially in serum-free 
conditions, regulatory mechanisms may be absent and the effect of protease 
expression on pre-bound protein complexes, such as that of VN an IGFBP and IGF-
I, may result in destruction of the protein substrate causing less efficient growth rates 
of cells. On the other hand proteolytic degradation of some of the components, such 
as IGFBPs, may be required for mediation of cellular responses by liberation of 
latent growth factors. 
 
Among the most prevalent proteases expressed by osteoblasts are the Matrix 
Metalloproteinases (MMPs), in particular MMP-2 and MMP-9. These 2 proteases 
have been demonstrated as being able to liberate active TGF-β1 from ECM by 
proteolytic cleavage of the latent transforming growth factor-β-binding protein 1 
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(LTBP1) complex (Dallas et al. 2002). MMP-3 (stromelysin 1), also expressed by 
osteoblasts (Bord et al. 1998; Breckon et al. 1999), was recently found to play a role 
in the regulation of cellular proliferation by disruption of IGF-I / IGFBP-3 
complexes, thus liberating active IGF-I leading to activation of the IGF-I receptor 
(Fowlkes et al. 2004). Similarly, some members of the ADAMs (a disintegrin and 
metalloprotease) family of proteins, a subfamily of the MMPs, are also able to cleave 
IGFBP-3 and / or IGFBP-5 (ADAM 12-S and ADAM 9 respectively) (Loechel et al. 
2000; Mohan et al. 2002). More recently, MMP-7 has been shown to be capable of 
proteolytically degrading all of the IGFBPs (Nakamura et al. 2005). However, Payet 
and co workers demonstrated in 2003 that amino and carboxy terminal fragments of 
IGFBP-3 bind to IGF-I and -II with high affinity and inhibit IGF mediated 
phosphorylation of the IGFIR and IGF-II interaction with the CIMPR (Payet et al. 
2003). Thus the biological function of proteolytic degradation of the IGFBPs in 
relation to IGF bioavailability remains unclear. 
 
Plasmin is a well known VN protease which has been shown to activate MMP-2 in 
conjunction with MT1-MMP (Monea et al. 2002). In addition, MT1-MMP is known 
to degrade VN and clips pro αv integrins to give the active form. The authors found 
that inhibition of MT1-MMP with AG3340 (Prinomastat) protected VN from 
degradation by MT1-MMP over the short term, therefore increasing cell motility. 
However over the long term (~24 hrs) inhibition of MT1-MMP resulted in the 
cessation of cell migration, as cell surface αv integrins were replaced with inactive 
pro αv integrins. MT1-MMP half life is short (only a few hrs), whereas αv integrins 
have a relatively long half life at the cell membrane (~24 hrs) on MCF-7 cells 
(Deryugina et al. 2003). A number of questions arise from the above information: do 
cells cultured on pre-bound matrix / growth factor complexes express proteases 
which degrade the protein substrate and thus regulate cell function? If so which 
ones? And if these proteases are inhibited how would cell function be affected?  
While the most recognised role of the MMPs is ECM degradation, their role in 
facilitating cellular access to stored growth factors is attracting greater research 
interest. Indeed, MMP-3 has been shown to release the large latent TGF-β1 complex 
from the ECM prior to further proteolysis of the complex by other proteases such as 
MMP-2 and plasmin to release biologically active TGF-β1 (Maeda et al. 2002). 
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Another point of interest was the recent report that TGF-β1 and IGF-II could up 
regulate the expression and facilitate the function, respectively, of the IGFBP-4 
protease pregnancy-associated plasma protein-A (PAPP-A) (a metalloproteinase). 
This resulted in irreversible liberation of IGFBP-4 bound IGF-I and subsequent 
enhanced growth of cultured human osteoblasts (Ortiz et al. 2003). IGFBP-4 has 
been demonstrated as inhibitory to IGF-I mediated cell responses in human 
osteoblast cells due to sequestration of IGF-I away from cultured cells (Mohan et al. 
1995b). However, Kricker et al., (2003) demonstrated that the 4 IGFBPs, including 
IGFBP-4 / IGF-I complexes, could be immobilised at tissue culture surfaces bound 
to VN (Kricker et al. 2003). Taken together, these data suggest that addition of VN 
to IGFBP-4 / IGF-I complexes could provide a useful mechanism by which a certain 
amount of IGF-I could be immobilised on a substrate seeded with cells and released 
at some later time by the addition of IGF-II and TGF-β1.  
 
1.9 BONE TISSUE ENGINEERING  
Bone tissue engineering is a relatively recent approach to the long established field 
of skeletal engineering, or iatrogenic restoration, which has been practiced for many 
centuries in the repair of fractures and recently with the implantation of dental and 
orthopaedic devices. The development of this new approach offers the prospect of 
new therapies for clinically significant skeletal defects caused by developmental, 
pathologic or traumatic events. Bone tissue engineering, in general, encompasses a 
broad range of disciplines including cell and molecular biology, biochemistry, 
physiology, engineering, chemistry and medicine (Doll et al. 2001; Atala and Lanza 
2002).  
 
Over the past decade great emphasis has been placed on the development of cell 
based strategies for the repair of orthopaedic defects. In particular, technologies for 
the isolation and culture of bone marrow derived hMSCs have been developed 
(Haynesworth et al. 1992b). The in vitro expansion capability of these cells has been 
shown to exceed 1 billion fold (Bruder et al. 1997b). Osteoblasts are one of the end 
stage phenotypes of these cells and therefore are considered as a potential source of 
large numbers of cells which can be used in bioengineering of new bone tissue 
(Jaiswal et al. 1997). hMSCs are also capable of differentiating into chondrocytes, 
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myoblasts, stromal cells, fibroblasts and adipocytes (Caplan 2000). These cell types 
are responsible for the production and maintenance of cartilage, muscle, marrow 
stroma, tendon, ligament and connective tissue respectively. Entrance into and 
progression along individual lineage pathways for bone, cartilage, muscle and fat 
tissues can be stimulated by known inductive agents (Wakitani et al. 1995; Jaiswal et 
al. 1997; Johnstone et al. 1998; Pittenger et al. 1999). However, an area of 
continuing investigation is the molecular mechanism that governs each lineage 
pathway.  
 
The population of hMSCs present in the marrow of the aged is considerably less than 
in the young, ~1:2,000,000 marrow cells compared to ~1:10,000 marrow cells 
respectively. As osteoblasts arise from hMSCs, this decrease in hMSC concentration 
in the aged may account for the observed decreased rates of bone repair. However, 
hMSCs can be mitotically expanded in culture and retain their ability to differentiate 
into the osteogenic lineage regardless of the donor’s age (Ohgushi and Caplan 1999). 
This property of hMSCs, could enable aged patients to benefit from stem cell based 
bone tissue engineering therapeutics. However, a significant obstacle to the clinical 
use of ex vivo expanded stem cells of any type is that current culture methods require 
the use of animal derived additives to the culture media, commonly foetal bovine 
serum, potentially facilitating the transmission of pathogens to the patient. Moreover, 
serum contains a milieu of various proteins, cytokines, growth factors and ECM 
proteins, which can affect cell behaviour. Consequently, growth media used for 
classical tissue culture methods, where additives such as serum are used, are 
essentially undefined. Current regulatory trends find ill-defined reagents undesirable 
and therefore methods must be established which enable the ex vivo expansion of 
hMSCs for clinical use, in a highly defined growth media without animal derived 
products. 
 
A great deal of progress has been made over the last decade developing novel 
biomaterials for use as implants and bone tissue substitutes for the repair of large 
orthopaedic defects. Some of these have been developed with a view to providing 
both a substrate for cell attachment and subsequent tissue in-growth and as a delivery 
vehicle for growth factors and cytokines to support normal bone tissue development 
and growth. Much effort has been directed toward development of materials which 
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exhibit both ‘osteoconductive’ and ‘osteoinductive’ properties. Osteoconductive 
materials are defined as being able to support bone in-growth and bone formation. 
Ceramics such as calcium phosphate, of which HA is the most common, and 
polymers such as collagens, have been shown to be effective conductors of bone 
formation. Osteoinductive materials stimulate de novo bone growth and can be 
classified as either physical or chemical stimulators. It is well documented that 
application of appropriate physical stress on bone augments bone tissue formation. 
Therefore, biomaterials, which mimic the mechanical properties of natural bone, and 
transmit normal physiological levels of stress to cells within the graft / implant or 
surrounding bone tissue, will assist the induction of bone formation and growth. 
Materials which contain chemical stimulators of bone formation are typically 
adsorbent materials able to bind biochemical elements such as ECM proteins, protein 
growth factors, other cytokines / hormones and / or drugs. Again, various calcium 
phosphates feature prominently in this category. There remains, however, significant 
knowledge gaps including identification of appropriate protein complexes which 
result in optimal bone growth and tissue formation. Logically, potential candidate 
proteins for inducement of bone tissue growth are those present in bone tissue itself. 
These include among others the IGFs, their associated binding proteins, particularly 
IGFBP-5, transforming growth factor-β1 (TGF-β1) and ECM proteins including, but 
not limited to, type I collagen, fibronectin and VN. Members of our laboratory have 
discovered novel interactions between VN and members of the IGF / IGFBP family 
which then elicit enhanced biological responses compared to any of the components 
in isolation (Upton et al. 1999; Kricker et al. 2003; Noble et al. 2003).  In addition, 
TGF-β1, also highly expressed in bone, has been found to interact with VN 
(Schoppet et al. 2002). Together these ECM protein / growth factor complexes may 
provide a way of expanding hMSCs in culture in the absence of animal derived 
products, while coincidently being able to finely control cell phenotype and function 
through the delivery of specific signals to the cell surface.  
 
There are many studies in which MSCs and ECM proteins and / or growth factors 
have been combined with biomaterial matrices in animal models of connective tissue 
repair. These include MSC / collagen matrices for use in tendon repair (Young et al. 
1998), hMSC / gelatin sponge composites in a rabbit model of cartilage regeneration 
(Ponticiello et al. 2000) and hMSC / porus hydroxyapatite / β-tricalcium phosphate 
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ceramic composites inserted in critical-sized femoral defects in athymic rats (Bruder 
et al. 1998b). In addition, MSCs have been shown to repair femoral defects in 
Spraugue-Dawley rats when injected into the gap in a rat femoral distraction model 
(Richards et al. 1999). Taken together, these studies demonstrate that the principle of 
stem-cell seeded scaffolds for bone tissue repair and regeneration has promise. 
 
1.10 CONCLUSION 
This review has outlined some of the major growth factors present in bone tissue and 
their common relationships with VN and FN. While little is known about whether 
these molecules (the IGFs, IGFBP-5, TGF-β1, VN and FN) associate naturally in 
bone, it is apparent that these relationships could be important for ex vivo, animal 
product free culture of hMSCs for application in potential tissue engineered 
therapeutics. It is clear from the literature that there is a keen interest in the 
combined effects of TGF-β1 and IGF-I on osteoblast function, bone formation and 
bone repair processes, especially in the context of tissue engineering (Blumenfeld et 
al. 2002a; Blumenfeld et al. 2002b; Schmidmaier et al. 2003; Wong et al. 2003). 
Equally, there is emerging evidence which suggests that proteases, especially the 
MMPs, play a direct role in regulation of bone cell function, such as cell 
proliferation and differentiation, by the extra-cellular processing of various growth 
factor complexes. 
 
Through determination of the functional effects of and association between the 
above-mentioned molecules, it is my belief that more appropriate tissue culture 
methodologies can be developed that facilitate the clinical use of biomaterial / stem 
cell composite technologies for bone / connective tissue repair. Such studies will also 
help us to gain a greater understanding of the spatial relationships between growth 
factors, their binding proteins, the ECM / substrate and in vitro cultured bone cells. 
Utilising the knowledge and understanding gained so far in these convergent areas of 
study may also assist in the development of serum free culture methodologies for the 
ex vivo expansion of hMSCs for research and therapeutic purposes.   
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1.11 OUTLINE OF PROJECT 
1.11.1 Hypothesis 
The hypothesis tested by this thesis was that: 
Specific combinations of the ECM protein VN and members of the IGF family of 
growth factors, such as IGFBP-3 or 5 and IGF-I, can support cell attachment,  
migration, proliferation and / or differentiation of human osteoblast like cells (SaOS-
2) and hMSCs in culture in the absence of animal derived culture media additives. 
 
1.11.2 Aims 
Thus the specific aims of my PhD studies were to: 
1) Determine the functional effect of various combinations of VN, IGFBP-5 and 
IGF-I on SaOS-2 cell migration, attachment and proliferation in vitro. 
2) Determine the functional effect of various combinations of VN, IGFBP-3 or -
5 and IGF-I or TGF-β1 on hMSC in vitro expansion. 
3) Determine the functional effect of various combinations of FN, IGFBP-5 and 
IGF-I on SaOS-2 cell migration and proliferation in vitro. 
4) Determine the effect of selected combinations of ECM protein and growth 
factors on the expression of various osteogenic differentiation markers in 
SaOS-2 cells. 
 
 
 
 
 
 
 
 
 
 
 39 
 
 
 
 
CHAPTER 2: 
 
MATERIALS AND METHODS 
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2.1 MATERIALS 
All general reagents were of the highest laboratory grade and were purchased from 
various companies.  
 
2.1.1 Proteins 
Purified human VN was purchased from Promega Corporation (Annandale, NSW, 
Australia). Recombinant human IGFBP-5, chicken anti IGFBP-5 polyclonal 
antibody and rabbit anti chicken-HRP conjugated 2° antibodies were produced as 
described previously (Baxter et al. 2002) and purchased from Dr Sue Firth (Kolling 
Institute of Medical Research, Sydney, NSW, Australia). IGFBP-3 N109D was 
purchased from Upstate (Waltham, MA, USA) while, IGF-I was purchased from 
GroPep Ltd (Adelaide, SA, Australia). Recombinant human TGF-β1 and 
recombinant human bFGF was purchased from Chemicon Pty / Ltd (Boronia, Vic, 
Australia). Purified human FN was purchased from Sigma-Aldrich (St Louis, MO, 
USA) and recombinant human EGF was supplied by Invitrogen (Auckland, New 
Zealand). 
 
2.1.2 Tissue culture 
Tissue culture flasks and 96 well tissue culture plates were supplied by Nalge Nunc 
(Rochester, NY, USA) while 6 well tissue culture plates were supplied by Greiner 
Bio-one (Frickenhausen, Germany). Black CulturPlate™-96F tissue culture plates 
were supplied by PerkinElmer (Boston, MA, USA) and Costar® Transwells® were 
purchased from Corning COSTAR (New York, NY, USA). Dulbecco’s Modified 
Eagle Medium (DMEM), Minimal Essential Medium, Alpha formulation (αMEM), 
Hanks Balanced Salt Solution (HBSS), penicillin / streptomycin, gentamycin and 
trypsin / EDTA were purchased from Invitrogen / GIBCO (Auckland, New Zealand). 
Foetal calf serum (FCS) was purchased from ThermoTrace (Noble Park, Vic, 
Australia) or Hyclone (Logan, UT, USA). 
 
2.1.3 Experimental and general reagents 
WST-1 reagent was purchased from Roche Applied Sciences (Brisbane, QLD, 
Australia). First Strand (AMV) cDNA synthesis kit, HEPES, Agarose, Collagenase 
B, DNase, 1-4-dithiolthetol (dTT) and Tris base were supplied by Roche Diagnostics 
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(Mannheim, Germany). Cyquant™ reagent was acquired from Molecular Probes / 
Invitrogen (Eugene, OR, USA). Crystal violet powder, Sigmacote® for coating 
plastic ware involved in preparation of VN or IGFBP solutions, Dexamethasone, 
Glycerol-2-phosphate, porcine gelatin, trypan blue, paraformaldehyde, 
diethylpyrocarbonate (DEPC) and Tri-Reagent were supplied by Sigma-Aldrich (St 
Louis, MO, USA). Fraction V RIA grade bovine serum albumin were obtained from 
Sigma-Aldrich (St Louis, MO, USA) or Calbiochem (San Diego, CA, USA). L-
Ascorbic acid 2-phosphate trisodium salt was purchased from Wako chemical Ltd 
(Osaka, Japan). SYBR® green PCR master mix was purchased from Applied 
Biosystems (Warrington, UK). ECL Plus™ western blot detection system was 
supplied by Amersham Biosciences (Little Chalfont, Buckinghamshire, UK). 
Magnesium chloride, Gycerol, Triton X100, D-Glucose, potassium chloride, 
chloroform, propane-2-ol (isopropanol), methanol and ethanol were acquired from 
BDH Laboratory Supplies (Poole, UK). Pre-cast 4-20% Tris-HCl gradient gels and 
gelatin zymograms were run on gel electrophoresis equipment obtained from 
BIORAD Laboratories Pty / Ltd (Regents Park, NSW, Australia). Coomasie G250, 
TEMED and 40% acrylamide / Bis were also supplied by BIORAD Laboratories.  
Tween-20 was obtained from Research Organics (Cleveland, OH, USA) while 
phosphate buffered saline (PBS) was purchased from Oxoid (Basingstoke, 
Hampshire, England). 
 
2.2 CELLS AND CULTURE CONDITIONS 
2.2.1 SaOS-2 cells 
Human osteoblast like, SaOS-2 cells, originally isolated from a human 
osteosarcoma, were obtained from the American Type Culture Collection (Rockville, 
Maryland, USA; HTB-85). The cells were maintained in αMEM (Gibco) 
supplemented with 10% FCS (ThermoTrace or Hyclone) 50 U/mL penicillin / 
streptomycin (Gibco) and 5 µg/mL gentamycin (Gibco) (αMEM+) and were 
incubated in a humidified 5% CO2/95% air atmosphere at 37°C. Culture media was 
changed twice weekly and sub-cultivated prior to confluence. Cultures were 
discarded after 20 passages to ensure the phenotype of the cell population was 
maintained. 
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2.2.2 Human bone marrow derived mesenchymal stem cells (hMSCs)  
Bone marrow samples were collected with hospital and university ethics committee 
approvals and informed consent from both female and male patients presenting for 
total knee or hip joint replacement surgery for treatment of osteoarthritis at either 
The Prince Charles Hospital or The Holy Spirit Northside Hospital in Brisbane. 
Typically 2-5 mL of bone marrow was collected during surgery by the surgeon and 
placed into tubes containing 5 mL PBS supplemented with 200 U/mL heparin and 
placed on ice for transport to QUT. Collagenase B (0.02%) and DNase (100 U/mL) 
were occasionally employed to assist in the break up of any clots, otherwise the 
marrow suspension was repeatedly passed through a 19 gauge needle to dislodge 
clumped cells. The samples were then diluted to 30 mL with PBS, thoroughly mixed 
and passed through a 100 µm filter to remove extracellular debris and bone 
fragments. Following overlaying of 30 mL of the filtrate onto 15 mL of 
Lymphoprep™ the samples were centrifuged at 400 g for 35 min at 20°C with zero 
brake. The mononuclear cell fraction (buffy coat) was removed, placed into a fresh 
tube and with 20 mL DMEM (Gibco) supplemented with 10% FCS (ThermoTrace), 
50 U/mL penicillin/streptomycin (Gibco) and 5 µg/mL gentamycin (Gibco) 
(DMEM+), then centrifuged at 1000 rpm for 10 min. The pellet was resuspended in 1 
mL of DMEM+ (cells for culture) or serum-free DMEM (sf-DMEM) (for CFU-F 
assays) prior to counting with a haemocytometer. Cells were then seeded into tissue 
culture flasks at 1.6 x 105 cells/cm2 and incubated in a humidified 5% CO2/95% air 
atmosphere at 37°C. Culture media (DMEM+) was changed after 5 days in the first 
instance, then twice weekly thereafter. At passages 4-6 each patient’s cells were 
characterised for their multilineage (osteogenic, chondrogenic and adipogenic) 
potential by myself and / or others within our team using standard histochemical, 
bioactivity and marker expression assays relavent to each of the lineages (Yameen et 
al. 2007).  
 
2.3 PRE-BINDING OF VITRONECTIN, FIBRONECTIN, IGFBP-5 
AND IGF-I TO TISSUE CULTURE WELLS  
SaOS-2 cell attachment and proliferation were assessed on pre-bound combinations 
of vitronectin (VN) (Promega), fibronectin (FN)(Sigma-Aldrich), IGFBP-5 (Dr Sue 
Firth) and IGF-I (Gropep). Specifically, 52 µL of 1 µg/mL VN / sf-αMEM, 6 µg/mL 
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FN / sf-αMEM or sf-αMEM alone was added to each well of a 96 well tissue culture 
plate (Nalge Nunc) or a black 96F tissue culture plate (PerkinElmer) and incubated 
for 2 hr in a humidified 5% CO2/95% air atmosphere at 37°C. Following incubation, 
the ± VN / sf-αMEM solution was removed and each well was washed with 174 µL 
of freshly made 0.5% BSA / Hepes Binding Buffer (HBB) (0.1 M Hepes, 0.12 M 
NaCl, 5 mM KCl, 1.2 mM MgSO4.7H2O, 8 mM D-Glucose, pH 7.6). Wells were 
then blocked with 44 µL of freshly made 1% BSA / HBB and incubated for 30 mins 
in the above conditions, the blocking solution was then removed and each well 
washed with 174 µL 0.5% BSA / HBB and 43.5 µL of IGFBP-5 (1.6 µg/mL) in 
0.5% BSA / HBB, either alone or in combination with IGF-I (0.4 µg/mL), were 
added to wells with or without VN and incubated at 4°C overnight. 
 
2.4 PRE-BINDING OF VITRONECTIN, FIBRONECTIN, IGFBP-5 
AND IGF-I TO TRANSWELLS™ 
SaOS-2 cell migration was assessed on pre-bound combinations of VN or FN, 
IGFBP-5 and IGF-I. Specifically, 1 mL of 1 µg/mL VN / sf-αMEM, 6 µg/mL FN / 
sf-αMEM or sf-αMEM alone was added to the lower chamber of each well of 12 
well Transwell™ tissue culture plates (Costar) and incubated for 4 hr in a humidified 
5% CO2/95% air atmosphere at 37°C. Following incubation, the ± VN or FN / sf-
αMEM solutions were removed and each well was washed twice with 1 mL of 
freshly made 0.5% BSA / HBB. Subsequently, duplicate 0.5 mL aliquots of IGFBP-
5 (0.1 µg/mL) in 0.05% BSA / HBB /sf-αMEM together with either 0.5 mL IGF-I 
(0.025 µg/mL) in 0.05% BSA / HBB / sf-αMEM or 0.5 ml  of 0.05% BSA / HBB / 
sf-αMEM was added to wells with or without VN and incubated at 4°C overnight. 
Following incubation (during cell preparation), the growth factor solutions were 
aspirated and the lower chambers washed twice with 1 mL 0.05% BSA / HBB / sf-
αMEM followed by the addition of 1 mL 0.05% BSA / HBB / sf-αMEM to the 
lower chamber of each Transwell™ and returned to the incubator until required. 
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2.5 PREPARATION OF SOLUTION PHASE VN AND GROWTH 
FACTORS FOR hMSC STUDIES. 
hMSC cell metabolic activity and change in total protein were assessed in the 
presence of solution phase combinations of VN, IGFBP-3 or -5 and IGF-I or TGF-
β1. Specifically, 52 µL of 1 µg/mL (52 ng/well) or 3.346 µg/mL (174 ng/well) VN / 
serum-free-DMEM (sf-DMEM) solution or sf-DMEM alone was added to each well 
of 96 well tissue culture plates (Nalge Nunc) and incubated for 2 hr in a humidified 
5% CO2/95% air atmosphere at 37°C. Following incubation, 43.5 µL of 0.16 µg/mL 
(7 ng/well) TGF-β1 or 1.6 µg/mL (70 ng/well) IGFBP-3 or -5 in 0.5% BSA / sf-
DMEM either alone or in combination with 0.4 µg/mL (17.4 ng/well) IGF-I were 
added to wells with or without VN and incubated at 4°C overnight. Plates were then 
allowed to return to room temperature prior to seeding of cells. Final concentrations 
of added proteins following seeding of cells (final volume of 195.5 µL) were 0.266 
µg/mL (3.55 nM) or 0.890 µg/mL (11.9 nM) (VN), 0.358 µg/mL (11.9 nM) 
(IGFBPs), 89 ng/mL (11.9 nM) (IGF-I) and 36 ng/mL (1.43 nM) (TGF-β1).  
 
2.6 MIGRATION ASSAYS 
SaOS-2 cell migration through the microporus membranes of 12 µm pore 
Transwells™ was measured using a modified version of the Transwell™ migration 
assay described previously by (Leavesley et al. 1992; Leavesley et al. 1993). Briefly, 
sub-confluent cultures of SaOS-2 cells were passaged 1:1 the day prior to assay and 
incubated over night in a humidified 5% CO2/95% air atmosphere at 37°C.  Cultures 
were then washed once with HBSS for 5 min and serum starved for 4 hr in sf-
αMEM to minimise the influence of residual serum proteins in the assay without 
adversely affecting cell viability. Cells were then washed again with HBSS and 
harvested with 1 mL of 0.05% trypsin / EDTA solution. The cells were suspended in 
sf-αMEM, centrifuged; the pellet resuspended in fresh 0.05% BSA / HBB / sf-
αMEM and the cells were counted prior to dilution to 5 x 105 cells/mL. Previously 
prepared Transwell™ plates were removed from the incubator and the upper 
chamber of each Transwell™ were seeded with 2 x 105 cells and were then allowed 
to incubate for 5 hr in a humidified 5% CO2/95% air atmosphere at 37°C. Cells 
seeded into wells without VN were employed as controls. Following incubation, the 
Transwell™ plates were placed on ice to reduce further migration. Transwell™ 
 45 
inserts were individually removed from the plates and un-migrated cells removed 
from the upper surface of the insert by cleaning with a cotton bud for approximately 
1.5 min/insert as previously described by (Leavesley et al. 1993) and J. Kricker 
(Kricker 2005). Migrated cells were then fixed by immersing the membranes in 
formaldehyde for 20 min and subsequently stained by immersing the membranes in 
crystal violet for 20 min. Inserts were then immersed in a beaker of circulating tap 
water to remove the excess stain and were allowed to air dry prior to extraction of 
crystal violet in 1 mL of 10% acetic acid. Duplicate 100 µL sub-samples were then 
transferred to individual wells of a 96 well microtitre plate and the absorbance read 
in a BioRad Bench Mark Plus microplate reader (BIORAD Laboratories Pty / Ltd 
(Regents Park, NSW, Australia) at 595 nm. Results are expressed as the absorbance 
as a percentage above the VN only control ± the standard error of the means (SEM).  
 
2.7 ATTACHMENT ASSAY 
SaOS-2 cell attachment was measured in cultures grown for 3 hr on each treatment 
by spectrophotometric detection of the cleavage product (Formazan) of the 
tetrazolium salt (4-[3-(4-Iodophenyl)-2-(4nitrophenyl)-2H-5-tetrazolio]1,3-benzene 
disulfonate) (WST-1) (Roche Diagnostics).  Briefly, sub-confluent cultures of SaOS-
2 cells were washed twice with Hanks Balanced Salt Solution (HBSS) (Gibco) for 5 
min and serum starved for 4 hr in sf-αMEM. Cells were then washed again with 
HBSS and harvested with 1 mL of 0.05% trypsin / EDTA solution. The cells were 
suspended in sf-αMEM, centrifuged, the pellet resuspended in fresh sf-αMEM and 
cells counted prior to dilution to 5 x 104 cells/mL.  Each well received 5 x 103 cells 
suspended in 100 µL of sf-αMEM and were allowed to incubate for 3 hr in a 
humidified 5% CO2/95% air atmosphere at 37°C. Cells seeded into wells without 
VN, or cells seeded in normal growth media containing 10% FCS, were employed as 
controls. Following incubation, the media was removed and each well was washed 
once with sf-αMEM prior to addition of 110 µL of 1:10 dilution of WST-1: sf-
αMEM to each well, and incubated for a further 2 hr in a humidified 5% CO2/95% 
air atmosphere at 37°C. Following incubation the plates were placed in a Beckman 
microplate reader (Beckman, Inc. Fullerton, USA) and the absorbance of the 
formazan dye cleavage product quantitated at 450 nm using 650 nm as reference. 
Results are from 3 separate experiments with treatments performed in at least 
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triplicate per experiment and are expressed as the corrected absorbance at 450 nm - 
650 nm as a percentage of the +VN control ± standard error of the means (SEM). 
 
2.8 CyQUANT® CELL PROLIFERATION ASSAY 
SaOS-2 cell number was measured in cultures grown for 24 hr, 48 hr or 72 hr on 
each treatment by fluorescent detection of cellular nucleic acids using CyQUANT® 
GR nucleic acid binding dye (Molecular Probes). Briefly, sub-confluent cultures of 
SaOS-2 cells were washed twice with HBSS (Gibco) for 5 min and serum starved for 
4 hr in sf-αMEM. The cells were then washed with HBSS and harvested with 1 mL 
of 0.05% trypsin / EDTA solution. The cells were suspended in sf-αMEM, 
centrifuged at 1000 rpm for 6 min, the pellet resuspended in fresh sf-αMEM and the 
cells counted prior to dilution to 5 x 104 cells/mL. Each well of the pre-prepared 
black 96F plates (as detailed above) received 5 x 103 cells suspended in 100 µL of 
sf-αMEM and were allowed to incubate for 24 hr, 48 hr or 72 hr in a humidified 5% 
CO2/95% air atmosphere at 37°C. Cells seeded into wells without VN or FN, or cells 
seeded in normal growth media containing 10% FCS, were employed as controls. 
For the purposes of constructing a cell number standard curve, 1 x 106 cells were 
added to a conical tube, centrifuged at 1000 rpm for 6 min, the supernatant was 
removed and the pellet stored at -80°C until required for analysis. Following 
incubation, the spent media was removed from each well and the plates were 
wrapped in parafilm and stored at -80°C until analysis with CyQUANT® GR dye. 
On the day of analysis fresh CyQUANT® GR reagent was prepared as per the 
manufacturers instructions. Briefly, a 1X CyQUANT® GR working solution was 
prepared in foil-covered 50 mL polypropylene conical tubes by addition of ddH2O, 
kit component B (20X concentrated lysis buffer) and kit component A (400X 
CyQUANT® GR stock solution) and thorough mixing. A cell number standard curve 
was prepared by firstly adding 1 mL of  CyQUANT® GR working solution to the 
pellet of cells kept from the time of seeding of the assay, followed by breaking of the 
cell pellet and cells by trituration and vortexing. The resulting suspension thus 
represented the total nucleic acid content of 1 x 106 cells. Serial dilutions made to 
correspond to cell numbers ranging from 50 cells to 50,000 cells in 200 µL volumes 
were added in triplicate to a black 96F microtitre plate. CyQUANT® GR working 
solution alone served as a “0 cells” control. Each treatment well of the black 96F 
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plates received 200 µL of CyQUANT® GR working solution and was incubated for 
~ 15 min, (protected from light) prior to measurement of the sample fluorescence at 
480 nm excitation and 520 nm emission using a POLARstar OPTIMA fluorescence 
micro-plate reader (BMG Labtech, Offenburg, Germany). The raw data were 
corrected with plate blanks (CyQUANT® GR working solution alone), converted to 
cell number and the results expressed as the mean cell number ± SEM. Data were 
pooled from at least triplicate samples and the experiments were repeated at least 3 
times.  
 
2.9 METABOLIC ACTIVITY ASSAY 
SaOS-2 or hMSC metabolic activity was measured in cultures grown for 48 hr 
(SaOS-2) or 24 hr, 48 hr and 72 hr (hMSCs) on each treatment by 
spectrophotometric detection of the cleavage product (Formazan) of the tetrazolium 
salt WST-1 (Roche Diagnostics). Briefly, sub-confluent cultures of SaOS-2 cells 
were washed twice with HBSS (Gibco) for 5 min and serum starved for 4 hr in sf-
αMEM. SaOS-2 cells or hMSCs were then washed with HBSS and harvested with 1 
mL of 0.05% trypsin / EDTA solution. The cells were suspended in sf-αMEM 
(SaOS-2 cells) or sf-DMEM (hMSCs), centrifuged, the pellet resuspended in fresh 
sf-media and cells counted prior to dilution to 5 x 104 cells/mL. Each well received 5 
x 103 cells suspended in 100 µL of respective sf-media and were allowed to incubate 
for 48 hr (SaOS-2) or 24 hr, 48 hr or 72 hr (hMSCs) in a humidified 5% CO2/95% 
air atmosphere at 37°C. Cells seeded into wells without VN, or cells seeded in 
normal growth media containing 10% FCS, were employed as controls. Following 
incubation, 10 µL of WST-1 reagent was added to each well (SaOS-2 cells) or the 
media was removed and 110 µL of 1:10 dilution of WST-1:sf-DMEM was added to 
each well (hMSCs), and incubated for a further 2 hr in a humidified 5% CO2/95% air 
atmosphere at 37°C. Following incubation the plates were placed in a BioRad Bench 
Mark Plus microplate reader (BIORAD Laboratories Pty / Ltd (Regents Park, NSW, 
Australia) and the absorbance of the formazan dye cleavage product quantitated at 
450 nm using 650 nm as reference. Results are from 3 (SaOS-2 cells) or 4 (hMSCs) 
separate experiments performed in at least triplicate and are expressed as the 
corrected absorbance at 450 nm - 650 nm as a percentage of the +VN control (SaOS-
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2 cells) or as a percentage of the 24 hr –VN control ± standard error of the means 
(SEM). 
 
2.10 COLONY FORMING UNIT-FIBROBLASTIC ASSAY 
Plate preparation for colony forming unit fibroblastic assay included pre-binding of 
VN and growth factors similar to that described in section 2.3 or leaving the growth 
factors in solution. The colony forming unit assays were performed in 6 well plates 
(Costar). While the growth factor concentrations were kept the same as described in 
section 2.3 the VN concentration was increased. Specifically, 1.4 mL of 4 µg/mL 
(5.6 µg/well) VN / sf-DMEM solution was added to each well of a 6 well tissue 
culture plate and incubated for 2.5 hr in a humidified 5% CO2/95% air atmosphere at 
37°C. Following incubation the VN solution was removed and 1.4 mL of 0.16 
µg/mL (224 ng/well) TGF-β1 or 1.6 µg/mL (2.24 µg/well) IGFBP-3 or -5 in 0.5% 
BSA / HBB either alone or in combination with 0.4 µg/mL (560 ng/well) IGF-I were 
added to wells with VN and incubated at 4°C overnight. Growth factor solutions 
were then removed prior to seeding of freshly harvested bone marrow mononuclear 
cells at a density of 1.6 x 105 cells/cm2 in a final volume of 3 mL/well (3.4 mL/well 
solution phase studies). For solution phase studies the VN was allowed to pre-bind as 
described above, however, the growth factors were left in solution upon seeding of 
cells. Therefore the final growth factor concentrations for the solution phase studies 
were 0.066 µg/mL (2.6 nM) TGF-β1 or 0.659 µg/mL (22 nM) IGFBP-3 or -5 either 
alone or in combination with 0.164 µg/mL (22 nM) IGF-I. hMSCs exposed to un-
treated wells or to 10% FCS served as controls. Cells were allowed to attach and 
grow for up to 7 days during which each culture was observed using a Nikon TS100 
inverted phase contrast microscope (NIKON, Tokyo, Japan) and digital photographic 
images taken on days 1, 3 or 4 and day 7 using a microscope mounted NIKON 
COOLPIX 4500 digital camera (NIKON).     
 
2.11 TOTAL PROTEIN ASSAY 
hMSCs were harvested by trypsin digestion prior to seeding of 5000 cells/well into 
96 well plates containing various combinations of VN, IGFBP-5 and IGF-I in 
solution as detailed in section 2.5. Briefly, sub-confluent cultures of hMSCs were 
washed twice with HBSS and harvested with 1 mL of 0.05% trypsin / EDTA 
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solution. The cells were suspended in sf-DMEM, centrifuged at 1000 rpm for 6 min 
and the pellet resuspended in fresh sf-DMEM prior to performing cell counts using a 
haemocytometer and trypan blue and subsequent dilution to 5 x 104 cells/mL. Each 
well received 5x103 cells suspended in 100 µL of sf-DMEM and was allowed to 
incubate for 24 hr, 48 hr or 72 hr in a humidified 5% CO2/95% air atmosphere at 
37°C. Conditioned media was then removed for protease activity analysis (see 
section 2.13 & 2.14) and monolayers were fixed by addition of 50 µL of 4% 
paraformaldehyde solution to each well and incubated for 20 min at room 
temperature. The fixative was removed prior to the addition of 50 µL of freshly pre-
pared crystal violet and incubated at room temperature for a further 20 min. The 
crystal violet was then removed and the plates immersed in a beaker of gently 
circulating tap water until the stain had visibly ceased washing from wells. Plates 
were allowed to air dry overnight, after which the bound crystal violet stain was 
solubilised with 100 µL of 10% acetic acid per well and mixed by gentle vibration. 
Each plate was placed in a BioRad Bench Mark Plus microplate reader (BIORAD 
Laboratories Pty / Ltd (Regents Park, NSW, Australia) and the absorbance readings 
taken at 595 nm. Results are from 4 separate experiments performed in at least 
triplicate and are expressed as the corrected absorbance at 595 nm as a percentage of 
the 24 hr -VN control ± standard error of the means (SEM). 
 
2.12 MORPHOLOGICAL ANALYSIS  
Where stated digital photographic images depicting culture morphology were taken 
at X100 or X200 magnification using a NIKON TS100 inverted, phase contrast 
microscope (NIKON, Tokyo, Japan) and a microscope mounted NIKON COOLPIX 
4500 digital camera (NIKON). Scale was determined using a stage micrometre 
(PYSER-SGI, Edenbridge, Kent, UK). 
 
2.13 GELATIN ZYMOGRAPHY 
Conditioned media was removed from representative wells from the total protein 
assays (section 2.11) immediately prior to fixing of cells with paraformaldehyde and 
were stored at -20°C until required for analysis. Samples were then analysed for 
MMP-2 and MMP-9 gelatinolytic activity. Briefly, 4 µL of 5X loading buffer 
(0.05% bromophenol blue, 50% glycerol, 10% SDS, 0.5 M Tris base, pH6.8) was 
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added to 16 µL of conditioned media samples and the samples were loaded onto 
freshly prepared 4% stacking / 10% resolving polyacrylamide gels containing 1 
mg/mL gelatin and subjected to electrophoresis in Tris-glycine running buffer (25 
mM Tris base, 246 mM glycine, 0.1% SDS, pH 6.8) under non-reducing conditions 
at 200 volts and 4°C until the dye front had just run off the gel. The gels were then 
washed in 2.5% Triton-X100 for 30 min and then again for 60 min to remove SDS 
and incubated in incubation buffer (50mM Tris base, 10mM CaCl2, 50mM NaCl, pH 
7.6) for 48 hr at 37°C. The gels were stained with 0.25% Coomasie Blue (4.5:4.5:1 –
water: methanol: acetic acid) and subsequently destained with 10% acetic acid and 
40% methanol (vol / vol). Gelatinase activity was visualised by the presence of clear 
bands and discriminated according to molecular weight and comparison to pro-
MMP-2 and pro-MMP-9 standards (Chemicon). 
 
2.14 IGFBP-5 DEGRADATION ASSAY 
The conditioned media from hMSCs cultured in sf-DMEM alone was collected and 
stored as above (section 2.11) prior to testing for the ability to degrade IGFBP-5. 
Briefly, 20 µL samples of phosphate buffered saline, sf-DMEM or hMSC 
conditioned media were mixed with 2 µL of 200 ng/µL IGFBP-5 (400 ng) (Dr Sue 
Firth, Kolling Institute of Medical Research) or vehicle and were incubated 
overnight at 37°C. Samples were pulsed centrifuged followed by the addition of 5 
µL of 50 mM 1-4-dithiolthetol (dTT) to 20 µL of each sample and were 
subsequently heated at 95°C for 15 min. Samples were then pulse centrifuged and 12 
µL of each sample was subsequently run on a 4%-20% gradient polyacrylamide gel 
(BIORAD) in Tris-glycine buffer (25 mM Tris base, 200 mM glycine, 0.1% SDS, 
pH 8.3) at 100 volts for 1 hr at 4°C. Proteins were then transferred to a BioTrace® 
NT nitrocellulose membrane (Pall Corporation, Pensacola, FL, USA) in transfer 
buffer composed of 25 mM Tris base, 40 mM Glycine, 10% methanol.  The 
nitrocellulose membrane was subsequently blocked with 3%BSA (w / v) in TBST 
(10 mM Tris base, 140 mM NaCl, 1% Tween 20) for ~2 hr and was then washed in 
TBST for 30 min, with the buffer replaced every 5 min. The bound proteins were 
then interrogated with a 1:1000 dilution of a chicken anti IGFBP-5 polyclonal 
antibody (Dr Sue Firth) in 0.3% BSA / TBST at 4°C over night. The membrane was 
then washed for 30 min, with the buffer replaced every 5 min and subsequent 1° 
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antibody detection with a 1:10,000 dilution of a rabbit anti chicken-HRP conjugated 
2° antibody (Dr Sue Firth) in 0.3% BSA / TBST at room temperature for 40-45 min. 
The membrane was washed in TBST for 30 min with the buffer replaced every 5 min 
prior to the detection of the 2° antibody by incubation of the membrane for 2 min in 
2 mL of chemiluminescent substrate prepared as per manufacturers instructions 
(ECL Plus Western Blot detection kit)(Amersham). Chemiluminescence was then 
captured by brief exposure of the membrane to x-ray film (Agfa) and subsequently 
developed using an Agfa automated film developer CP-1000 (Mortsel, Belgium).  
 
2.15 SOLUTION PHASE CULTURE OF SAOS-2 CELLS 
Solutions of VN / sf-αMEM (1 µg/mL) or FN / sf-αMEM (6 µg/mL) or VN / FN / 
sf-αMEM (1 µg/mL and 6 µg/mL for VN and FN respectively) were added to 
individual wells of a 6 well tissue culture plate (Greiner) together with either EGF (5 
ng/mL) or bFGF (5 ng/mL). SaOS-2 cells were harvested as detailed below (section 
2.16) prior to addition of 1.44 x 105 cells/well and incubation in a humidified 5% 
CO2/95% air atmosphere at 37°C. Media was changed twice weekly using protein 
concentrations detailed above. Digital images were captured at various time points 
throughout the culture period as indicated in the figures and detailed in section 2.12.    
 
2.16 DIFFERENTIATION ASSAY CULTURES 
SaOS-2 cell osteoblast marker expression was assessed on the following pre-bound 
combinations of proteins: VN alone; VN / IGFBP-5 / IGF-I; VN / TGF-β1 and VN / 
FN / EGF. Specifically, 1.5 mL of a 13.3 nM solution of VN / sf-αMEM (1 µg/mL) 
or FN / sf-αMEM (6 µg/mL) or VN / FN / sf-αMEM (1 µg/mL / 6 µg/mL) were 
added to individual wells of a 6 well tissue culture plate (Greiner) and incubated for 
2 hr in a humidified 5% CO2/95% air atmosphere at 37°C. Following incubation, VN 
± FN sf-αMEM solutions were removed and each well was washed with 1.5 mL of 
freshly made 0.5% BSA / HBB. Wells were then blocked with 1.26 mL of freshly 
made 1% BSA / HBB and incubated for 30 mins in the above conditions after which, 
the blocking solution was removed and each well washed again with 1.5 mL 0.5% 
BSA / HBB. Specific wells then received 1.263 mL of sf-αMEM with either 5.34 
nM IGFBP-5 / IGF-I (160 ng/mL / 40 ng/mL for IGFBP-5 and IGF-I respectively), 
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4.61 nM TGF-β1 (115.2 ng/mL) or 17.7 nM EGF (115.2 ng/mL) or sf-αMEM alone. 
Plates were then sealed with parafilm and incubated at 4°C overnight. Growth factor 
solutions were then aspirated and each well then washed with 1.5 mL sf-αMEM 
prior to the addition of 1.5 mL of sf-αMEM to treatment wells, 10% FCS or 
osteogenic supplemented media (+OS media) (100 nM Dexamethasone, 50 µM 
Ascorbic acid-2-phosphate, 10 mM β-glycerophosphate, sf-αMEM) to control wells. 
Sub-confluent cultures of SaOS-2 cells were washed twice with HBSS prior to 
harvest by Trysin / EDTA digestion and re-suspension in sf-αMEM. Cells were 
counted and seeded at 5 x 105 cells per well in a total volume of 3 mL. Plates were 
incubated in a humidified 5% CO2/95% air atmosphere at 37°C for 48 hr or for 7 
days (with 1 media change for the 7 day experiment on day 4 using the same growth 
factor concentrations as described above). Digital photographs were taken to assess 
culture morphology prior to RNA extraction or on other days as stated. 
 
2.17 REALTIME PCR ANALYSIS 
Real time PCR analysis was performed to determine if VN alone, VN / IGFBP-5 / 
IGF-I, VN / TGF-β1 or VN / FN / EGF could induce osteoblast marker expression in 
SaOS-2 cells. The spent media from differentiation assay cultures at either 48 hr or 7 
days was aspirated and the remaining cell monolayer harvested using a rubber cell 
scraper and 1 mL per well of Tri-Reagent (Sigma-Aldrich). The cell suspension was 
then transferred to sterile 2 mL eppendorf tubes, immediately placed on ice and 
subsequently stored at -80°C until required for RNA extraction. RNA extraction was 
performed as per the Tri-Reagent RNA extraction protocol (Sigma-Aldrich). Briefly, 
following thawing to room temperature, 0.2 mL of chloroform was added to each 
sample followed by gentle shaking for 15-20 sec. Samples were then allowed to 
stand at room temperature for 10 min and subsequently centrifuged at 12,000 x g for 
15 minutes at 4°C. The colourless upper aqueous phase was carefully transferred to 
individual fresh 2 mL eppendorf tubes followed by addition of 0.5 mL of 100% 
isopropanol and gentle mixing. Samples were then allowed to stand at room 
temperature for 10 min prior to further centrifugation at 12,000 x g for 10 min at 
4°C. The supernatant was carefully removed and the RNA pellets washed with 1 mL 
75% ethanol followed by gentle mixing and centrifugation at 7500 x g for 5 min at 
4°C. The supernatant was removed and the pellets were allowed to air dry to remove 
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excess ethanol. Each pellet was resuspended in 20 µL of diethylpyrocarbonate 
(DEPC) treated ddH20, then transferred to fresh 0.5 mL eppendorf tubes and 
immediately placed on ice. RNA integrity was ascertained by subjecting 1 µL of 
each sample, together with 9 µL ddH20 and 2 µL loading dye, to gel electrophoresis 
through a 1.5% agarose gel containing 0.01% ethidium bromide. Gels were run for 
~25 min at 106 volts in TBE buffer prior to image capture in a Syngene UV 
transilluminator cabinet using GeneSnap image software. RNA concentration and 
quality of each sample was determined by subjecting 2 µL of total RNA and 78 µL 
of TE buffer to UV spectrophotometry using a GeneQuant II UV spectrophotometer 
(Pharmacia Biotech, Cambridge, UK). RNA samples were subsequently stored at -
80°C until required for cDNA synthesis.  
 
cDNA synthesis was performed on each total RNA sample using a First Strand 
cDNA synthesis kit (AMV) according to manufacturers instructions (Roche). 
Briefly, 0.5 µg of total RNA was added to a reaction mixture containing 10 mM Tris, 
50 mM KCl, 5 mM MgCL2, 1 mM dNTPs (dATPs, dCTPs, dTTPs, dGTPs 1 mM 
each), 2.0 µL (3.2 µg) random hexamers, 1.0 µL (50 units) RNase inhibitor, 0.8 µL 
(≥ 20 units) AMV reverse transcriptase and ddH20 to a final volume of 20 µL in 0.2 
mL PCR tubes. Each cDNA synthesis reaction tube was gently mixed, pulse 
centrifuged and incubated in a PTC-200 Peltier Thermal Cycler (MJ Research, 
Watertown, MA, USA) at 25°C for 10 min, 42°C for 60 min, 99°C for 5 min and 
finally 4°C overnight. The cDNA samples were then stored at -80°C until required 
for real time-PCR analysis. Real time-PCR was carried out using an ABI Prism® 
7000 real time-PCR machine (Applied Biosystems, Foster City, CA, USA) and 
Axygen PCR microplates (Axygen Scientific, Union City, CA, USA) were utilised 
for sample reactions. Immediately prior to real time-PCR analysis each cDNA 
sample was diluted 1:5 with TE buffer. Two µL of diluted cDNA template was then 
added in triplicate to individual PCR reaction mixtures containing 10 µL of SYBR® 
green PCR master mix (Applied Biosystems), 5 pM of forward primer, 5 pM of 
reverse primer and ddH20 to a final volume of 20 µL per well. The loaded PCR 
microplates were pulse centrifuged, placed into the ABI Prism 7000 real time-PCR 
machine and subjected to the following cycle protocol: 50°C for 2 min, 95.0°C for 
10 min then 40 cycles of 95.0°C for 15 sec and 60.0°C for 1 min followed by a 
dissociation stage of 95.0°C for 15 sec, 60°C for 20 sec and 95°C for 15 sec. Raw 
 54 
data was exported to Microsoft Excel, transformed and analysed using the 2-∆∆CT 
method according to User Bulletin # 2 for ABI Prism® 7000 Sequence Detection 
System and Livak and Schmittgen (Livak and Schmittgen 2001). cDNA prepared as 
above from cells just prior to seeding (un-seeded cells) was utilised as a time 0 
control to which all treatments were compared. The raw data was normalised against 
the expression of 18s ribosomal RNA expression levels and the results are expressed 
as mean fold change compared to the time 0 (un-seeded) cell control ± SD from 
triplicate PCR reactions for each of 3 separate differentiation experiments. PCR 
primer sequences targeting the osteoblast marker genes transcript cDNA for core 
binding factor-1 (cbfa-1), alkaline phosphatase (ALP) and type 1 collagen (COL-1) 
are presented in table 2.1. (Sequences for cbfa-1 were kindly shared by Shea Carter, 
ALP and COL-1 primers were kindly donated by Anna Coussens and 18s sequences 
were kindly shared by Dr Steven Myers).  
 
Table 2.1 Real time-PCR Primer Sequences 
Target  Primer Sequence 
cbfa -1 
Forward  5′-TGATGACACTGCCACCTCTGA-3′ 
Reverse  5′-AAAGGTGGCTGGATAGTGCAT-3′ 
ALP 
Forward  5′-CGTGGCTAAGAATGTCATCATGTT-3′ 
Reverse  5′-TGGTGGAGCTGACCCTTGA-3′ 
COL-1 
Forward  5′-CGAAGACATCCCACCAATCAC-3′ 
Reverse  5′-TTGTCGCAGACGCAGATCC-3′ 
18s 
Forward  5′-TTCGGAACTGAGGCCATGAT-3′ 
Reverse  5′-CGAACCTCCGACTTTCGTTC-3′ 
 
2.18 STATISTICAL ANALYSIS 
Results are expressed as the pooled means as a percentage of either the negative 
control or of VN alone as indicated ± the standard error of the means (SEM). In 
some instances the results are expressed as the pooled means of cell number ± SEM 
as indicated. Differences between groups were analysed by post-hoc t-test generally 
or post-hoc Dunnet’s test for the attachment assay in Chapter 3, and significance was 
accepted at p<0.05. Experiments were repeated at least 3 times unless otherwise 
stated in the experimental procedures section of each results chapter. 
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CHAPTER 3: 
 
EFFECTS OF PRE-BOUND VITRONECTIN, 
IGFBP-5 AND IGF-I ON OSTEOBLAST 
LIKE SAOS-2 CELL MIGRATION, 
ATTACHMENT, METABOLIC ACTIVITY 
AND PROLIFERATION 
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3.1 INTRODUCTION 
The IGFs (IGF-I and IGF-II) are 2 of the most abundant growth factors present in the 
bone matrix (Mohan and Baylink 1996). Osteoblasts (cells which lay down new 
bone matrix) are known to express large quantities of the IGFs (Canalis et al. 1988) 
which they secrete along with IGF binding proteins (IGFBPs), including IGFBP-5 
(Andress and Birnbaum 1992). IGFBP-5 is thought to be responsible for securing the 
IGFs within the bone matrix due to its ECM and hydroxyapatite (the mineral 
component of bone tissue) binding capabilities (Bautista et al. 1991). IGFBP-5 has 
also been shown to bind to a wide range of ECM proteins such as type III and IV 
collagens, laminin (Jones et al. 1993), osteopontin, thrombospondin (Nam et al. 
2000), fibronectin (Jones et al. 1993; Xu et al. 2004) and importantly, vitronectin 
(Nam et al. 2002; Kricker et al. 2003). IGF-I is known to have stimulatory effects on 
osteoblast proliferation both in vivo and in vitro (Andress and Birnbaum 1992). 
Similarly IGFBP-5 has been associated with the stimulation of cell proliferation in 
general (Andress and Birnbaum 1992; Miyakoshi et al. 2001; Schneider et al. 2002). 
However, IGF-I has also been associated with the progression of osteoblast 
differentiation processes (Jia and Heersche 2000). This is of interest because 
generally when pre-osteoblast cultures begin to differentiate the rate of proliferation 
decreases (Stein and Lian 1993). This suggests that IGF-I may not have a role in 
initiating these processes but rather, may act as a driving mechanism for 
differentiation.    
 
VN, is a 75 kDa, multifunctional glycoprotein found in blood plasma and in the 
ECM (Bale et al. 1989; Seiffert 1996; Seiffert et al. 1996a; Seiffert et al. 1996b; 
Seiffert and Schleef 1996; Schvartz et al. 1999). VN is synthesised by osteoblasts 
during bone development and remodelling and is a significant component of non 
collagenous bone ECM (Seiffert 1996; Kumagai et al. 1998; Schvartz et al. 1999). 
VN is thought to play a role in facilitating cellular processes during bone 
remodelling and was recently found to influence osteoblastic differentiation 
(Salasznyk et al. 2004). VN contains an RGD sequence which enables integrin-
binding (Felding-Habermann and Cheresh 1993; Schvartz et al. 1999), and both 
osteoblasts and osteoclasts express αvβ3 integrins which facilitate cell attachment to 
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various ECM proteins including VN (Pytela et al. 1985; Koistinen et al. 1999; 
Cheng et al. 2001; Kilpadi et al. 2004; Lai and Cheng 2005).  
 
In 1999, Upton et al. reported that insulin like growth factor II was able to bind 
directly to VN, but also found that IGF-I could not bind directly to VN (Upton et al. 
1999). IGFBP-5 has since been found to bind to VN with high affinity and via this 
interaction was able to modulate IGF-I actions in vitro (Nam et al. 2002; Kricker et 
al. 2003). In particular, IGF-I mediated migration and DNA synthesis in porcine 
aortic smooth muscle cells is modulated (Nam et al. 2002). It has also been 
demonstrated that pre-bound combinations of VN, IGFBP-5 and IGF-I can facilitate 
protein synthesis and migration in both a human keratinocyte cell line (HaCAT) and 
primary human keratinocytes, as well as enhance migration in MCF-7 breast cancer 
cells (Kricker et al. 2003; Noble et al. 2003; Hyde et al. 2004; Hollier et al. 2005).  
 
The functional responses that have been observed in epithelial tissue types in 
response to pre-bound combinations of VN, IGFBP-5 and IGF-I, along with the 
prevalence of these factors in bone tissue, and the important role they play in 
osteoblast function, suggested that these factors may mediate similar responses in 
mesenchymal type cells such as osteoblasts. Furthermore, many modern strategies 
for the development of advanced connective tissue therapeutics are focusing on 
implantable constructs consisting of a biomaterial scaffold, incorporating some form 
of ECM with incorporated growth factors and/or ex vivo expanded undifferentiated 
cells (Goshima et al. 1991; Dennis and Caplan 1993; Wakitani et al. 1995; Bruder et 
al. 1997; Jaiswal et al. 1997; Bruder et al. 1998a; Bruder et al. 1998b; Caplan et al. 
1998; Johnstone et al. 1998; Pittenger 1999; Noshi et al. 2000; Caplan and Bruder 
2001; Shimaoka et al. 2004). This approach is designed to deliver a large number of 
precursor cells, which subsequently differentiate into appropriate tissue types 
through interactions with both the accompanying scaffold / ECM and the 
surrounding host tissue.  
 
Based on the previous findings within our research team, and the growing interest in 
ECM/growth factor complexes for use in bone tissue therapeutics, I decided to 
investigate the efficacy of combinations of VN, IGFBP-5 and IGF-I as a pre-bound 
stimulus for bone cell function. In particular, these studies focussed on exploring the 
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hypothesis that pre-bound combinations of VN, IGFBP-5, and IGF-I would mediate 
migration, attachment and proliferation responses in osteoblasts. In order to test this 
hypothesis the osteoblast-like cell line SaOS-2 was selected as they have been 
extensively characterised in the literature (Murray et al. 1987; Rodan et al. 1987; 
Fedde et al. 1988; Farley et al. 1991; Mayr-Wohlfart et al. 2001; Schmid et al. 2001; 
Kilpadi et al. 2004; Pautke et al. 2004), they are responsive to IGF-I (Schmid et al. 
1999; Schmid et al. 2001) and attach to VN (Degasne 1999; Kilpadi et al. 2004). In 
addition, they have been widely used for investigations involving the IGF system 
and interactions with various ECM proteins (Mohan et al. 1993; Kudo et al. 1996; 
Kudo et al. 1997; Degasne 1999; Schmid et al. 1999; Bostedt et al. 2001; Schmid et 
al. 2001; Kilpadi et al. 2004). The following experiments were designed to assess 
SaOS-2 osteoblast function, namely: 1) cell migration; 2) cell attachment; 3) cellular 
metabolic activity; and 4) cell proliferation in response to various pre-bound 
combinations of VN, IGFBP-5 and IGF-I.    
 
3.2 EXPERIMENTAL PROCEDURES 
Full details of both the materials and methods used in the generation of the data 
presented in this chapter are described in chapter 2. The following are brief 
summaries of the materials and experimental procedures used for the generation of 
data presented in section 3.3.  
 
3.2.1 Materials 
Purified human VN was purchased from Promega Corporation. IGFBP-5 was 
produced as described previously by Firth et al. (1999) and purchased from Dr Sue 
Firth, while IGF-I was purchased from GroPep Ltd. Costar® Transwells® were 
purchased from Corning Corporation. WST-1 reagent was purchased from Roche 
Applied Science. Cyquant™ reagent was purchased from Molecular Probes. 
Standard 96 well tissue culture plates were supplied by Nalge Nunc. Black 96F 
tissue culture plates were supplied by Perkin Elmer, while fraction V RIA grade 
Bovine serum albumin was supplied by Sigma or Calbiochem. Sigmacote® for 
coating of plastic-ware used in the preparation of VN or IGFBP-5 solutions and 
crystal violet powder for use in migration assays was purchased from Sigma. 
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3.2.2 Pre-binding of proteins 
For full details of this method please refer to section 2.3 and 2.4. SaOS-2 cell 
migration was assessed on pre-bound combinations of VN, IGFBP-5 and IGF-I. 
Briefly, the underside of Transwell™ tissue culture plate inserts (Costar) were 
coated with 1 mL of 6 µg/mL VN / sf-αMEM or sf-αMEM alone for 4 hr in a 
humidified 5% CO2/95% air atmosphere at 37°C. Following incubation, the cells 
were washed 2 times with 1 mL of 0.5% BSA / HBB. Duplicate, 0.5 mL aliquots of 
IGFBP-5 (0.1 μg/mL) in 0.05% BSA/HBB / sf-αMEM, together with either 0.5 mL 
IGF-I (0.025 μg/mL) in 0.05% BSA / HBB / sf-αMEM or 0.5 ml  of 0.05% BSA / 
HBB / sf-αMEM, was added to wells with or without VN and incubated at 4°C 
overnight. Following incubation the lower chambers were washed twice with 1 mL 
0.05% BSA / HBB / sf-αMEM prior to the addition of 1 mL 0.05% BSA / HBB / sf-
αMEM to the lower chamber of each Transwell™ and incubation until required. 
  
SaOS-2 cell attachment, proliferation and metabolic activity were assessed on pre-
bound combinations of VN, IGFBP-5 and IGF-I. Specifically, 52 μL of a 1 μg/mL 
VN / sf-αMEM solution or sf-αMEM alone was added to each well of a 96 well 
tissue culture plate and incubated for 2 hr in a humidified 5% CO2/95% air 
atmosphere at 37°C. Following removal of +/-VN / sf-αMEM solution, wells were 
washed with 0.5% BSA/HBB. Wells were then blocked with 1% BSA / HBB, 
incubated for 30 min in the above conditions and then each well washed with 0.5% 
BSA / HBB followed by addition of 43.5 μL of IGFBP-5 (1.6 μg/mL) in 0.5% BSA / 
HBB either alone or in combination with IGF-I (0.4 μg/mL), and with or without 
VN. The plates were incubated at 4°C overnight. 
 
3.2.3 Transwell™ Migration Assay 
For full details of this method please refer to section 2.6. Sub-confluent cultures of 
SaOS-2 cells were passaged 1:1 the day prior to assay and serum starved for 4 hrs 
before harvesting and seeding 2 x 105 cells into the upper chamber of 12 µm pore 
Transwells™ which had been pre-coated with various combinations of VN, IGFBP-
5 and / or IGF-I. Following 5 hr incubation, un-migrated cells were removed from 
the upper surface of the Transwell™ membrane with a cotton bud. Migrated cells 
were fixed in formaldehyde and stained with crystal violet. Excess stain was 
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removed and the membranes were allowed to air dry prior to extraction of crystal 
violet dye with 10% acetic acid. Sub-samples were transferred to a 96-well 
microtitre plate and the absorbance read at 595 nm. Results are from 2 (-VN 
treatments) or 3 (+VN treatments) separate experiments with each treatment tested in 
triplicate and are expressed as the mean absorbance as a percentage above the +VN 
control ± the standard error of the mean (SEM).  
 
3.2.4 Attachment Assay 
For full details of this method please refer to section 2.7. Sub-confluent cultures of 
SaOS-2 cells were serum-starved for 4 hr prior to harvest and seeding of 5000 
cells/well into 96-well plates containing various pre-bound combinations of VN, 
IGFBP-5 and IGF-I. Cells were allowed to attach for 3 hr prior to washing of wells 
to remove unattached cells and subsequent treatment of each well with WST-1 / 
αMEM solution. Absorbance readings at 450 nm - 650 nm were taken following a 2 
hr incubation. Results are from 2 separate experiments performed in at least 
quintuplicate and are expressed as the corrected absorbance at 450 nm-650 nm as a 
percentage of the +VN control ± standard error of the means (SEM). 
 
3.2.5 Proliferation Assay 
For full details of this method please refer to section 2.8. Sub-confluent cultures of 
SaOS-2 cells were serum-starved for 4 hr prior to harvest and seeding of 5000 
cells/well into black 96-well plates containing various pre-bound combinations of 
VN, IGFBP-5 and IGF-I. Cells were allowed to proliferate for 24 hr, 48 hr or 72 hr 
prior to removal of the spent media and storage of the culture plates at -80°C until 
analysis. Cyquant™ reagent was added to each well and the fluorescence measured 
at 480 nm excitation and 520 nm emission. Fluorescence units were converted to cell 
number by using cells kept from the time of seeding to construct a cell number 
standard curve as per the manufacturer’s instructions. Results are from 3 separate 
experiments and are expressed as the mean cell number ± standard error of the 
means (SEM). 
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3.2.6 Metabolic Activity Assay 
For full details of this method please refer to section 2.9. Sub-confluent cultures of 
SaOS-2 cells were serum starved for 4 hr prior to harvest and seeding of 5000 
cells/well into 96-well plates containing various pre-bound combinations of VN, 
IGFBP-5 and IGF-I. Cells were allowed to grow for 48 hr prior to addition of WST-
1 reagent. Absorbance readings at 450 nm - 650 nm were taken following a 2 hr 
incubation. Results are from 3 separate experiments and are expressed as the 
corrected absorbance at 450 nm - 650 nm as a percentage of the +VN control ± 
standard error of the means (SEM). 
 
3.3 RESULTS 
3.3.1  Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell migration 
VN is widely known to facilitate the migration of a variety of cell types (Leavesley 
et al. 1992). Indeed members of our laboratory have previously demonstrated that 
pre-bound combinations of VN / IGFBP / IGF-I enhance MCF-7 cell migration 
through Transwells™ with 12 µm pore membranes (Kricker et al. 2003). Therefore I 
performed Transwell™ migration assays in order to assess whether or not pre-bound 
combinations of VN / IGFBP-5 / IGF-I stimulated a migration response in the 
osteoblast-like, osteosarcoma cell line, SaOS-2 (Figure 3.1).  
 
SaOS-2 cell migration was significantly enhanced in the presence of VN (p<0.01, 
n=9) over treatments without VN (n=6). Indeed, in the absence of VN, responses 
were less than 13% ± 2.6% of the +VN control, irrespective of subsequent IGFBP-5 
and / or IGF-I treatment. When either IGFBP-5 or IGF-I were pre-bound to VN 
coated Transwells™, cell migration responses were 96.7 ± 8.7% and 126.8 ± 9.9% 
of the +VN control respectively. Statistical analysis of these data using post-hoc t-
test revealed that there was no significant difference between either of these values 
and the +VN control. However, this analysis revealed that there was a significant 
difference between the VN / IGFBP-5 response and the VN / IGF-I response 
(p<0.05). When IGFBP-5 and IGF-I were both pre-bound to VN-coated 
Transwells™ the migratory response was 198.1 ± 6.8% of the +VN control and was 
significantly higher than any other treatment (p<0.01). The significant increase in 
cell migration response to treatments containing pre-bound VN suggests that the 
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presence of VN was vital to support the migration of SaOS-2 cells through the 
membranes. In addition, the results obtained for the VN / IGFBP-5 / IGF-I treatment 
reflect a synergistic effect on the cell migration response of SaOS-2 cells. 
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Figure 3.1. Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell 
migration. SaOS-2 cells (2 x 105 cells/Transwell™) were incubated in sf-αMEM 
and allowed to migrate for 5 hr on pre-bound combinations of IGFBP-5 (50 ng/well) 
and IGF-I (12.5 ng/well) in the presence or absence of pre-bound VN (1 μg/well). 
Following incubation, un-migrated cells were removed from the upper surface of the 
Transwell™ by cleaning with a cotton bud for 1.5 minutes/insert. Migrated cells 
were then fixed in formaldehyde for 20 min and subsequently stained with crystal 
violet for 20 min. Excess stain was removed by immersion of the inserts in a 
reservoir of circulating tap water and air dried prior to extraction of crystal violet in 
0.5 mL of 10% acetic acid. Triplicate 100 μL sub-samples were then transferred to 
individual wells of a 96-well micro-titre plate and the absorbance read at 595 nm. 
Results were corrected using data from plate blanks (10% acetic acid alone) and are 
expressed as the corrected absorbance as a % of the VN only control (100%) ± 
standard error of the means (SEM). Significant difference to the VN only control is 
indicated by β (p<0.01) and was determined by post-hoc t-test. Significant difference 
to all other groups or select groups (where linked by line) is indicated by # (p<0.05) 
or * (p<0.01).  
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3.3.2  Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell attachment 
VN is well known for mediation of cell attachment in vitro via interaction with its 
cell surface receptors the αv integrins, in particular the αvβ3 integrin. In view of this 
attachment assays were performed in order to determine the effects of pre-bound 
combinations of VN / IGFBP-5 / IGF-I on SaOS-2 cell attachment. As expected, 
SaOS-2 cells exhibited significantly enhanced attachment to treatments where pre-
bound VN was present (p<0.01, n=11) compared to wells without VN (n=11)(Figure 
3.2). Post-hoc Dunnet’s test, was used in this instance in order to compare the effects 
of single treatments to baseline conditions ie +VN. The results obtained for 
treatments where VN was not present were similar to the background levels 
indicating that after 3 hr essentially no cells had been able to attach to the culture 
surface of the wells. When IGF-I, IGFBP-5 or both were pre-bound to wells 
containing pre-bound VN or in the presence of 10% FCS, values obtained for SaOS-
2 cell attachment were 45.5 ± 21.4%, 39.9 ± 11.5%, 38.4 ±18.0% or 20.7 ± 15.5% 
respectively above the +VN control. However, statistical analysis of these data 
indicated that the increase was not significant. Observation of the cultures supported 
the quantitative data, as cells cultured in the presence of VN or 10% FCS appeared to 
be firmly attached and had well spread morphologies. In contrast, cells seeded into 
wells without VN or FCS appeared weakly attached and had rounded morphologies 
following the 3 hr incubation time period and prior to wash steps (not shown). These 
results indicate that, within this system, VN is a vital component for facilitating 
SaOS-2 cell attachment to the tissue culture surface and neither IGF-I nor IGFBP-5 
together, or in isolation, have a significant effect.  
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Figure 3.2. Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell 
attachment.  SaOS-2 cells were incubated in sf-αMEM and allowed to attach for 3 
hr on pre-bound combinations of IGFBP-5 (70 ng/well) and IGF-I (17 ng/well) in the 
presence or absence of pre-bound VN (52 ng/well). The media was then removed 
and the cells were washed once with sf-αMEM prior to addition of 110 μL of 1:10 
dilution of WST-1 reagent / sf-αMEM and incubated for a further 2 hr. Cells seeded 
into wells without VN, or with normal growth media containing 10% FCS were 
employed as controls. The absorbance of the formazan dye cleavage product was 
then quantitated at 450 nm using 650 nm as reference. Results were corrected using 
data from plate blanks (serum free media and WST-1 alone) and are expressed as the 
corrected absorbance at 450 nm - 650 nm ± standard error of the means (SEM). 
Significant difference between individual treatments and the +VN control was 
determined by post-hoc Dunnet’s test and is indicated by α (p<0.05) or β (p<0.01).  
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3.3.3  Effect of various doses of pre-bound VN on SaOS-2 cell proliferation. 
In order to determine if VN alone has an effect on SaOS-2 cell proliferation, a dose 
response time course was performed (Figure 3.3). Cell number for each of the VN  
concentrations, 10% FCS and the –VN control were not significantly different after 
24 hr and had not increased above the initial cell seeding density of 5000 cells (for 
simplicity select data for the 24 hr time point is shown in Figure 3.3c). At 48 hr the 
10% FCS control had increased to 6999 ± 212 cells (n=15), which was not 
significantly more than the cell density observed with 4 µg/mL of VN (6012 ± 328 
cells, n=6) but was significant compared to the 2 µg/mL (4887 ± 340 cells, n=13), 1 
µg/mL (4831 ± 288 cells, n=15), 0.5 µg/mL (4268 ± 332 cells, n=9), 0.25 µg/mL 
(4420 ± 426 cells, n=9), 0.125 µg/mL (4152 ± 210 cells, n=9) or 0.0625 µg/mL 
(4548 ± 338 cells) VN treatments, as well as to the –VN control (3606 ± 278 cells, 
n=15) (p<0.01) (Figure 3.3a). Cell number in the 4 µg/mL, 2 µg/mL and 1 µg/mL 
VN concentrations were all significantly higher than the –VN control (p<0.01). 
However, there was no statistical difference between these treatments; indeed they 
had not substantially changed from the initial number of cells seeded (5000 
cells/well). Interestingly, cell numbers in the 0.0625 µg/mL VN treatment were also 
found to be significantly higher than the –VN control (p<0.05), although significance 
was only just attained.  
 
By 72 hr, however, the 10% FCS control had increased to 8442 ± 231 cells (n=12). 
This is significantly greater than the number of cells observed for the 4 µg/mL (5618 
± 328 cells, n=6), 2 µg/mL (4418 ± 435 cells, n=12), 1 µg/mL (4802 ± 389 cells, 
n=12), 0.5 µg/mL (3645 ± 339 cells, n=6), 0.25 µg/mL (3665 ± 237 cells, n=6), 
0.125 µg/mL (3536 ± 136 cells, n=6) or 0.0625 µg/mL (3083 ± 203 cells, n=6) VN 
treatments and the –VN control (2767 ± 193 cells, n=12) (p0.01) (Figure 3.3b). Since 
1 µg/mL is the standard VN concentration used in assays with other cell types 
(Kricker et al. 2003; Hyde et al. 2004; Hollier et al. 2005), I also determined the 
statistical significance between this concentration and the various other VN 
concentrations evaluated. Again there was no statistical difference between the 4 
µg/mL, 2 µg/mL or 1 µg/mL VN concentrations at 72 hr; indeed, there had been no 
significant increase or decrease in cell number between 24 hr and 72 hr in these 3 
treatments. There was also no statistical difference between the 1 µg/mL treatment 
and the 0.25 µg/mL or 0.5 µg/mL VN treatments, and although cell numbers had 
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decreased between 48 hr and 72 hr in these 2 treatments the decrease was not 
significant. A 24hr time point was not measured for VN concentrations below 1 
µg/mL, however, there was a general trend for a decrease in cell number in 
treatments below 1 µg/mL over the 72 hr period. However, it is likely that the 
decrease would be significantly less than the initial number of cells seeded. As 
expected, the –VN control resulted in a steady decrease in cell number over 72 hr to 
2767 ± 193 cells, which was significantly less than at 24 hr (4053 ± 312 cells) 
(p<0.01) and significantly less than all VN treatments above 0.125 µg/mL at 72 hr 
(p<0.01). Taken together the results described here and shown in figure 3.3 indicate 
that VN alone is able to sustain SaOS-2 cell survival for up to 72 hr in a dose 
dependent manor within the range of doses tested. 
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Figure 3.3. Effect of various doses of pre-bound VN on SaOS-2 cell 
proliferation.  SaOS-2 cells (5000/well) were incubated in sf-αMEM and allowed to 
proliferate for various times, (a) 48 hr; b) 72 hr; and c) select time course data, in 
wells pre-coated with 50 µL solutions of VN at various concentrations as indicated. 
Cells seeded into wells without VN or in 10% FCS were employed as controls. 
Following incubation, the media was aspirated and the tissue culture plates were 
stored at -80°C. Cyquant reagent was then added to each well as per the 
manufacturer’s instructions and the fluorescence measured at 480 nm excitation and 
520 nm emission. Results were corrected using data from plate blanks (Cyquant 
reagent only) and cell number calculated from a cell number standard curve and 
expressed as mean cell number ± standard error of the means (SEM). Statistical 
significance was determined by post-hoc t-test. Significance between treatments and 
the –VN control is indicated by α (p<0.05) or β (p<0.01). Significance between the 1 
µg/mL treatment and all other treatments is indicated by # (p<0.05) or * (p<0.01), 
while ns indicates no significant difference between select data.  
 
 69
0 
0.0
62
5
0.1
25 0.2
5 0.5 1.0 2.0 4.0
10
% 
FC
S
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
-VN
+VN
10% FCS
a) (48 hr)
β*
α β β
β
ns
[VN]μg/mL
C
el
l #
0 
0.0
62
5
0.1
25 0.2
5 0.5 1.0 2.0 4.0
10
% 
FC
S
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
-VN
+VN
10% FCS
b) (72 hr) β*
β β
β
α# α α*
[VN]μg/mL
C
el
l #
0 10 20 30 40 50 60 70 80
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
0 μgmL VN
1.0 μgmL VN
2.0 μgmL VN
10% FCS
β
ns
β
ns
4.0 μgmL VN
c) (time course)
Time (hr)
C
el
l #
 
Figure 3.3 
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3.3.4 Effect of various doses of pre-bound IGFBP-5 and IGF-I on SaOS-2 cell 
proliferation. 
In order to determine if IGFBP-5 / IGF-I complexes have a dose-response effect on 
SaOS-2 cell proliferation, dose response assays were performed over 72 hr (Figure 
3.4).  Increasing amounts of IGFBP-5 and IGF-I in stoichiometrically equivalent 
ratios were added to tissue culture wells coated with 1 μg/mL VN (50 ng/well) or un-
coated wells. Similar to the previous results, the -VN control significantly decreased 
in cell number from the initial seeding density of 5000 cells/well to 2407 ± 171 
cells/well after 72 hr (p<0.01, n=9) (Figure 3.4). While increasing the IGFBP-5 / 
IGF-I dose in the absence of VN had a significant dose effect on increasing cell 
number compared to the –VN control, higher cell numbers were not attained until the 
230 ng/mL IGFBP-5 / 57.6 ng/mL IGF-I dose (3321 ± 200 cells/well, n=9) (p<0.01). 
However, there was no further increase in cell number despite a 4 fold increase in 
IGFBP-5 / IGF-I to 920 ng/mL / 230.4 ng/ml. The overall response in the absence of 
VN reflected significant cell loss over 72 hr. Conversely, a dose-dependent increase 
was observed with increasing dose of pre-bound IGFBP-5 / IGF-I in the presence of 
pre-bound VN. Specifically, significantly higher cell number was reached in the 115 
ng/mL IGFBP-5 / 28.8 ng/mL IGF-I treatment (6741 ± 256 cells/well, n=9) (p<0.01) 
compared to the +VN control (5312 ± 269 cells/well, n=9), whereas lower doses 
were found to not be significantly different to the +VN control. Similar to the higher 
IGFBP-5 / IGF-I doses without VN, the maximum significant increase in cell 
number over 72 hr in the presence of VN was reached with the 115 ng/mL IGFBP-5 
/ 28.8 ng/mL IGF-I treatment, with the higher doses not significantly increasing the 
cell number after 72 hr of culture. The largest mean increase, however, was observed 
for the highest IGFBP-5 / IGF-I dose (6909 ± 390 cells/well, n=9). Nevertheless, as 
stated above, this was not significantly different from the 115 ng/mL IGFBP-5 / 28.8 
ng/mL IGF-I treatment. All the same it is worth noting that this represents 
approximately 70% of the response found with the 10% FCS control (9855 ± 332 
cells/well, n=9). 
 
The inset in Figure 3.4 shows time course data for the 115 ng/mL / 28.8 ng/well, 
IGFBP-5 / IGF-I dose in the presence of VN and indicate increases in cell number 
between 24 hr (n=9) and 72 hr (n=9), thus demonstrating cell proliferation (Figure 
3.4 inset).   
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Figure 3.4. Effect of various doses of pre-bound IGFBP-5 and IGF-I on SaOS-2 
cell proliferation.  SaOS-2 cells (5000/well) were incubated in serum free-αMEM 
and allowed to proliferate for up to 72 hr in wells pre-coated with solutions of 
IGFBP-5 and IGF-I at various concentrations (as indicated) in the presence or 
absence of pre-bound VN (1 µg/mL). Cells seeded into wells without VN or in 10% 
FCS were employed as controls. Following incubation, media was aspirated and the 
tissue culture plates were stored at -80°C. Cyquant reagent was then added to each 
well as per the manufacturer’s instructions and the fluorescence measured at 480 nm 
excitation and 520 nm emission. Results were corrected using data from plate blanks 
(Cyquant reagent only) and cell number calculated from a cell number standard 
curve and expressed as mean cell number ± standard error of the means (SEM). 
Statistical significance was determined by post-hoc t-test. Significant difference to 
the +VN control is indicated by α (p<0.05) or β (p<0.01). Significant difference to 
all other groups is indicated by * (p<0.01). Horizontal red line indicates initial 
number of cells seeded per well. Inset shows the increase in cell number over time in 
the 115 ng/mL IGFBP-5 / 28.8 ng/mL IGF-I treatment in the presence (VN/5/I) or 
absence (nil VN/5/I) of VN, thus demonstrating cell proliferation. Significant 
difference to the 24 hr value for each treatment is indicated by α (p<0.05) and β 
(p<0.01). 
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3.3.5  Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell metabolic 
activity 
A series of assays for metabolic activity were performed to determine the viability of 
individual cultures on pre-bound combinations of VN, IGFBP-5 and IGF-I after 48 
hr of culture. In general, SaOS-2 cell metabolic activity was significantly higher 
(post-hoc t-test) for all treatments in the presence of VN (n=16) compared to those 
treatments without VN (n=16) (p<0.01) (Figure 3.5). Specifically, SaOS-2 cells 
cultured in the presence of VN / IGFBP-5 / IGF-I had significantly higher metabolic 
activity (227.2 ± 11.6%) than that of the +VN control (100 ± 1.5%), VN / IGF-I 
(124.2 ± 3.7%), and VN / IGFBP-5 (133.4 ± 5.7%) (p<0.01) treatments but was 
equivalent to that measured for cells cultured in 10% FCS (262.5 ± 37.6%). While, 
no statistical difference was found between the results obtained for cells cultured in 
the presence of VN / IGF-I and VN / IGFBP-5, both of these treatments significantly 
enhanced the cell metabolic activity over the +VN control (p<0.01). The same trends 
were observed for those treatments without VN. Specifically, cells exposed to 
IGFBP-5 / IGF-I had significantly higher metabolic activity (110.2 ± 8.1%) than that 
of the -VN control (27.8 ± 2.0%), IGF-I only (44.4 ± 2.0%), and IGFBP-5 only (45.1 
± 2.5%) (p<0.01) treatments. No statistical difference was found between the results 
obtained for cells cultured in the presence of IGF-I only, and IGFBP-5 only; 
however, both of these treatments significantly enhanced cell metabolic activity over 
the -VN control (p<0.01). Also, there was no difference between the results for the 
+VN control and IGFBP-5 / IGF-I, suggesting that IGFBP-5 was able to bind to the 
tissue culture surface, retain IGF-I and sustain biological activity. Interestingly, 
adding the results of the +VN control and IGFBP-5 / IGF-I, following correction of 
each by subtraction of the –VN control value, gives a value significantly less (154.7 
± 11.8) than the corrected VN / IGFBP-5 / IGF-I value (199.4 ± 13.6) (p<0.05) 
(Figure 3.5 inset). This clearly indicates that the combination of VN, IGFBP-5 and 
IGF-I has a synergistic effect on SaOS-2 cell metabolic activity over 48 hr. It is not 
clear however whether or not the increased metabolic activity is due to an increase in 
the number of metabolically active cells or due to an increase in metabolic activity of 
individual cells.  
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Figure 3.5. Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell 
metabolic activity.  SaOS-2 cells were incubated in serum free-αMEM and allowed 
to proliferate for 48 hr on pre-bound combinations of IGFBP-5 (69.5 ng/well) and 
IGF-I (17.4 ng/well) in the presence or absence of pre-bound VN (52.1 ng/well). 
Following incubation, 10 μL of WST-1 reagent was added to each well and 
incubated for a further 2 hr. Cells seeded into wells without VN or with normal 
growth media containing 10% FCS were employed as controls. The absorbance of 
the formazan dye cleavage product was then quantitated at 450 nm using 650 nm as 
reference. Results were corrected using data from plate blanks (serum free media and 
WST-1 alone) and are expressed as the corrected absorbance at 450 nm - 650 nm ± 
standard error of the means (SEM). Statistical significance was determined by post-
hoc t-test. Significant difference to the +VN control is indicated by β (p<0.01). 
Significant difference between IGFBP-5 / IGF-I groups (± VN) and the individual 
components alone (± VN) is indicated by * (p<0.01). Inset shows the VN (   ) and 
IGFBP-5 / IGF-I (   ) values following correction of each by subtraction of the -VN 
control. The additive effect of these corrected values (   ) is compared to the 
corrected value for the VN / IGFBP-5 / IGF-I treatment (   ). Significance between 
the 2 values is indicated by # (p<0.05). Horizontal red line indicates +VN control 
(100%). 
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3.3.6  Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell proliferation. 
I wished to determine the effects that various combinations of VN, IGFBP-5 and 
IGF-I had on SaOS-2 cell proliferation and to determine if the observed increase in 
metabolism observed after 48 hr (Fig 3.5) was due to an increase in the number of 
metabolically active cells. I therefore performed a series of cell proliferation assays 
to determine the cell number at 24 hr intervals up to 72 hr (Figure 3.6a, b, c, n=18 
for all treatments unless otherwise specified). After 24 hr only the 10% FCS control 
(5577 ± 123 cells/well) had increased in cell number above the initial cell seeding 
density of 5000 cells/well. In contrast, the +VN control was unchanged (4927 ± 154 
cells/well) (p<0.01) (Figure 3.6a), yet was significantly higher than the –VN control 
(3948 ± 206 cells/well)(p<0.01), IGF-I only (4027 ± 174 cells/well)(p<0.01), 
IGFBP-5 only (3587 ± 235)(p<0.01) and VN/IGFBP-5 (4415 ± 180 cells/well) 
(p<0.05) treatments. Statistical analysis indicated there was no significant difference 
between the results obtained for VN / IGF-I (4733 ± 150 cells/well), IGFBP-5 / IGF-
I (4810 ± 258 cells/well), VN / IGFBP-5 / IGF-I (4691 ± 199 cells/well) and the 
+VN control. However, the VN / IGFBP-5 treatment (4415 ± 180 cells/well) had 
significantly less cells than the +VN control after 24 hr. 
  
At 48 hr all treatments exposed to pre-bound VN had increased above the initial cell 
seeding density (Figure 3.6b). In particular, increased cell number between the 24 hr 
time point and the 48 hr time point were recorded for the + VN control (5589 ± 174 
cells/well), VN / IGF-I (5754 ± 179 cells/well), VN / IGFBP-5 (5312 ± 210 
cells/well), VN / IGFBP-5 / IGF-I (5935 ± 185 cells/well) and 10% FCS (7248 ± 286 
cells/well) treatments. While there was no statistical significance between any of the 
groups exposed to pre-bound VN and the +VN control, a significant difference in 
cell number existed between the VN / IGFBP-5 / IGF-I treatment and the VN / 
IGFBP-5 treatment (p<0.05). Cell numbers in the 10% FCS control at 48 hr were 
significantly higher than any other group (p<0.01). Cell numbers declined between 
24 hr and 48hr in the –VN control (3123 ± 108 cells/well), IGF-I only (3558 ± 154 
cells/well), IGFBP-5 only (3137 ± 133 cells/well) and IGFBP-5 / IGF-I (4560 ± 130 
cells/well) treatments. All were found to be significantly different to the +VN control 
(p<0.01). Interestingly, the decrease in cell number for the IGFBP-5 / IGF-I 
treatment between 24 hr and 48 hr was not statistically significant. This is compared 
to all other groups in which either a significant increase or decrease in cell number 
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were recorded between 24 hr and 48 hr. In addition, while there was no difference 
between cell numbers recorded for the IGFBP-5 / IGF-I and VN / IGFBP-5 / IGF-I 
treatments at 24 hr, there were significantly more cells in the VN / IGFBP-5 / IGF-I 
treatment compared to the IGFBP-5 / IGF-I treatment at 48 hr (p<0.01).  
  
By 72 hr the 10% FCS control had increased to 9495 ± 219 cells/well, significantly 
more than any other treatment (p<0.01) (Figure 3.6c). The VN / IGFBP-5 / IGF-I 
treatment also had significantly more cells (8207 ± 236 cells/well) (p<0.01) after 72 
hr compared to all other treatments except the 10% FCS control and had 
significantly increased in cell number between 48 hr and 72 hr (p<0.01). Both the 
VN / IGF-I and the VN / IGFBP-5 treatments resulted in significantly higher cell 
number, 6914 ± 225 cells/well and 6490 ± 166 cells/well respectively, than the +VN 
control (5382 ± 297 cells/well) (p<0.01). While both the VN / IGF-I and the VN / 
IGFBP-5 treatments significantly increased cell numbers between 48 and 72 hr 
(p<0.01) cell numbers in the +VN control did not change significantly over the same 
period. All wells not exposed to pre-bound VN had, as expected, significantly lower 
cell number compared to the +VN control at 72 hr (p<0.01). In addition, there were 
no differences in cell number between the –VN control (3466 ± 109 cells/well) and 
either IGF-I only (3681 ± 171 cells/well), IGFBP-5 only (3281 ± 120 cells/well) or 
IGFBP-5 / IGF-I (3821 ± 171 cells/well) treatments. However, the difference 
between the calculated cell number for the IGFBP-5 only treatment and the IGFBP-5 
/ IGF-I treatment was found to be statistically significant (p<0.05). These data 
indicate that while VN is able to sustain SaOS-2 survival over 72 hr, increases in cell 
number over time (proliferation) require the addition of either IGF-I or IGFBP-5 and 
may be greatly enhanced by pre-binding both IGFBP-5 and IGF-I. In addition, the 
absence of VN resulted in net cell loss compared to the initial cell seeding density of 
5000 cells/well.  
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Figure 3.6. Effect of pre-bound VN, IGFBP-5 and IGF-I on SaOS-2 cell 
proliferation.  SaOS-2 cells (5000/well) were incubated in sf-αMEM and allowed to 
proliferate for a) 24 hr, b) 48 hr, and c) 72 hr in wells pre-coated with solutions of 
IGFBP-5 (69.5 ng/well) and / or IGF-I (17.4 ng/well) in the presence or absence of 
pre-bound VN (52.1 ng/well). Cells seeded into wells without VN or in 10% FCS 
were employed as controls. Following incubation, media was aspirated and the tissue 
culture plates were stored at -80°C. Cyquant reagent was then added to each well as 
per the manufacturer’s instructions and the fluorescence measured at 480 nm 
excitation and 520 nm emission. Results were corrected using data from plate blanks 
(Cyquant reagent only) and cell number calculated from a cell number standard 
curve and expressed as mean cell number ± standard error of the means (SEM). 
Statistical significance was determined by post-hoc t-test. Significant difference to 
the +VN control is indicated by α (p<0.05) or β (p<0.01). Significant difference to 
all other groups or select groups (where linked by line) is indicated by # (p<0.05) or 
* (p<0.01). Horizontal red line indicates initial number of cells seeded per well.  
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Figure 3.6 
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3.4 DISCUSSION 
In 1999 Upton et al. reported that IGF-II was able to bind to the ECM protein VN 
and that this complex retained IGF-II biological functionality. However it was also 
found that IGF-I was not able to bind to VN (Upton et al. 1999). Inspired by this 
initial work, Kricker et al. (2003) hypothesised that IGF-I may bind to VN via one or 
more of the 6 known IGFBPs. Significantly, this work demonstrated that IGFBP-2, -
3, -4 and 5 could mediate binding of IGF-I to VN and that these complexes had 
functional effects on MCF-7 cell migration (Kricker et al. 2003).  Since this work, 
others have reported effects on cell proliferation in HaCAT cells and primary human 
skin keratinocytes (Hyde et al. 2004; Hollier et al. 2005). Prior to the 
commencement of the present study, assessment of the ability of pre-bound 
combinations of VN, IGFBPs and IGF-I to elicit functional responses in cells had 
only been performed in epithelial type cells. Given that VN and a number of 
members of the IGF family of proteins, including IGF-I and IGFBP-5, are highly 
prevalent in bone tissue and have been demonstrated to influence osteoblast function 
(Bautista et al. 1990; Bautista et al. 1991; Mohan and Baylink 1991; Knutsen et al. 
1995; Schmid et al. 1995; Miyakoshi et al. 2001; Pepene et al. 2001), I proposed that 
pre-bound combinations of VN, IGFBP-5 and IGF-I could also elicit functional 
responses in connective, or mesenchymal cell types.  
 
This study has shown that when VN, IGFBP-5 and IGF-I are pre-bound to tissue 
culture plastic in serum-free conditions the osteoblast-like cell line SaOS-2 exhibits 
enhanced cell migration, metabolic activity and proliferation up to 72 hr of culture. 
Specifically, I have demonstrated that without pre-bound VN present, relatively few 
SaOS-2 cells were able to migrate through 12 µm pore Transwell™ membranes, 
regardless of whether IGFBP-5 or IGF-I or both were present or not (Figure 3.1). 
This result is similar to previous studies with MCF-7 cells and HaCAT cells reported 
from our laboratory (Kricker et al. 2003; Hyde et al. 2004; Hollier et al. 2005). 
Interestingly, the HaCAT cell line migration response to complexes of IGFBP-5 and 
IGF-I alone has been shown to be equivalent to that of VN alone. This is likely due 
to the ability of HaCAT cells, to attach to tissue culture plastic without the addition 
of any exogenous adhesion protein such as VN (Kricker et al. 2003; Hyde et al. 
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2004; Hollier et al. 2005) whereas, as discussed below, SaOS-2 cell attachment to 
tissue culture plastic is dependent on the presence of an adhesion factor such as VN.  
 
SaOS-2 cells are known to express αvβ3 integrin receptors which mediate cell 
attachment to a variety of ECM proteins, including VN (Koistinen et al. 1999; 
Postiglione et al. 2003; Kilpadi et al. 2004). The β3 subunit of the αvβ3 integrin has 
been found to play a key role in the facilitation of the migratory response in αvβ3 
integrin expressing M21 melanoma cells (Leavesley et al. 1992). The involvement of 
the β3 subunit in facilitating cell migration was confirmed by stably transfecting a 
human pancreatic carcinoma cell line with the β3 moiety, which they lacked, thus 
conferring the ability to migrate on a VN substrate, a function which they were 
previously unable to do (Leavesley et al. 1992).  
 
We considered the migration response of SaOS-2 cells to VN alone (+VN) to be the 
basal or control response and found that addition of either IGFBP-5 or IGF-I did not 
change the cell migration response compared to the +VN control alone. However, 
SaOS-2 cells migrated strongly in response to IGFBP-5 and IGF-I together in the 
presence of VN. These data support findings that IGF-I is not able to bind to VN 
(Upton et al. 1999; Kricker et al. 2003) and that while IGFBP-5 can bind VN, it has 
negligible effect on cell migration in the absence of IGF-I (Kricker et al. 2003; Hyde 
et al. 2004; Hollier et al. 2005). The significant increase in cell migration in response 
to VN, IGFBP-5 and IGF-I demonstrates that IGF-I, when retained on a surface by 
IGFBP-5 in the presence of VN, elicits strong functional effects on SaOS-2 cells. 
This finding may be significant because the migration response of mesenchymal type 
cells, such as osteoprogenitor cells or osteoblasts, is considered important for 
effective bone regeneration within 3 dimensional biomaterial constructs and on the 
surface of orthopaedic implants (Dee et al. 1999; Shea et al. 2000; Frosch et al. 
2002; Yang et al. 2003a; Yang et al. 2003b; Schleicher et al. 2005). 
  
Unlike previous studies performed in our laboratory using the HaCAT cell line, 
SaOS-2 cells were found to be unable to attach to tissue culture wells without the 
presence of VN (Figure 3.2) (Hyde et al. 2004; Hollier et al. 2005). However, this 
study revealed that the presence of VN facilitates SaOS-2 cell attachment to the 
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culture surface equivalent to that mediated by 10% FCS. Further, while the addition 
of IGF-I, IGFBP-5 or both, seemed to increase cell attachment, this increase was not 
statistically significant. These results are supported by the findings of Underwood 
and Bennett (1989) who demonstrated that VN is able to bind to tissue culture plastic 
surfaces even in the presence of other serum proteins such as FN. In addition, these 
authors showed that while BHK-21 cells or bovine aortic endothelial cells attached 
and grew normally in the presence of serum which had been stripped of FN they did 
not attach well to the culture surface and failed to thrive in the presence of serum 
which had been stripped of VN (Underwood and Bennett 1989). Thus, these data 
indicate that VN is the principle serum protein regulating cell attachment and growth 
in standard tissue culture systems.  
  
In order to evaluate the proliferative response of SaOS-2 cells to VN, I performed a 
series of time course experiments using a range of doses of VN. While there was no 
difference in cell number between the treatments measured after 24 hr, the cells 
exposed to the 10% FCS treatment steadily increased in number over the following 
48 hr, while cell number steadily decreased in the –VN control. Cell number did not 
increase nor decrease over the 72 hr in wells coated with 1 µg/mL VN or higher; 
indeed there was no difference in cell number between these treatments despite a 
four fold difference in VN concentration. However, at lower VN concentrations cell 
number decreased over time in a dose dependent manner. These data indicate that 
VN elicits a dose dependent effect on SaOS-2 cell survival over 72 hr. This result 
could be explained through a number of possibilities. Firstly, there may have been a 
steady rate of cell proliferation concomitant with a steady rate of cell death leading 
to no net change in cell number over 72 hr. In addition, it is possible that a 
significant proportion of cells had already committed to the completion of their cell 
cycle (Peeper et al. 1994; Cooper 2000). Therefore the maintenance of cell numbers 
over 72 hr may simply be the result of a proportion of the cells completing their cell 
cycle, rather than the presence of VN facilitating bona fide cell proliferation. 
Alternatively, there may have been no proliferation of cells and no cell death 
resulting in no net change in cell number. In which case VN will not have influenced 
cell proliferation, but rather, will have had a protective effect, inhibiting cell 
apoptosis.  
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VN has previously been shown to reduce microvascular endothelial cell apoptosis in 
vitro resulting in a slight increase in cell number over 72 hr. This response was a 
consequence of ligand occupancy of αvβ3 integrins by VN, with the αv subunit being 
critical for mediation of the effect (Isik et al. 1998). Similar effects have been 
observed in osteoclasts where lack of αvβ3 ligand occupancy resulted in caspase-8 
mediated apoptosis. The authors also found that caspase-8 was associated with the 
unoccupied αvβ3 integrin, but was not associated with this integrin in adherent cells 
(Zhao et al. 2005). More specifically, these authors and others have shown that the 
β3 subunit is responsible for the recruitment and interaction with caspase-8 at the cell 
membrane (Stupack et al. 2001; Zhao et al. 2005). Thus a reasonable hypothesis 
arising from the results of the present study is that SaOS-2 cells cultured on low 
concentrations of pre-bound VN undergo apoptosis due to non-ligation of αvβ3 
integrins and that saturating concentrations of pre-bound VN attenuate the integrin-
mediated apoptotic response.  
 
IGF-I is widely known to elicit mitogenic effects on many cell types, including 
osteoblasts, and the presence of IGFBP-5 is known to enhance cell responsiveness to 
IGF-I when bound to the culture substrate, especially when bound to ECM (Jones et 
al. 1993). Others have demonstrated similar effects in keratinocytes when IGFBP-5 
together with IGF-I were pre-bound to culture substrates (Hyde et al. 2004; Hollier 
et al. 2005). I performed a series of assays to determine if SaOS-2 cells respond in a 
dose dependent manner to pre-bound VN and various concentrations of IGFBP-5 
and IGF-I. After 72 hr, a clear dose dependent response to IGFBP-5 and IGF-I was 
evident (Figure 3.4). Indeed, the highest IGFBP-5 / IGF-I concentration facilitated an 
increase in cell number equivalent to 70% of that attained in the positive control, 
10% FCS. In addition, IGFBP-5 / IGF-I concentrations above 115 ng/mL / 28.8 
ng/mL did not significantly increase the response. A possible reason for this may be 
that the culture surface could not retain higher amounts of IGFBP-5 / IGF-I; that is, 
the culture surface / IGFBP-5 / IGF-I interaction was the limiting factor. 
Indeed  experimental studies  from our laboratory (Kricker et al. (2003), 
(2005)) found that that IGFBP-5 exhibited a concentration-dependent increase in 
binding with VN coated surfaces at concentrations <50 ng/mL and saturated at ~50 
ng/mL (Kricker et al. 2003; Kricker 2005). However, the actual concentration of the 
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individual protein species bound to the tissue culture surface was not measured 
during this study. 
 
As observed in the previous experiments the 1 µg/mL treatment (+VN control in 
these experiments) maintained, but did not increase, cell number above the initial 
cell seeding density of 5000 cells/well. VN was, however, found to be critical for 
facilitating the dose dependent mitogenic effect of IGFBP-5 / IGF-I. Even without 
VN there was a slight dose dependent response to IGFBP-5 / IGF-I, although even at 
the highest IGFBP-5 / IGF-I concentrations the cell number/well after 72 hr 
remained significantly lower than that attained for the +VN control. Thus IGFBP-5 / 
IGF-I complexes alone were not sufficient to maintain cell number.   
 
To show that there had in fact been an increase in cell number for each treatment, 
assays were performed as a time course. Figure 3.4 inset shows the increase in cell 
number for the 115 ng/mL IGFBP-5 / 28.8 ng/mL IGF-I treatment, indicating a 
proliferative response to this treatment. All treatments exposed to VN either 
maintained or increased cell number by 72 hr, indicating that at least cell attachment 
is required for cell proliferation to occur and that this attachment factor (VN in this 
case) can be provided in a pre-bound form. As in the previous experiment, these data 
also suggest a possible role for VN in reducing SaOS-2 cell apoptosis. It is also 
possible that the enhanced response to the higher concentrations of IGFBP-5 / IGF-I 
reflects a further protective effect against apoptosis, especially if, as discussed above, 
the increase in cell number is partly or wholly due to a percentage of the cells having 
already traversed the G1 checkpoint of the cell cycle, thus committing them to S 
phase and DNA synthesis and not due to bona fide cell proliferation.  
 
Because there is some evidence in the literature that IGFBP-5 has IGF-I independent 
effects on some cells, including osteoblasts, I measured the functional SaOS-2 cell 
response to the various combinations of VN, IGFBP-5 and IGF-I (Andress and 
Birnbaum 1992; Miyakoshi et al. 2001). Initially I decided to use WST-1, a water 
soluble tetrazolium salt which is cleaved by mitochondrial dehydrogenases to yield 
formazan, a coloured dye product which can be read spectrophotometrically and 
indicates cell viability.  This study showed that indeed IGFBP-5 in the presence of 
VN could significantly, and synergistically, enhance SaOS-2 cell viability over VN 
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alone (Figure 3.5). Most interesting, however, was the finding that IGFBP-5 / IGF-I 
complexes without VN mediated an equivalent response to that of VN alone. 
Significantly, this indicates that IGFBP-5 / IGF-I complexes can bind to the culture 
surface without VN and subsequently influence cellular metabolic activity to a much 
greater extent than either of the 2 components in isolation. Others have also recorded 
elevated functional responses to IGFBP-5 / IGF-I complexes alone, indicating that 
perhaps IGFBP-5 / IGF-I complexes bind to the tissue culture surface and that this 
complex retains IGF-I bioactivity (Hyde et al. 2004; Hollier et al. 2005). Further, 
IGFBP-5 has been shown to mediate binding of [125I]-IGF-I to VN in solid plate 
binding assays. However, IGFBP-5 was not able retain [125I]-IGF-I tracer in the 
absence of VN (after the wells were blocked with 0.5% BSA) indicating that IGFBP-
5 could not bind to the well surface (Kricker et al. 2003). These solid plate binding 
studies were performed on high protein binding plastic rather than tissue culture 
plastic thus the efficacy of BSA in blocking the non-specific binding of IGFBP-5 
may account for the differences. Because in the present study ‘tissue culture’ 
modified polystyrene plates were used, it is possible that some IGFBP-5 / IGF-I 
complexes bind to VN, while others bind to the tissue culture surface. Indeed 
IGFBP-5 is known to be a very “sticky protein” and it is likely that this property 
explains the apparent retention of biologically active protein at the culture surface in 
this and previous studies (Gropep; Hyde et al. 2004; Hollier et al. 2005). As 
described above, solid plate binding studies previously performed in our laboratory 
have shown that IGFBP-5 binds to VN in a concentration dependent manner, 
saturating at higher doses (Kricker et al. 2003; Kricker 2005). However, it is not 
known how much IGFBP-5 / IGF-I binds to tissue culture plastic, nor what 
concentrations of IGFBP-5 and IGF-I are optimal for the binding interaction in our 
system. As far as I am aware this has not been investigated previously. 
 
Investigation of the effect of the various combinations of VN, IGFBP-5 and IGF-I on 
cell proliferation revealed that all treatments without VN resulted in a steady 
decrease in cell number over time. In contrast, treatments which incorporated VN 
resulted in either an increase in cell number (VN / IGFBP-5 / IGF-I, VN / IGFBP-5 
and VN / IGF-I) or maintenance in cell number (+VN control) as described above 
for previous experiments (Figure 3.6 a, b and c). Curiously, the trends revealed in 
Figure 3.5, which were measured after 48 hr culture, more closely mirror the trends 
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for the cell number data collected at 72 hr of culture (Figure 3.6c). Together these 
data suggest that at 48 hr SaOS-2 cells exposed to VN, IGFBP-5 and IGF-I were 
actively proliferating, whereas the other VN treatments resulted in at most, only 
slightly increased cell number. Thus the metabolic activity of the cells at 48 hr were 
reflected in terms of cell number 24 hr later ie. at 72 hr. This has implications for the 
common use of reagents such as tetrazolium salts as indicators of cell number since 
the present study shows there is a clear discrepancy between the WST-1 results and 
cell number results at 48 hr.  
 
Interestingly, IGF-I ligation of the IGF-IR has been shown to simultaneously 
promote the mitogenic pathway and anti-apoptotic signalling pathways via parallel 
PI-3 kinase and p42 / 44 MAPK signalling in SaOS-2 cells (Grey et al. 2003). In 
addition, IGFBP-5 and IGF-I together have been shown to significantly enhance the 
mitogenic response of various connective tissue cells, particularly when the IGFBP-5 
/ IGF-I complex is immobilised on the culture surface via the ECM (Andress and 
Birnbaum 1992; Jones et al. 1993). This is believed to occur because IGF-I has a 
reduced affinity for IGFBP-5 when IGFBP-5 is bound to the ECM, compared to 
IGFBP-5 in solution, therefore cells are better able to access or sequester the IGF-I 
from the bound IGFBP-5. Localisation of the complex in the vicinity of the cell 
layer, along with the reduced affinity of IGF-I for bound IGFBP-5, would drive the 
IGF equilibrium away from the binding protein and toward the receptor, thus 
resulting in enhanced interaction between IGF-I and its receptor and the observed 
enhanced responses of cells cultured on bound IGFBP-5 / IGF-I complexes (Jones et 
al. 1993).  
 
Moreover, a number of studies have investigated the interaction between the IGF1R 
signalling pathway and the αvβ3 integrin signalling pathway. Exposure of smooth 
muscle cells to VN has been shown to increase the degree of tyrosine 
phosphorylation of IRS-1, a member of the IGF1R signalling pathway, in response 
to IGF-I stimulation (Zheng and Clemmons 1998). The same effect was not seen 
when cells were plated on laminin / type IV collagen matrix, which bind α2β1 
integrins, indicating that the effect of VN on the IGF1R is specifically mediated by 
αvβ3 integrins. This was further supported by blocking αvβ3 with echistatin which 
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significantly reduced IRS-1 and 2 tyrosine phosphorylation and association of the 
p85 subunit of PI-3 kinase with IRS-1 (Zheng and Clemmons 1998). More recently, 
various components of the β3 subunit of the αvβ3 integrin, in particular its 
cytoplasmic tail, has been identified as being required for the modulation of IGF-I 
mediated phosphorylation of the IGF1R, further supporting the interrelationship of 
αvβ3 integrin and IGF1R signalling pathways (Maile et al. 2001). Therefore I 
hypothesise that a similar mechanism of cross talk exists in osteoblasts, including 
SaOS-2 cells, thus providing a mechanistic explanation for the results detailed in this 
chapter. Furthermore, it is likely that the increase in cell migration, metabolic 
activity and cell number in response to VN, IGFBP-5 and IGF-I is a combination of 
protection from apoptosis by VN via ligation to αvβ3 or other integrins, IGF-I 
mediated anti-apoptotic signalling and the mitogenic action of IGF-I.    
 
In conclusion, the initial responses of SaOS-2 cells to pre-bound VN, IGFBP-5 and 
IGF-I detailed in this chapter indicate that these proteins together hold potential as a 
ECM / growth factor coating for biomaterial scaffolds in order to induce cell 
responses such as cell migration into and proliferation within the scaffold. 
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CHAPTER 4:  
EFFECTS OF SOLUTION PHASE 
VITRONECTIN, IGFBP-3 OR -5 AND IGF-I 
OR TGF-β1 ON hMSC METABOLIC 
ACTIVITY, MORPHOLOGY AND 
GELATINASE EXPRESSION. 
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4.1 INTRODUCTION 
Over the last 2 decades human mesenchymal stem cells have become integral 
constituents of many modern tissue engineered constructs for bone or connective 
tissue repair (Otto and Rao 2004). This is due to their demonstrated ability to 
facilitate regeneration of mesenchymal tissues including bone, cartilage, adipose 
tissue, muscle, marrow stroma and their capacity for self renewal (Bruder et al. 
1997; Jaiswal et al. 1997; Pittenger et al. 1999; Lennon et al. 2000). Differentiation 
of hMSCs into these various tissue types is largely controlled by a complex interplay 
of specific growth factors, cytokines, vitamins and other factors in the 
microenvironment to which they are exposed, such as ECM molecules (Bruder et al. 
1997; Jaiswal et al. 1997; Pittenger et al. 1999; Coelho et al. 2000; Coelho and 
Fernandes 2000; Lennon et al. 2000; Bennett et al. 2001). Some modern strategies 
for the development of connective tissue therapeutics focus on implantable 
constructs which consist of some form of ECM bound to a biomaterial scaffold, 
often with ex vivo expanded, undifferentiated hMSCs. These constructs are designed 
to deliver large numbers of precursor cells to the site of injury, which will 
differentiate into appropriate tissue types through interactions with the surrounding 
host tissue and the accompanying scaffold / ECM (Bruder et al. 1998b; Bruder et al. 
1998c; Young et al. 1998; Ponticiello et al. 2000). MSCs that have been expanded in 
vitro and seeded onto biodegradable collagen scaffolds and implanted into large 
segmental bone defects in mice have been shown to synthesise new bone (Turgeman 
et al. 2001). Similarly, MSCs seeded onto β-tricalcium phosphate scaffolds which 
were then implanted into significant femoral defects in rats, support bone 
regeneration with superior properties than the scaffold alone (Bruder et al. 1998c). 
Thus, tissue engineered constructs which contain incorporated MSCs have the ability 
to regenerate bone tissue in critical sized defects in animal models, this in turn 
strongly suggests this approach has an equivalent potential in humans. These data 
support my own view, that hMSCs which are expanded ex vivo and seeded into 
tissue engineered constructs which have been coated with appropriate matrix / 
growth factors will enhance integration of the implant into the repair site. Therefore, 
characterisation of the responses of ex vivo expanded hMSC interacting with surface 
bound ECM in the presence of some of the most highly expressed growth factors in 
bone tissue is of great interest.   
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The major matrix component of bone is type I collagen, although adult bone is also 
rich in other matrix proteins such as fibronectin and to a lesser extent VN (Grzesik 
and Robey 1994; Seiffert 1996). In addition, the IGF–I and –II along with the IGF 
binding protein, IGFBP-5, and TGF-β1 are among the most abundent growth factors 
in bone (Bautista et al. 1991; Andress and Birnbaum 1992; Hakeda et al. 1996; 
Franchimont et al. 1997a; Franchimont et al. 1997b). Recently, the IGFs together 
with the IGFBPs have been shown to interact with each other and the matrix protein 
VN in vitro and to stimulate functional responses in a number of epithelial cell types 
(Kricker et al. 2003; Hyde et al. 2004; Hollier et al. 2005). TGF-β1 has also recently 
been shown to associate with VN and retain functional effects on cells (Schoppet et 
al. 2002). Furthermore, interactions between the ECM and components of the IGF 
system and other growth factors such as TGF-β1 are believed to affect hMSC 
function and bone tissue growth and turnover (Golombick et al. 1995; Martin et al. 
2002; Longobardi et al. 2003; Govoni et al. 2005; Minuto et al. 2005; Kiepe et al. 
2006), thus facilitating interest in the potential use of these compounds in the 
development of novel tissue engineered therapeutics. Importantly, hMSCs are known 
to express a range of integrins which include αvβ3 integrins (the VN receptor) and 
also express growth factor receptors including the IGF-IR, and receptors for TGF-β1 
(Conget and Minguell 1999). Some studies have suggested that VN can induce 
osteogenic differentiation in hMSCs (Salasznyk et al. 2004a; Salasznyk et al. 
2004b), while TGF-β1 has been shown to mediate proliferative responses in hMSCs 
through induction of IGFBP-3 and IGF-I expression which act in an autocrine 
manner (Kveiborg et al. 2001b). TGF-β1 has also been implicated in the mediation of 
differentiation responses in transitory stage osteoblasts but seems to inhibit the 
expression of some osteogenic markers such as osteocalcin in later secretory stage 
osteoblasts (Kassem et al. 2000). Thus the effects of TGF-β1 on hMSC and 
osteoblast function are complex and obscure. 
 
There is little data available on the effects of IGFBP-5 on hMSCs despite the finding 
that hMSCs express both IGFBP-3 and -5 and IGF-I (Kveiborg et al. 2001b) and that 
both IGFBP-5 and IGF-I are down regulated by the pro-differentiation steroid 
dexamethasone (Cheng et al. 1998). However, IGFBP-5 and its proteolytic 
fragments have been shown to elicit IGF independent effects on osteoblast cell 
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function in mouse and human cells, including proliferation and the phosphorylation 
of serine residues on a 420 kDa membrane bound putative IGFBP-5 receptor 
(Andress 1995a; b; 1998). 
 
Another major impediment for the re-implantation of culture expanded hMSCs for 
therapeutic use in vivo is that current culture methodologies require the use of animal 
sera to supply appropriate nutrients and growth factor / ECM components required to 
support cell viability and growth. This poses a number of risks including the 
xenobiotic transfer of disease, and accounts for the increasing regulatory constraints 
on using cells which have been cultured in animal sera for therapeutic applications 
(Federal Register). As such a number of studies have applied various strategies as an 
attempt to address this issue, including the use of patient-derived sera (Stute et al. 
2004; Cenni et al. 2005) or platelet rich plasma (a rich source of growth factors) 
(Weibrich et al. 2002; Sanchez et al. 2003; Yazawa et al. 2003). However, 
regulatory bodies find such undefined media components also undesirable. Thus 
there is an urgent need for the development of highly defined culture media for ex 
vivo expansion of hMSCs without the use of animal products. In light of this and the 
natural abundance of members of the IGF system, TGF-β1 and the presence of VN in 
bone, I believe that the combination of these proteins may have potential for 
replacing serum for ex vivo expansion of hMSCs.   
 
4.2 EXPERIMENTAL PROCEDURES  
Full details of both the materials and methods used in the generation of data 
presented in this chapter have been described in chapter 2. The following are brief 
summaries of the materials and experimental procedures used for the generation of 
data presented in section 4.3.  
 
4.2.1 Materials 
Purified human VN, IGFBP-5, IGF-I, WST-1 reagent, 96-well tissue culture plates 
and Fraction V RIA grade BSA were obtained as detailed in the previous chapter and 
the Materials and Methods chapter. MMP-2 and MMP-9 standards were purchased 
from Chemicon Pty / Ltd (Boronia, Vic, Australia). 
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4.2.2 Isolation and culture of hMSC from donor bone marrow samples.  
For full details of this method please refer to section 2.2.2. Bone marrow samples 
were collected, following informed consent and with hospital and university ethics 
committee approvals, from both female and male patients presenting for total knee or 
hip joint replacement surgery as part of their treatment for osteoarthritis at The 
Prince Charles Hospital and The Holy Spirit Northside Hospital, Brisbane. Typically 
2-5 mL of bone marrow was collected during surgery by the surgeon into tubes 
containing 5 mL PBS supplemented with 200 U/mL heparin and the tubes were 
placed on ice for transport to QUT. Collagenase B (0.02%) and DNase (100 U/mL) 
were occasionally employed to assist in disaggregation of clots, otherwise the 
marrow suspension was repeatedly passed through a 19 g needle to dislodge clumped 
cells. The samples were then diluted to 30 mL with PBS, thoroughly mixed and 
passed through a 100 µm filter to remove extracellular debris and bone fragments. 
Following overlaying of 30 mL of the filtrate onto 15 mL Lymphoprep™, the 
samples were centrifuged at 400 g for 35 min at 20°C with zero brake. The 
mononuclear cell fraction (buffy coat) was removed, placed into a fresh tube with 20 
mL DMEM+ and centrifuged at 1000 rpm for 10 min. The cell pellet was 
resuspended in 1 mL of DMEM+ (for culture) or sf-DMEM (for CFU-F assays) prior 
to counting in a haemocytometer. Cells were then seeded into tissue culture flasks at 
1.6 x 105 cells/cm2 and incubated in a humidified 5% CO2/95% air atmosphere at 37 
°C. Culture media was changed after 5 days in the first instance, then twice weekly.  
 
4.2.3 Colony Forming Unit-Fibroblastic Assay 
For full details of this method please refer to section 2.10. While the growth factor 
concentrations were maintained as described for the last chapter, the concentration of 
VN was increased to see if the addition of a higher concentration of VN would affect 
the response of hMSCs to any of the treatments. Specifically, 1.4 mL of 4 µg/mL 
(5.6 µg/well) VN / sf-DMEM solution was added to each well of a 6-well tissue 
culture plate and incubated in a humidified 5% CO2/95% air atmosphere at 37 °C. 
Following incubation for 2.5 hr, the VN solution was removed and 1.4 mL of 0.16 
µg/mL (224 ng/well) TGF-β1, or 1.6 µg/mL (2.24 µg/well) IGFBP-3 or -5 in 
0.5%BSA / HBB, alone or in combination with 0.4 µg/mL (560 ng/well) IGF-I, were 
added to wells with VN and incubated at 4 °C overnight. Growth factor solutions 
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were removed prior to seeding with freshly harvested bone marrow mononuclear 
cells at a density of 1.6 x 105 cells/cm2 in a final volume of 3 mL/well or 3.4 
mL/well for solution phase studies. For the solution phase studies, VN was allowed 
to pre-bind as described above, however, the growth factors were left in situ upon 
seeding of cells. Therefore the final growth factor concentrations for the solution 
phase studies were 0.066 µg/mL (2.6 nM) (TGF-β1) or 0.659 µg/mL (22 nM) 
(IGFBP-3 or -5) either alone or in combination with 0.164 µg/mL (22 nM) (IGF-I).   
 
4.2.4 Preparation of tissue culture plates with VN and growth factors for 
metabolic activity and total protein assays.  
For full details of this method please refer to section 2.5. hMSC cell metabolic 
activity and total protein were assessed in the presence of solution phase 
combinations of VN, IGFBP-3 or -5 and IGF-I or TGF-β1. Specifically, 52 µL of 1 
µg/mL (52 ng/well) or 3.346 µg/mL (174 ng/well) VN / sf-DMEM solution or sf-
DMEM alone was added to each well of 96 well tissue culture plates and incubated 
for 2 hrs in a humidified 5% CO2/95% air atmosphere at 37°C. Following 
incubation, 43.5 µL of 0.16 µg/mL (7 ng/well) TGF-β1 or 1.6 µg/mL (70 ng/well) 
IGFBP-3 or -5 in 0.5%BSA / sf-DMEM, either alone or in combination with 0.4 
µg/mL (17.4 ng/well) IGF-I, were added to wells with or without VN and incubated 
at 4°C overnight. Plates were then allowed to return to room temperature prior to 
seeding of cells. Final concentrations of added proteins following seeding of cells 
(final volume of 195.5 µL) were 0.266 µg/mL (3.55 nM) or 0.890 µg/mL (11.9 nM) 
VN, 0.358 µg/mL (11.9 nM) IGFBPs, 89 ng/mL (11.9 nM) IGF-I and 36 ng/mL 
(1.43 nM) TGF-β1.  
 
4.2.5 Metabolic Activity Assay 
For full details of this method please refer to section 2.9. Sub-confluent cultures of 
hMSCs were harvested by trypsin digestion prior to seeding of 5000 cells/well into 
96 well plates containing various combinations of VN, IGFBP-5 and IGF-I in a final 
volume of 195.5 µL. Cells were allowed to incubate for 24 hr, 48 hr or 72 hr prior to 
removal of conditioned media and addition of 110 µL of WST-1 reagent / SF-
DMEM solution to each well. Absorbance readings at 450 nm - 650 nm were taken 
following a 2 hr incubation. Results are from 4 separate experiments with each 
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treatment performed in at least triplicate and are expressed as the corrected 
absorbance at 450 nm - 650 nm as a percentage of the 24 hr -VN control ± standard 
error of the means (SEM). 
 
4.2.6 Total Protein assay  
For full details of this method please refer to section 2.11. Sub-confluent cultures of 
hMSCs were harvested by trypsin digestion prior to seeding of 5000 cells/well into 
96 well plates containing various combinations of VN, IGFBP-5 and IGF-I in a final 
volume of 195.5 µL. Cells were allowed to incubate for 24 hr, 48 hr or 72 hr. 
Conditioned media was then removed and cell monolayers were fixed with 4% 
paraformaldehyde solution, incubated for 20 min and subsequently stained with 
crystal violet. The plates were immersed in a beaker of gently circulating tap water 
and destained until no further stain visibly eluted from the wells. The plates were 
then allowed to air dry o/n after which the crystal violet stain was solubilised with 
10% acetic acid and absorbance readings were taken at 595 nm. Results are from 4 
separate experiments with each treatment performed in at least triplicate and are 
expressed as the corrected absorbance at 595 nm as a percentage of the 24 hr -VN 
control ± standard error of the means (SEM). 
 
4.2.7 Morphological analysis  
For full details of this method please refer to section 2.12. Photographic images 
depicting culture morphology were captured from air dried cultures prepared for the 
total protein assay (above), just prior to solubilisation of crystal violet with 10% 
acetic acid. A single image of each well was taken at X100 magnification with a 
Nikon Cool pix digital camera mounted on a Nikon TE100 reverse stage, phase 
contrast microscope.  
 
4.2.8 Gelatin Zymography  
For full details of this method please refer to section 2.13. Conditioned media was 
removed from representative wells of the total protein assays immediately prior to 
fixation of cells with paraformaldehyde and stored at -20 °C until required for 
analysis. Samples were then analysed for MMP-2 and MMP-9 gelatinolytic activity. 
Briefly, conditioned media samples were applied to 10% polyacrylamide gels 
containing 1 mg/mL gelatin and subjected to electrophoresis at 4 °C. The gels were 
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washed in 2.5% Triton-X100 to remove SDS and then incubated in incubation buffer 
(50 mM Tris base, 10 mM CaCl2, 50 mM NaCl, pH 7.6) for 48 hr at 37 °C. 
Gelatinase activity was visualised by staining the gels with Coomasie Blue R250 and 
destained in 10% acetic acid and 40% methanol (vol/vol).     
 
4.2.9 Western blot of IGFBP-5 degradation by hMSC conditioned media 
For full details of this method please refer to section 2.14. The conditioned media 
from hMSCs cultured in sf-DMEM alone was collected and stored as above. 
Samples of serum free hMSC conditioned media, phosphate buffered saline or sf-
DMEM were incubated with or without 400ng of recombinant human IGFBP-5 o/n 
at 37° C and then separated under reducing conditions on a 4%-20% gradient 
polyacrylamide gel. Proteins were then transferred to a nitrocellulose membrane 
prior to interrogation with a chicken anti IGFBP-5 polyclonal antibody and detection 
with a rabbit anti chicken-HRP conjugated 2° antibody and chemiluminescent 
substrate. Chemiluminescence was then recorded onto photographic film. 
 
4.3 RESULTS 
4.3.1 Effect of pre-bound or solution phase VN, IGFBPs and IGF-I on bone 
marrow derived fibroblastic cell attachment. 
The colony forming unit fibroblastic assay (CFU-F) has been used for many years as 
a means of determining the efficiency of hMSC colony formation from the 
mononuclear cell fraction of whole bone marrow (Owen and Friedenstein 1988; 
Gronthos and Simmons 1995; Majumdar et al. 2000; Meuleman et al. 2006). In 
order to determine if pre-bound combinations of VN and either IGFBP-3 or -5 and 
IGF-I or TGF-β1 could initiate bone marrow derived fibroblast colony formation, I 
performed an initial colony forming unit fibroblast assay. In this experiment I 
observed that after 7 days almost no cells were attached to the culture surface of any 
wells containing any combination of pre-bound protein; thus figure 4.1a & b show 
the VN / IGFBP-3 / IGF-I treatment at 1 and 7 days and is typical of the response 
obtained for the other pre-bound treatments (Fig 4.1a & b). In contrast, cells cultured 
in the presence of 10% FCS had established a number of distinct colonies by day 1, 
which had then expanded in size by day 7 with clearly visible fibroblast-like cells in 
the vicinity of the colony (Fig 4.1c & d). These cultures continued to thrive and 
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further develop into near confluent cultures by day 13 (data not shown). This 
indicates that the cells used for these studies were viable under standard culture 
conditions and that pre-bound treatments of VN and / or IGFBPs and / or IGF-I and / 
or TGF-β1 failed to support the adhesion of fibroblastic cells from bone marrow. 
Based on these observations I investigated whether pre-bound VN with solution 
phase IGFBP-3 or -5 and / or IGF-I or TGF-β1 could support CFU-F formation from 
bone marrow. This approach indeed, resulted in attachment of many elongated 
shaped cells after the first day, which, then went on to form spindle shaped 
fibroblastic cells by day 3 (Fig 4.1e-h). Interestingly, the fibroblast like cells in these 
cultures did not form, nor seem to arise from colonies. In fact none of the treatments 
induced colony formation except the 10% FCS control which, by day 13, as stated 
above, had induced large numbers of fibroblastic cells in large colonies (data not 
shown). In addition, only the 10% FCS culture continued to thrive after 3-4 days of 
culture. In contrast, cells cultured in the presence of VN and solution phase growth 
factors declined in number from about day 4 and few viable cells remained after day 
7 (data not shown). 
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Figure 4.1. Effect of pre-bound or solution phase VN, IGFBPs and IGF-I on 
bone marrow derived fibroblastic cell attachment.  Whole bone marrow from 
patients undergoing orthopaedic surgery was obtained with informed consent. The 
mononuclear cell fraction was seeded onto pre-bound VN, IGFBP-3 and IGF-I (a & 
b) or pre-bound VN with solution phase IGFBP-3 (e & f) or IGFBP-5 (g & h) and 
IGF-I at a density of 1 x 106cells/cm2 and incubated in a humidified 5% CO2/95% air 
atmosphere at 37°C for up to 13 days. Mononuclear cells cultured in the presence of 
10% FCS served as positive control cultures (c & d). Photographs of cultures were 
taken at X200 magnification on day 1 and then as indicated. Bar = 100µm. 
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4.3.2 Effect of solution phase VN, IGFBP-5 and IGF-I on hMSC metabolic 
activity. 
Because the mononuclear fibroblastic cells had failed to thrive after 4 days of culture 
I elected to use hMSCs, which had been established in culture, for subsequent 
experiments. In addition, I decided to pre-bind VN to the culture surface as I had 
done previously but to leave the un-bound fraction of VN and growth factors in 
solution. Furthermore, as stated above I also wanted to examine if the addition of a 
higher concentration of VN would affect the response of hMSCs to any of the 
treatments. 
 
In the first instance, I found that hMSCs from established cultures, attached and 
spread well on all treatments in which VN was present. In contrast, where VN was 
absent the cells were rounded and appeared to be poorly attached. I measured the 
metabolic activity of hMSCs at 24 hr, 48 hr and 72 hr and found that after 72 hr there 
was no difference in the response of hMSCs to VN alone at either 52 ng/well (3.55 
nM), or 174 ng/well (11.9 nM) (Fig 4.2a). Indeed the VN concentration did not 
affect the metabolic activity response of hMSCs to any of the treatments unless it 
was absent altogether. However, VN alone at 52 ng/well, or at 174 ng/well (108.3 ± 
15.0% (n=11) or 105.8 ± 17.3% (n=12) of 24 hr –VN control respectively) resulted 
in significantly higher metabolic activity after 72 hr than hMSCs exposed to sf-
DMEM alone (72 hr –VN control) (64.5 ± 8.5% (n=16) of 24 hr –VN 
control)(p<0.05). Similarly, IGF-I in the presence of VN at 52 ng/well, or 174 
ng/well (130.7 ± 18.4% (n=11) or 121.9 ± 16.4% (n=12) of 24 hr –VN control 
respectively), resulted in significantly higher metabolic activity after 72 hr than the 
72 hr –VN control (p<0.01), as did hMSCs exposed to IGFBP-5 / IGF-I in the 
presence of VN at 52 ng/well, or 174 ng/well (104.4 ± 18.6% (n=11) or 110.6 ± 
16.0% (n=12) of 24 hr –VN control respectively)(p<0.01). In contrast, cultures 
exposed to IGFBP-5 alone but in the presence of VN at 52 ng/well, or 174 ng/well 
(92.0 ± 15.9% (n=11) or 96.7 ± 15.0% (n=12) of the 24 hr –VN control 
respectively), were not significantly different to the 72 hr –VN control. Interestingly, 
of the treatments containing VN, only the VN / IGFBP-5 treatments were 
statistically different to the response obtained for hMSCs exposed to 10% FCS 
(133.0 ± 8.0% (n=24) of the 24 hr –VN control)(p<0.05) (Fig 4.2a). These data 
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indicate that after 72 hr, VN was the major factor contributing to hMSC metabolic 
activity. 
However, analysis of the 174 ng/well VN time course data revealed that after 24 hr, 
the metabolic activity of hMSCs exposed to VN alone (150.3 ± 10.3% (n=12)), VN / 
IGFBP-5 / IGF-I (157.8 ± 10.3% (n=12)) or 10% FCS (155.0 ± 13.9% (n=30)) was 
significantly greater than the 24 hr –VN control (100.0 ± 1.4 % (n=17))(p<0.01). 
Surprisingly, the IGFBP-5 / IGF-I treatment (71.5 ± 2.8% (n=17)) sustained less 
metabolic activity than the 24 hr –VN control (p<0.01)(Fig 4.2b and Table 4.2.1). 
All treatments resulted in a decrease in metabolic activity over the next 48 hr prior to 
stabilising by 72 hr. Only in the presence of 10% FCS was a significant recovery of 
the metabolic activity observed between 48 hr and 72 hr (105.2 ± 3.0% (n=27) and 
133.0 ± 8.0% (n=24) of the 24 hr –VN control respectively)(p<0.01). However, the 
metabolic activity of the 10% FCS control measured after 72 hr was not significantly 
different to the activity after 24 hr, indicating that the hMSCs had recovered from the 
decrease observed between 24 hr and 48 hr.  
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Figure 4.2. Effect of solution phase VN, IGFBP-5 and IGF-I on hMSC 
metabolic activity. Sub-confluent cultures of hMSCs were harvested by trypsin 
digestion prior to seeding into wells of 96 well plates containing various 
combinations of either 3.55 nM or 11.9 nM VN (52 ng/well or 174 ng/well), 11.9 
nM IGFBP-5 (70 ng/well) and 11.9 nM IGF-I (17.4 ng/well) at a density of 5000 
cells/well. Cells seeded into wells without VN or with normal growth media 
containing 10% FCS were employed as controls. Plates were incubated for 24 hr b), 
48 hr b) or 72 hr a) & b) in a humidified 5% CO2/95% air atmosphere at 37°C prior 
to removal of conditioned media, addition of 110 µL of WST-1 / sf-DMEM solution 
and incubation in the same conditions for a further 2 hr. The absorbance of the 
coloured formazan cleavage product was quantitated at 450 nm using 650 nm as 
reference. Results were corrected using data from plate blanks (serum free media and 
WST-1 alone) and are expressed as the mean corrected absorbance as a percentage 
of the 24 hr –VN control (depicted by horizontal red line) ± standard error of the 
means (SEM). Results are from 4 separate experiments. a) Depicts results obtained at 
72 hr, while significance (post-hoc t-test) between individual treatments and the 72 
hr –VN control or between individual treatments where connected by line is 
indicated by α (p<0.05) or β (p<0.01). b) Depicts time course results obtained for –
VN, VN at 174ng/well (+VN) and ±VN / IGFBP-5 / IGF-I (±VN / 5 / I) treatments 
while significance between treatments is indicated by * (p<0.05) or # (p<0.01) and 
are presented below in table 4.2.1. 
 
Table 4.2.1 Summary of statistical analysis for Figure 4.2b 
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4.3.3 Effect of solution phase VN, IGFBP-3 and IGF-I on hMSC metabolic 
activity. 
hMSCs exposed to IGFBP-3 / IGF-I in the presence of VN at 52 ng/well or 174 
ng/well (114.0 ± 18.0% (n=11) or 119.3 ± 16.7% (n=12) of 24 hr –VN control 
respectively) were also examined and cells were found to exhibit significantly higher 
metabolic activity than the 72 hr –VN control (64.5 ± 8.5% (n=16) of the 24 hr –VN 
control) (p<0.01), indicating that IGFBP-3 / IGF-I has a similar effect on hMSC 
metabolic activity to IGFBP-5/IGF-I. However, unlike IGFBP-5, cultures exposed to 
IGFBP-3 alone but in the presence of VN at 52 ng/well, or 174 ng/well (99.2 ± 
15.6% (n=11) or 97.7 ± 14.8% (n=12) of the 24 hr –VN control respectively) 
possessed a significantly higher metabolic activity after 72 hr compared to the 72 hr 
–VN control (p<0.05) (Fig 4.3a). In addition, the VN / IGFBP-3 treatments yielded a 
response that was statistically different to the response observed when hMSCs were 
exposed to 10% FCS (133.0 ± 8.0% (n=24) of the 24 hr –VN control)(p<0.05). Thus 
after 72 hr, VN was the major factor contributing to measurable hMSC metabolic 
activity and the addition of either IGFBP-5, or IGFBP-3, with IGF-I could not 
stimulate metabolic activity over that obtained by VN alone or VN together with 
IGF-I (Fig 4.3a). 
 
Once again, analysis of the 174 ng/well VN data revealed that after 24 hr the 
metabolic activity of hMSCs exposed to VN / IGFBP-3 / IGF-I (165.1 ± 9.9% 
(n=12)) was significantly higher than the 24 hr –VN control (100.0 ± 1.4 % 
(n=17)(p<0.01), while cells treated with IGFBP-3 / IGF-I (80.5 ± 2.7% (n=17)) 
exhibited significantly lower metabolic activity (p<0.01) (Fig 4.3b and Table 4.3.1). 
As previously observed and noted the metabolic activity of hMSCs exposed to any 
treatment containing IGFBP-3 decreased between 24 hr and 48 hr and then stabilised 
by 72 hr.  
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Figure 4.3. Effect of solution phase VN, IGFBP-3 and IGF-I on hMSC 
metabolic activity. Sub-confluent cultures of hMSCs were harvested by trypsin 
digestion prior to seeding into wells of 96 well plates containing various 
combinations of either 3.55 nM or 11.9 nM VN (52 ng/well or 174 ng/well), 11.9 
nM IGFBP-3 (70 ng/well) and 11.9 nM IGF-I (17.4 ng/well) at a density of 5000 
cells/well. Cells seeded into wells without VN or with normal growth media 
containing 10% FCS were employed as controls. Plates were incubated for 24 hr b), 
48 hr b) or 72 hr a) & b) in a humidified 5% CO2/95% air atmosphere at 37°C prior 
to removal of conditioned media, addition of 110 µL of WST-1 / sf-DMEM solution 
and incubation in the same conditions for a further 2 hr. The absorbance of the 
coloured formazan cleavage product was quantitated at 450 nm using 650 nm as 
reference. Results were corrected using data from plate blanks (serum free media and  
WST-1 alone) and are expressed as the mean corrected absorbance as a percentage 
of the 24 hr –VN control (depicted by horizontal red line) ± standard error of the 
means (SEM). Results are from 4 separate experiments. a) Depicts results obtained at 
72 hr, while significance (post-hoc t-test) between individual treatments and the 72 
hr –VN control or between individual treatments where connected by line is 
indicated by α (p<0.05) or β (p<0.01). b) Depicts time course results obtained for –
VN, VN at 174ng/well (+VN) and ±VN / IGFBP-3 / IGF-I (±VN / 3 / I) treatments 
while significance between treatments is indicated by * (p<0.05) or # (p<0.01) and 
are presented below in table 4.3.1. 
 
Table 4.3.1 Summary of statistical analysis for Figure 4.3b 
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4.3.4 Effect of solution phase VN and TGF-β1 on hMSC metabolic activity. 
TGF-β1 and VN have been shown to associate in vitro and retain TGF-β1-mediated 
cell responses (Schoppet et al. 2002). TGF-β1 is highly expressed in bone tissue 
(O'Connor-McCourt and Wakefield 1987; Bonewald 1999) and has been shown to 
elicit a number of effects in hMSCs (Kassem et al. 2000; Kveiborg et al. 2001b; 
Spinella-Jaegle et al. 2001). I wished to determine if TGF-β1 together with VN, 
albeit presented in solution, could influence hMSC metabolic activity. Therefore, 
while performing the experiments detailed above, I included a selection of TGF-β1 
treatments similar to those used to investigate the influence of the IGFBPs. 
 
We found that by 72 hr the metabolic activity of hMSC cultures exposed to TGF-β1 
in the presence of VN at 52 ng/well, or 174 ng/well (164.5 ± 8.2% (n=11) or 204.5 ± 
7.7% (n=12) of the 24 hr –VN control respectively), was not only significantly 
different to that of the 72 hr –VN control (64.5 ± 8.5% (n=16) of the 24 hr –VN 
control) (p<0.01) but also higher than that for 1) cultures exposed to VN alone at 
either 52 ng/well, or 174 ng/well (108.3 ± 15.0% (n=11) or 105.8 ± 17.3% (n=12) of 
the 24 hr –VN control respectively) (p<0.01) and, significantly, 2) the 10% FCS 
control (133.0 ± 8.0% (n=24) of the 24 hr –VN control) (p<0.05 or p<0.01 
respectively) (Fig 4.4a). In addition the metabolic activity of hMSC cultures exposed 
to TGF-β1 alone was equivalent to that found after 72 hr in the –VN control. Taken 
together these data suggest that when TGF-β1 is combined with VN a synergistic 
effect on hMSC metabolic activity is observed after 72 hr.  
 
As previously observed, analysis of the 174 ng/well VN time course data revealed 
that after 24 hr the metabolic activity of hMSCs exposed to VN / TGF-β1 (173.1 ± 
16.0% (n=12)) was significantly enhanced relative to the 24 hr –VN control (100.0 ± 
1.4 % (n=17))(p<0.01). In contrast, the cells treated with TGF-β1 only (81.4 ± 8.0% 
(n=17)) possessed significantly lower metabolic activity than the 24 hr –VN control 
(p<0.01). Unlike any other treatment, however, hMSC metabolic activity did not 
significantly change between 24 hr and 72 hr in cultures exposed to TGF-β1 alone. 
Likewise, cultures exposed to the 174 ng/well VN / TGF-β1 treatment did not alter 
metabolic activity between 24 hr and 48 hr (173.1 ± 16.0% (n=12) and 139.1 ± 7.1% 
(n=12) of the 24 hr –VN control respectively) but did significantly increase hMSC 
metabolic activity between 48 hr and 72 hr (204.5 ± 7.7% (n=12) of the 24 hr –VN 
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control) (p<0.01). However, the level of metabolic activity assayed after 72 hr was 
not significantly different to that assayed after 24 hr (Fig 4.4b and Table 4.4.1). 
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Figure 4.4. Effect of solution phase VN and TGF-β1 on hMSC metabolic 
activity. 
Sub-confluent cultures of hMSCs were harvested by trypsin digestion prior to 
seeding into wells of 96 well plates containing various combinations of either 3.55 
nM or 11.9 nM VN (52ng/well a) or 174ng/well a) & b)) and 1.43nM TGF-β1 
(7ng/well) at a density of 5000 cells/well. Cells seeded into wells without VN or 
with normal growth media containing 10% FCS were employed as controls. Plates 
were incubated for 24 hr b), 48 hr b) or 72 hr a) & b) in a humidified 5% CO2/95% 
air atmosphere at 37°C prior to removal of conditioned media, addition of 110 µL of 
WST-1 / sf-DMEM solution and incubation in the same conditions for a further 2 hr. 
The absorbance of the coloured formazan cleavage product was quantitated at 450 
nm using 650 nm as reference. Results were corrected using data from plate blanks 
(serum free media and WST-1 alone) and are expressed as the mean corrected 
absorbance as a percentage of the 24 hr –VN control (depicted by horizontal red line) 
± standard error of the means (SEM). Results are from 4 separate experiments. a) 
Depicts results obtained at 72 hr, while significance (post-hoc t-test) between 
individual treatments and the 72 hr –VN control or between individual treatments 
where connected by line is indicated by α (p<0.05) or β (p<0.01). b) Depicts time 
course results obtained for –VN, VN at 174ng/well (+VN) and ±VN / TGF-β1 (±VN 
/ TGF-β1) treatments while significance between treatments is indicated by * 
(p<0.05) or # (p<0.01) and are presented below in table 4.4.1. 
 
Table 4.4.1 Summary of statistical analysis for Figure 4.4b 
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4.3.5 Effect of solution phase VN, IGFBP-5 and IGF-I on hMSC total protein. 
While measurement of metabolic activity may provide an indication of the effect of a 
particular treatment on cell function at the time of measurement, it does not 
necessarily give an indication as to any cumulative effects that the treatment may 
cause such as protein synthesis or cell proliferation. Therefore in order to broadly 
determine whether various combinations of VN, IGFBP-3 or -5 and IGF-I or TGF-β1 
may facilitate any cumulative effect on hMSCs, I decided to coincidently measure 
the relative total protein of hMSCs in the assays detailed above. hMSC monolayer 
cultures stained with the vital dye crystal violet demonstrated that after 72 hr there 
was no difference in the total protein of hMSCs exposed to VN at either 52 ng/well 
(3.55 nM) or 174 ng/well (11.9 nM) in any treatment (Fig 4.5a). Thus the VN 
concentration had no effect on the total protein accumulation within the monolayers 
of hMSCs exposed to any of the treatments, except when absent altogether. 
However, VN alone at 174 ng/well (173.7 ± 21.8% (n=12) of 24 hr –VN control) 
yielded a significantly higher total protein accumulation after 72 hr than hMSCs 
exposed to sf-DMEM alone (72 hr –VN control) (115.3 ± 11.1% (n=12) of 24 hr –
VN control) (p<0.05). Interestingly, VN at 52 ng/well (162.5 ± 20.0% (n=12) of the 
24 hr –VN control), while elevated, did not support significantly higher protein 
accumulation compared to the 72 hr –VN control. Where IGF-I was present with VN 
at 52 ng/well or 174 ng/well (206.9 ± 26.1% (n=12) or 198.6 ± 19.8% (n=12) of 24 
hr –VN control respectively) significantly more protein was present after 72 hr than 
the 72 hr –VN control (p<0.01). Similarly, hMSCs exposed to IGFBP-5 alone, but in 
the presence of VN at 52 ng/well or 174 ng/well (168.0 ± 21.8% (n=12) or 194.3 ± 
26.8% (n=12) of the 24 hr –VN control respectively), also displayed significantly 
elevated levels of total protein compared to the 72 hr –VN control (p<0.05), as did 
cultures exposed to IGFBP-5 / IGF-I with VN at 52 ng/well or 174 ng/well (209.0 ± 
28.4% (n=12) or 232.9 ± 32.0% (n=12) of 24 hr –VN control respectively) (p<0.01). 
Interestingly, of the treatments containing VN, only cultures exposed to either VN 
alone at 52 ng/well or VN at 52 ng/well with IGFBP-5  yield significantly less total 
protein than the 72 hr 10% FCS control (241.5 ± 21.8% (n=21) of the –VN control) 
(p<0.05).  
 
Analysis of the VN at 174 ng/well time course data showed that after 24 hr the total 
protein of cultures exposed to VN alone, VN / IGFBP-5 / IGF-I or 10% FCS (142.6 
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± 13.6% (n=12), 173.3 ± 18.4% (n=12) or 156.4 ± 11.5% (n=24) of the 24 hr –VN 
control respectively) was significantly higher than the 24 hr –VN control (100.0 ± 
9.5 % (n=12)) (p<0.05, p<0.01 and p<0.01 respectively). However, total protein 
measured in hMSC cultures exposed to IGFBP-5 / IGF-I (82.2 ± 8.2% (n=12) of the 
24 hr –VN control) or the 24 hr –VN control (Fig 4.5b and Table 4.5.1) were 
statistically equivalent. While all treatments increased hMSC total protein over 72 
hr, none of the increases were significant with the exception of the 10% FCS 
treatment, which produced a significant increase in total protein between 24 hr and 
72 hr (156.4 ± 11.5% (n=24) and 241.5 ± 21.8% (n=21) of the 24 hr –VN control 
respectively)(p<0.01). Taken together these data indicate that in this system VN is 
primarily responsible for influencing the total protein level of hMSCs after 72 hr and 
that the addition of IGF-I elevates this. The addition of IGFBP-5 together with IGF-I 
does not increase total protein levels over that assayed for IGF-I together with VN.   
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Figure 4.5. Effect of solution phase VN, IGFBP-5 and IGF-I on hMSC total 
protein. Sub-confluent cultures of hMSCs were harvested by trypsin digestion prior 
to seeding into wells of 96 well plates containing various combinations of either 3.55 
nM or 11.9 nM VN (52 ng/well or 174 ng/well), 11.9 nM IGFBP-5 (70 ng/well) and 
11.9 nM IGF-I (17.4 ng/well) at a density of 5000 cells/well. Cells seeded into wells 
without VN or with normal growth media containing 10% FCS were employed as 
controls. Plates were incubated for 24 hr b), 48 hr b) or 72 hr a) & b) in a humidified 
5% CO2/95% air atmosphere at 37°C. Cells and protein were fixed with 4% 
paraformaldehyde and then stained with freshly prepared crystal violet. Plates were 
then washed, allowed to air dry and the crystal violet extracted with 10% acetic acid. 
The absorbance of each well was then quantitated at 595 nm. Results were corrected 
using data from plate blanks (10% acetic acid alone) and are expressed as the mean 
corrected absorbance as a percentage of the 24 hr –VN control (depicted by 
horizontal red line) ± standard error of the means (SEM). Results are from 4 separate 
experiments. a) Depicts results obtained at 72 hr, while significance (post-hoc t-test) 
between individual treatments and the 72 hr –VN control or between individual 
treatments where connected by line is indicated by α (p<0.05) or β (p<0.01). b) 
Depicts time course results obtained for –VN, VN at 174ng/well (+VN) and ±VN / 
IGFBP-5 / IGF-I (±VN / 5 / I) treatments while significance between treatments is 
indicated by * (p<0.05) or # (p<0.01) and are presented below in table 4.5.1. 
 
Table 4.5.1 Summary of statistical analysis for Figure 4.5b 
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4.3.6  Effect of solution phase VN, IGFBP-3 and IGF-I on hMSC total protein. 
Similar to the results obtained for the metabolic activity assays, the total protein 
response of hMSCs exposed to the various treatments incorporating either IGFBP-3 
or IGFBP-5 were almost identical. Specifically, I found that after 72 hr hMSCs 
exposed to IGFBP-3 in the presence of VN at 52 ng/well (152.2 ± 17.3% (n=12) of 
the 24 hr –VN control) did not have significantly more total protein compared to the 
72 hr –VN control (115.3 ± 11.1% (n=12) of the 24 hr –VN control) and had 
significantly less total protein than the 72 hr 10% FCS control (241.5 ± 21.8% 
(n=12) of the 24 hr –VN control) (p<0.01) (Fig 4.6a). In contrast, hMSCs exposed to 
IGFBP-3 in the presence of VN at 174 ng/well (164.0 ± 17.1% (n=12) of the 24 hr –
VN control) had significantly more total protein compared to the 72 hr –VN control 
(p<0.05), as did cultures exposed to IGFBP-3 / IGF-I with VN at 52 ng/well or 174 
ng/well (209.5 ± 26.8% (n=12) or 237.3 ± 29.9% (n=12) of 24 hr –VN control 
respectively) (p<0.01). However, the hMSC response to the IGFBP-3 / 174 ng of VN 
treatment was also significantly less than the response to 10% FCS (p<0.05) after 72 
hr, whereas there was no statistical difference between either of the IGFBP-3 / IGF-I 
responses and the 72 hr 10% FCS control. Interestingly, I found that hMSCs exposed 
to IGFBP-3 / IGF-I in the presence of VN at 174 ng/well accumulated significantly 
more total protein than IGFBP-3 with VN at either 52 ng/well or 174 ng/well or than 
VN alone at 52 ng/well (p<0.05).  
 
Analysis of the response of cells to VN at 174 ng/well over time showed that after 24 
hr the total protein of the cultures exposed to VN / IGFBP-3 / IGF-I (182.2 ± 20.1% 
(n=12) of the 24 hr –VN control) was significantly higher than the 24 hr –VN control 
(100.0 ± 9.5 % (n=12)) (p<0.01). However, there was no difference in total protein 
between hMSC cultures exposed to IGFBP-3 / IGF-I (102.8 ± 9.1% (n=12) of the 24 
hr –VN control) or the 24 hr –VN control (Fig 4.6b and Table 4.6.1). Paralleling the 
responses found with cultures exposed to IGFBP-5, treatments containing IGFBP-3 
increased hMSC total protein over 72 hr although these increases were not 
statistically significant with the exception, as described above, of the 10% FCS 
treatment which produced a significant increase in total protein between 24 hr and 72 
hr. These data suggest that there is little effect if any on the total protein content of 
cultures exposed to either IGFBP-3 or IGFBP-5, regardless of whether VN or IGF-I 
or both are present or not. 
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Figure 4.6. Effect of solution phase VN, IGFBP-3 and IGF-I on hMSC total 
protein. Sub-confluent cultures of hMSCs were harvested by trypsin digestion prior 
to seeding into wells of 96 well plates containing various combinations of either 3.55 
nM or 11.9 nM VN (52 ng/well or 174 ng/well), 11.9 nM IGFBP-3 (70 ng/well) and 
11.9 nM IGF-I (17.4 ng/well) at a density of 5000 cells/well. Cells seeded into wells 
without VN or with normal growth media containing 10% FCS were employed as 
controls. Plates were incubated for 24 hr b), 48 hr b) or 72 hr a) & b) in a humidified 
5% CO2/95% air atmosphere at 37°C. Cells and protein were fixed with 4% 
paraformaldehyde and then stained with freshly prepared crystal violet. Plates were 
then washed, allowed to air dry and the crystal violet extracted with 10% acetic acid. 
The absorbance of each well was then quantitated at 595 nm. Results were corrected 
using data from plate blanks (10% acetic acid alone) and are expressed as the mean 
corrected absorbance as a percentage of the 24 hr –VN control (depicted by 
horizontal red line) ± standard error of the means (SEM). Results are from 4 separate 
experiments. a) Depicts results obtained at 72 hr, while significance (post-hoc t-test) 
between individual treatments and the 72 hr –VN control or between individual 
treatments where connected by line is indicated by α (p<0.05) or β (p<0.01). b) 
Depicts time course results obtained for –VN, VN at 174ng/well (+VN) and ±VN / 
IGFBP-3 / IGF-I (±VN / 3 / I) treatments while significance between treatments is 
indicated by * (p<0.05) or # (p<0.01) and are presented below in table 4.6.1. 
 
Table 4.6.1 Summary of statistical analysis for Figure 4.6b 
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4.3.7 Effect of solution phase VN and TGF-β1 on hMSC total protein. 
As discussed above, TGF-β1 can associate with VN and therefore I wished to 
investigate the effect of TGF-β1 on hMSC total protein over 72 hr. I found that after 
72 hr hMSCs exposed to TGF-β1 in the presence of VN at 52 ng/well (184.9 ± 
22.7% (n=12) of the 24 hr –VN control) accumulated significantly more total protein 
than either the 72 hr –VN control (115.3 ± 11.1% (n=12) of the 24 hr –VN control) 
or hMSCs cultured in the presence of TGF-β1 without VN (122.6 ± 14.7% (n=12) of 
the 24 hr -VN control) (p<0.05). Similarly, hMSCs exposed to TGF-β1 in the 
presence of VN at 174 ng/well (223.8 ± 26.9% (n=12) of the 24 hr –VN control) had 
significantly more protein than either the 72 hr –VN control or the TGF-β1 only 
treatment (p<0.01) (Fig 4.7a). Neither TGF-β1 / VN treatments resulted in 
statistically significant differences in total protein responses compared to the 72 hr 
10% FCS control (241.5 ± 21.8% (n=21) of the 24 hr –VN control), nor were they 
statistically different to the results of either of the VN only treatments after 72 hr. In 
a similar manner, hMSC total protein in TGF-β1 only was not different to that for the 
72 hr –VN control but had significantly less total protein than the 72 hr 10% FCS 
control (p<0.01) (Fig 4.7a).  Taken together, these data indicate that while culturing 
of hMSCs in the presence of TGF-β1 and VN in solution can increase hMSC total 
protein compared to VN alone, this increase is transient and is not significant after 
72 hr. 
 
The 174 ng/well time course data showed that after 24 hr the total protein of cultures 
exposed to VN / TGF-β1 (156.1 ± 14.9% (n=12) of the 24 hr –VN control) was 
significantly higher than the 24 hr –VN control (100.0 ± 9.5 % (n=12)) (p<0.01). 
However, there was no difference in total protein between hMSC cultures exposed to 
TGF-β1 (93.3 ± 10.1% (n=12) of the 24 hr –VN control) and the 24 hr –VN control. 
In contrast to the IGFBP-5 and IGFBP-3 data presented above, TGF-β1, in the 
presence of VN, significantly increased hMSC total protein between 24 hr and 72 hr 
(223.8 ± 26.9% (n=12) or the 24 hr –VN control) (p<0.05) (Fig 4.7b and Table 
4.7.1). This indicates that TGF-β1 together with VN can stimulate an increase in 
hMSC total protein over 72 hr and this seems to be in contrast (at least statistically) 
to VN / IGFBP-5 / IGF-I or IGFBP-3 / IGF-I. 
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Figure 4.7. Effect of solution phase VN and TGF-β1 on hMSC total protein. 
Sub-confluent cultures of hMSCs were harvested by trypsin digestion prior to 
seeding into wells of 96 well plates containing various combinations of either 3.55 
nM or 11.9 nM VN (52 ng/well or 174 ng/well) and 1.43 nM TGF-β1 (7 ng/well) at a 
density of 5000 cells/well. Cells seeded into wells without VN or with normal 
growth media containing 10% FCS were employed as controls. Plates were 
incubated for 24 hr b), 48 hr b) or 72 hr a) & b) in a humidified 5% CO2/95% air 
atmosphere at 37°C. Cells and protein were fixed with 4% paraformaldehyde and 
then stained with freshly prepared crystal violet. Plates were then washed, allowed to 
air dry and the crystal violet extracted with 10% acetic acid. The absorbance of each 
well was then quantitated at 595 nm. Results were corrected using data from plate 
blanks (10% acetic acid alone) and are expressed as the mean corrected absorbance 
as a percentage of the 24 hr –VN control (depicted by horizontal red line) ± standard 
error of the means (SEM). Results are from 4 separate experiments. a) Depicts 
results obtained at 72 hr, while significance (post-hoc t-test) between individual 
treatments and the 72 hr –VN control or between individual treatments where 
connected by line is indicated by α (p<0.05) or β (p<0.01). b) Depicts time course 
results obtained for –VN, VN at 174ng/well (+VN) and ±VN / TGF-β1 treatments 
while significance between treatments is indicated by * (p<0.05) or # (p<0.01) and 
are presented below in table 4.7.1. 
 
Table 4.7.1 Summary of statistical analysis for Figure 4.7b 
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4.3.8 Time dependent effect of IGF-I and TGF-β1 on hMSC culture 
morphology. 
Prior to solubilisation of the crystal violet stain in the total protein assays described 
above I inspected the stained cell monolayers under the microscope and noticed 
distinct morphological differences between some of the treatments; consequently 
each well was photographed in order to assess the impact of each treatment on 
hMSC culture morphology. Initially few cells remained attached in cultures which 
had been exposed to treatments without VN, after 24 hr (data not shown). This 
suggested that in this system VN was critical for facilitating hMSC attachment to the 
culture surface. In contrast hMSC cultures exposed to treatments containing VN at 
either 52 ng/well (Fig 4.8a.1 – a.8) or 174 ng/well (not shown), were relatively 
uniformly distributed throughout each well with most cells appearing spread and 
well attached. Cells cultured in 10% FCS appeared to have more homogeneous 
nuclei and cytoskeletal structure (Fig 4.8a.7). Cells in the VN containing treatments 
on the other hand appeared a little more heterogeneous in their cytoskeletal 
architecture. In addition, there was some evidence of slightly more intense crystal 
violet staining of isolated patches throughout the wells (Fig 4.8a.1-6 and 4.8a.8). 
After 48 hr distinct differences in culture morphology began to appear. Specifically, 
hMSC cultures exposed to VN at 52 ng/well and in the presence of either IGF-I 
(with or without either of the IGFBPs) or TGF-β1 began to contract and aggregate 
exposing large gaps/holes in the monolayer (Fig 4.8b.2, 4, 6 & 8). However, hMSC 
cultures which were exposed to 52 ng/well of VN in the presence of either of the 
IGFBPs developed only relatively small gaps/holes in their respective monolayers 
(Fig 4.8b.3 & 5). Cultures exposed to VN alone at 52 ng/well and 10% FCS 
remained relatively evenly distributed throughout their respective wells with little or 
no contraction (Fig 4.8b.1 & 7). After 72 hr hMSC cultures exposed to either IGF-I 
(with or without either of the IGFBPs) or TGF-β1, together with VN at 52 ng/well 
had further contracted, leaving large areas of culture surface devoid of cells (Fig 
4.8c.2, 4, 6 and 8). hMSC cultures exposed to VN at 52 ng/well and IGFBP-3, and to 
a slightly lesser extent IGFBP-5, had also started to develop similar but much 
smaller gaps/holes in their respective monolayers (Fig 4.8c.3 & 5). However, after 
72 hr, hMSC cultures exposed to VN alone at 52 ng/well or 10% FCS had still not 
formed any substantial gaps/holes similar to those observed for cultures in the 
presence of either IGF-I or TGF-β1 (Fig 4.8c.1 & 7). These data indicate that in this 
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system IGF-I and TGF-β1 can induce time dependent aggregation and contraction of 
hMSC cultures.    
 
4.3.9 Effect of VN concentration on IGF-I and TGF-β1 mediated hMSC culture 
aggregation.  
In contrast to the morphological changes observed when hMSC cultures were 
exposed to VN at 52 ng/well in the presence of IGF-I or TGF-β1, there was no 
evidence of any substantial contraction of hMSC cultures exposed to VN at 174  
ng/well after 48 hr (data not shown). Indeed, even after 72 hr hMSC cultures 
exposed to either IGF-I or TGF-β1 in the presence of VN at 174 ng/well had retained 
a similar confluent morphology in their monolayers (Fig 4.9a.2, 4, 6 & 8). 
 
Furthermore, hMSC cultures exposed to IGFBP-3 or -5 in the presence of VN at 174 
ng/well also did not develop any clear gaps / holes in the monolayers (Fig 4.9a.3 & 
5) unlike similarly treated cultures exposed VN at 52 ng/well as detailed above. 
Similarly, the hMSC cultures exposed to VN alone at 174 ng/well appeared 
confluent with no discernable aggregation of cells and no obvious gap / hole 
formation, as was the case for cells exposed to VN at 52 ng/well at the same time 
point (Fig 4.9a.1). Thus, VN at the higher concentration appears to have an 
antagonistic effect on the time dependent aggregation / contraction of hMSC cultures 
in response to IGF-I and TGF-β1 detailed above. 
 
4.3.10 Donor effect on IGF-I and TGF-β1 mediated hMSC culture aggregation.  
 In order to demonstrate that this effect was not a donor specific response I captured 
images of each well from the total protein assays detailed above (section 4.2.6 & 
4.2.7). A comparison of hMSC cultures, sourced from 3 separate donors, exposed to 
identical treatments detailed above, revealed that there was no donor specific effect. 
Representative images of hMSCs from each donor exposed to VN at either 52 
ng/well or 174 ng/well in the presence or absence of IGFBP-5 with or without IGF-I 
exhibited similar responses to each treatment between donors (Fig 4.10).   
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Figure 4.8a. Effect of IGF-I and TGF-β1 on hMSC culture morphology after 24 
hr. Sub-confluent cultures of hMSCs were harvested by trypsin digestion prior to 
seeding into wells of 96 well plates containing various combinations of  3.55 nM VN 
(52 ng/well) and 11.9 nM IGFBP-3 or -5 (70 ng/well) and 11.9 nM IGF-I 
(17.4ng/well) or 1.43nM TGF-β1 (7 ng/well) at a density of 5000 cells/well. Cells 
seeded into wells without VN or with normal growth media containing 10% FCS 
were employed as controls. Plates were incubated for 24 hr in a humidified 5% 
CO2/95% air atmosphere at 37°C. Cells and protein were fixed with 4% 
paraformaldehyde and then stained with freshly prepared crystal violet. Plates were 
then washed, allowed to air dry and digital images of each well captured at X100 
magnification. Bar = 200µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8a  
a.4  VN/IGFBP-3/IGF-I a.3  VN/IGFBP-3 
a.5  VN/IGFBP-5 a.6  VN/IGFBP-5/IGF-I 
a.8  VN/TGF-ß1a.7  10% FCS 
a.1  VN a.2 VN/IGF-I 
x100 
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Figure 4.8b. Effect of IGF-I and TGF-β1 on hMSC culture morphology after 48 
hr. Sub-confluent cultures of hMSCs were harvested by trypsin digestion prior to 
seeding into wells of 96 well plates containing various combinations of  3.55 nM VN 
(52 ng/well) and 11.9 nM IGFBP-3 or -5 (70 ng/well) and 11.9 nM IGF-I 
(17.4ng/well) or 1.43nM TGF-β1 (7 ng/well) at a density of 5000 cells/well. Cells 
seeded into wells without VN or with normal growth media containing 10% FCS 
were employed as controls. Plates were incubated for 48 hr in a humidified 5% 
CO2/95% air atmosphere at 37°C. Cells and protein were fixed with 4% 
paraformaldehyde and then stained with freshly prepared crystal violet. Plates were 
then washed, allowed to air dry and digital images of each well captured at X100 
magnification. Bar = 200µm. 
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Figure 4.8b   
b.3  VN/IGFBP-3 
b.5  VN/IGFBP-5 b.6  VN/IGFBP-5/IGF-I 
b.8  VN/TGF-ß1b.7  10% FCS 
b.1  VN b.2 VN/IGF-I 
x100 
b.4  VN/IGFBP-3/IGF-I 
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Figure 4.8c. Effect of IGF-I and TGF-β1 on hMSC culture morphology after 72 
hr. Sub-confluent cultures of hMSCs were harvested by trypsin digestion prior to 
seeding into wells of 96 well plates containing various combinations of 3.55 nM VN 
(52 ng/well) and 11.9 nM IGFBP-3 or -5 (70 ng/well) and 11.9 nM IGF-I 
(17.4ng/well) or 1.43nM TGF-β1 (7 ng/well) at a density of 5000 cells/well. Cells 
seeded into wells without VN or with normal growth media containing 10% FCS 
were employed as controls. Plates were incubated for 72 hr in a humidified 5% 
CO2/95% air atmosphere at 37°C. Cells and protein were fixed with 4% 
paraformaldehyde and then stained with freshly prepared crystal violet. Plates were 
then washed, allowed to air dry and digital images of each well captured at X100 
magnification. Bar = 200µm. 
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Figure 4.8c 
c.4  VN/IGFBP-3/IGF-I c.3  VN/IGFBP-3 
c.5  VN/IGFBP-5 c.6  VN/IGFBP-5/IGF-I 
c.8  VN/TGF-ß1c.7  10% FCS 
c.1  VN c.2 VN/IGF-I 
x100 
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Figure 4.9. Effect of VN concentration on IGF-I and TGF-β1 mediated hMSC 
culture aggregation. Sub-confluent cultures of hMSCs were harvested by trypsin 
digestion prior to seeding into wells of 96 well plates containing various 
combinations of 11.9 nM VN (174 ng/well) and 11.9 nM IGFBP-3 or -5 (70 ng/well) 
and 11.9 nM IGF-I (17.4 ng/well) or 1.43 nM TGF-β1 (7 ng/well) at a density of 
5000 cells/well. Cells seeded into wells without VN or with normal growth media 
containing 10% FCS were employed as controls. Plates were incubated for 72 hr in a 
humidified 5% CO2/95% air atmosphere at 37°C. Cells and protein were fixed with 
4% paraformaldehyde and then stained with freshly prepared crystal violet. Plates 
were then washed, allowed to air dry and digital images of each well captured at 
X100 magnification. Bar = 200µm. 
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Figure 4.9 
a.4  VN/IGFBP-3/IGF-I a.3  VN/IGFBP-3 
a.5  VN/IGFBP-5 a.6  VN/IGFBP-5/IGF-I 
a.8  VN/TGF-ß1a.7  10% FCS 
a.1  VN a.2 VN/IGF-I 
x100 
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Figure 4.10. Donor effect on IGF-I and TGF-β1 mediated hMSC culture 
aggregation. Sub-confluent cultures of hMSCs from 3 separate donors were 
harvested by trypsin digestion prior to seeding into wells of 96 well plates containing 
various combinations of either 3.55 nM (52 ng/well) or 11.9 nM (174 ng/well) VN 
and 11.9 nM IGFBP-5 (70 ng/well) and 11.9 nM IGF-I (17.4 ng/well) or 1.43 nM 
TGF-β1 (7 ng/well) at a density of 5000 cells/well. Cells seeded into wells without 
VN or with normal growth media containing 10% FCS were employed as controls. 
Plates were incubated for 72 hr in a humidified 5% CO2/95% air atmosphere at 
37°C. Cells and protein were fixed with 4% paraformaldehyde and then stained with 
freshly prepared crystal violet. Plates were then washed, allowed to air dry and 
digital images of each well captured at X100 magnification. Bar = 200µm. 
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Figure 4.10 
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4.3.11 Effect of solution phase VN, IGFBP-3 or -5 and IGF-I or TGF-β1 on 
expression of MMP-2 and MMP-9 by hMSCs. 
Because mesenchymal cells are known to express a variety of proteases including 
members of the matrix metalloprotease (MMP) family of proteins (Sternlicht and 
Werb 2001) and because IGF-I and TGF-β1 are both known to regulate expression of 
MMPs in cells of mesenchymal origin (Blumenfeld et al. 2002b), I hypothesised that 
the aggregation and contraction of cultures observed in the presence of either IGF-I 
or TGF-β1 was due to the action of secreted MMPs. I therefore decided to investigate 
whether the presence of IGF-I or TGF-β1 influenced the secretion of MMP-2 or -9 
(members of the metalloprotease family of proteases whose substrates include 
IGFBP-3, -5 and VN) by gelatin zymography. Somewhat surprisingly, I found that 
there was no difference in MMP-2 or -9 expression in any of the treatments and that 
both MMP-2 and MMP-9 were expressed in their pro-form. Thus, IGF-I and TGF-β1 
did not influence the secretion of these 2 proteases into the conditioned media, nor 
their activation. Indeed, the data obtained for the 72 hr –VN control (hMSCs 
cultured in serum free media alone) suggests that hMSCs constitutively secrete 
MMP-2 and -9 (Fig 4.11a.1 & b.1). Each donor’s cells produced similar results as 
demonstrated by comparison of gelatin zymograms of hMSC conditioned media 
derived from 2 separate donors depicted in Fig 4.11. Furthermore, MMP-2 and 
MMP-9 were both apparent after 24 hr and appeared to accumulate in the 
conditioned media over time, demonstrated by the increased lytic activity in the 48 
hr and 72 hr zymograms (Fig 4.12a, b & c). Thus, hMSCs constitutively express pro-
MMP-2 and pro-MMP-9 into the media. However, given that there were no 
discernable differences in the pro-MMP-2 or pro-MMP-9 expression between 
treatments, it is unlikely that either of these proteases were directly responsible for 
the aggregation or contraction of hMSC cultures in response to IGF-I or TGF-β1. 
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Figure 4.11. Effect of solution phase VN, IGFBP-3 or -5 and IGF-I or TGF-β1 
on expression of MMP-2 and MMP-9 by hMSCs. 
Conditioned media was sampled from representative wells of 72 hr cultures from 
separate donors prior to fixation of cells for crystal violet staining during the total 
protein assays as described in the materials and methods and section 4.2.6. Protease 
species present in conditioned media were detected and characterised with gelatin 
zymography as described in the materials and methods and section 4.2.8. Samples 
(20 µL) were separated on 10% gelatin SDS-PAGE gels. The gels were then washed 
in 2.5% Triton-X100 and then incubated for 48 hr at 37°C in activation buffer. 
Zymograms were then stained for 2 hr with Coomasie blue R250 stain de-stained in 
10% acetic acid and 40% methanol (vol / vol). Gelatinase activity was then 
visualised as clear bands and discriminated by comparison to purified pro-MMP-2 
and MMP-9 standards. IGFBP-3 or -5 are abbreviated to BP-3 or -5 for simplicity. 
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Figure 4.12. Time dependent expression of MMP-2 and –9 
Conditioned media was sampled from representative wells of a) 24, b) 48 and c) 72 
hr cultures from separate donors prior to fixation of cells for crystal violet staining 
during the total protein assays as described in the materials and methods and section 
4.2.6. Protease species present in conditioned media were detected and characterised 
with gelatin zymography as described in the materials and methods and section 
4.2.8. Samples (20 µL) were separated on 10% gelatin SDS-PAGE gels. The gels 
were then washed in 2.5% Triton-X100 and then incubated for 48 hr at 37 °C in 
activation buffer. Zymograms were then stained for 2 hr with Coomasie blue R250 
stain de-stained in 10% acetic acid and 40% methanol (vol / vol). Gelatinase activity 
was then visualised as clear bands and discriminated by comparison to purified pro-
MMP-2 and MMP-9 standards. IGFBP-3 or -5 are abbreviated to BP-3 or -5 for 
simplicity. 
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4.3.12 Degradation of IGFBP-5 by hMSC conditioned media. 
The IGFBPs, IGFBP-3 and -5 are known to be susceptible to proteolytic degradation 
by a wide variety of proteases including MMP-2 and -9 (Fowlkes et al. 1995). 
Therefore to determine if IGFBP-5 could be potentially degraded by the conditioned 
media I examined hMSC-conditioned media, which had been spiked with IGFBP-5, 
for degradation products by western blot analysis. I found that IGFBP-5 could be 
degraded by conditioned media from hMSCs cultured in serum free media for 72 hr 
(Fig 4.13). This indicates that some entity within the hMSC conditioned media is 
capable of degrading IGFBP-5 and the expression of this entity is independent of any 
additional treatment with VN, IGFBP-3 or -5, IGF-I, TGF-β1 or 10% FCS.  
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Figure 4.13 IGFBP-5 degradation by hMSC conditioned media. 
Samples of conditioned media from hMSCs cultured in sf-DMEM alone, collected 
from the total protein assays, were incubated over night at 37°C with or without 
recombinant human IGFBP-5 and then run under reducing conditions on a 4%-20% 
gradient SDS-PAGE gel. Recombinant human IGFBP-5 in phosphate buffered saline 
or sf-DMEM were employed as controls. Proteins were then transferred to a 
nitrocellulose membrane prior to interrogation with a chicken anti IGFBP-5 
polyclonal antibody and subsequent 1° antibody detection with a rabbit anti chicken-
HRP conjugated 2° antibody and chemiluminescent substrate. Chemiluminescence 
was then captured on photographic film. 
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4.4 DISCUSSION 
There has been a vast body of literature generated in the last decade describing the 
development and efficacy of hMSCs as a reparative therapeutic, whether as part of a 
tissue engineered biomaterial construct for bone repair or re-infusion of ex vivo 
expanded cells for treatment of cardiac failure (Bruder et al. 1998a; Bruder et al. 
1998c; Young et al. 1998; Koc et al. 1999; Ohgushi and Caplan 1999; Oreffo and 
Triffitt 1999; Richards et al. 1999; Koc et al. 2000; Bianco et al. 2001; Caplan and 
Bruder 2001; Minguell et al. 2001; Derubeis and Cancedda 2004; Hermann et al. 
2004). However, in vitro culture of these cells is still largely dependent on the use of 
animal-derived products, particularly FCS, which remains essentially undefined. 
With the changing regulatory climate concerning tissues for therapeutic applications, 
the development of culture methodologies for hMSCs which include defined media 
components and do not include poorly defined animal products has become a vital 
area of research within the field of tissue engineering (Kujawa et al. 1989; Rousche 
et al. 2001; Fukumoto et al. 2003; Stute et al. 2004; Meuleman et al. 2006). The 
concept of serum free media development was consistent with the investigations into 
the effects of pre-bound combinations of the ECM protein VN and the IGFs on cell 
function, including osteoblasts as discussed in the previous chapter. 
 
With this chapter I report broad preliminary studies into the effect of the ECM 
glycoprotein VN in association with various combinations of IGFBP-3 or -5, IGF-I 
or TGF-β1, on hMSC behaviour in a serum-free environment. Initially, I attempted to 
initiate hMSC culture from crude bone marrow-derived mononuclear cell fractions 
on pre-bound combinations of VN and IGFBP-3 or -5 and IGF-I, or VN and TGF-β1, 
by performing colony forming unit fibroblastic assays (Figure 4.1). Over 7 days of 
culture few cells had appeared to attach to the coated culture surfaces (Figure 4.1a & 
b) whereas, colony formation and fibroblastic cells were clearly visible in cultures 
exposed to 10% FCS, as expected (Figure 4.1c & d). Thus the donor cells used in 
these assays were viable and capable of forming healthy colonies and continued to 
develop beyond 7 days of culture. Based on this initial result I decided to pre-bind 
the VN but to leave the unbound fraction and growth factors in solution for 
subsequent assays in order to try and: 1) initiate fibroblastic cell attachment; and 2) 
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prolong the viability of any attached cells by leaving the unbound fractions of the 
VN and the growth factors in solution.  
 
Initially, this strategy seemed successful as after 1 day of culture a number of 
fibroblast-like cells were attached to the culture surface, although unexpectedly these 
were not incorporated into colonies but were discrete and seemingly randomly 
arranged throughout the wells (Figure 4.1e & g). After 3 days of culture the number 
of attached fibroblastic cells had increased, however, it is not clear whether the 
observed increase was due to cell proliferation or due to increased cell attachment 
from the existing population of mononuclear cells (Figure 4.1f & h). Curiously, the 
cells attached to the protein coated surface appeared more spindle shaped and 
smaller than the fibroblast-like cells present in the 10% FCS. Furthermore, the 
number of attached cells did not continue to increase but rather declined over the 
next few days of culture until few cells remained attached (data not shown). These 
data suggest that VN together with either IGFBP-3 or 5 and IGF-I or TGF-β1 can 
initiate fibroblast formation from crude preparations of bone marrow mononuclear 
cells but cannot sustain them past about 3-4 days of culture. Moreover, pre-bound 
VN in combination with pre-bound IGFBPs and IGF-I could not initiate fibroblast 
attachment from the bone marrow preparations.  
 
It is possible that non mesenchymal cell types present in the crude mix of 
mononuclear cells depleted the VN and growth factors, whereas, when the 
components were present at a higher concentration there may have been sufficient 
VN and growth factor in the media to facilitate fibroblast formation. It also remains 
unclear as to whether these cells were indeed hMSCs. A possible means of testing 
the hypothesis that these cells were in fact hMSCs would be to remove all non bound 
cells at the earliest convenience and replace the media with 10% FCS to ascertain 
how many of the discrete cells would go onto form colonies which could then be 
assayed for their multilineage potential.  
 
To the best of this author’s knowledge this is the only study reported where the 
adherent cells, derived from the mononuclear cell fraction of bone marrow, attached 
discreetly rather than forming in colonies. Gronthos et al, (2001) has previously 
reported that STRO-1+ hMSCs plated on a variety of ECM glycoproteins including 
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VN and FN formed equivalent numbers of colonies compared to 20% FCS. It is 
important to note, however, that the growth media was supplemented with PDGF, 
EGF, bovine insulin, BSA, human low density lipoprotein, iron-saturated human 
transferrin, L-glutamine, dexamethasone sodium phosphate, L-ascorbic acid 2-
phosphate and β-mercaptoethanol and the cells were sourced from healthy human 
donors (Gronthos et al. 2001), unlike the present study which utilised cells sourced 
from elderly patients presenting for total joint replacement surgery. Taken together, 
the differences in methodology between the study performed by Gronthos and co-
workers and the current study, may account for the difference in results obtained.  
 
Due to these results I then decided to measure the functional responses of hMSCs 
which had been previously expanded in vitro, to various combinations of VN, 
IGFBP-3 or -5, IGF-I or TGF-β1, where the unbound fraction of VN and the growth 
factors remained in solution. Firstly, I measured the metabolic activity of hMSCs 
exposed to the various combinations of VN and growth factors. Observation of these 
cultures revealed that cultured hMSCs were able to attach and spread on VN alone, 
which is consistent with previous studies which demonstrated that hMSCs express a 
range of integrins including the VN receptor, αvβ3 integrins (Conget and Minguell 
1999; Gronthos et al. 2001). Furthermore, Salasznyk and co–workers (2004) recently 
performed hMSC adhesion assays on a range of pre-bound purified ECM proteins 
and found that hMSCs adhered equally well to collagens type I and IV, FN and VN, 
although these assays were performed in the presence of FCS and thus other factors 
present in the serum will have influenced these findings (Salasznyk et al. 2004b).  
 
The major influence on hMSC metabolic activity in the present study was the 
presence or absence of VN, indicating that cell adhesion was vital in this system in 
order for the hMSCs to respond to any of the added growth factors. Furthermore, the 
addition of IGF-I alone with VN slightly enhanced the response of hMSCs while the 
addition of either of the IGFBPs alone with VN had no effect above that of VN 
alone. Moreover, the addition of IGF-I together with either of the IGFBPs and VN 
did not enhance the response of hMSCs compared to that of IGF-I alone with VN. In 
addition, I found that increasing the concentration of VN did not increase the 
metabolic activity of hMSCs after 72 hr in response to IGF-I.  These data are similar 
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to the findings of previous studies with hMSCs which found no increase in hMSC 
number when treated with either IGF-I, IGFBP-3 or IGF-I and IGFBP-3 together, 
although these responses were significantly enhanced over the control treatment 
alone (Kveiborg et al. 2001a) in contrast to the responses observed herein which 
were similar to the +VN control. However, in the study by Kveiborg et al, (2001a) 
the authors first cultured the cells in the presence of 10% FCS which was removed 
following 48 hr of culture and replaced with media containing 0.5% FCS 
supplemented with either IGF-I, IGFBP-3 or both; thus the elevated response 
compared to the control (0.5%FCS in media only) may have been due in part to 
additional factors present in the FCS (other than VN) which were not present in my 
study.  
 
Between 24 hr and 48 hr hMSC metabolic activity declined in all treatments, 
including the 10% FCS control, then stabilised or increased between 48 hr and 72 hr 
depending on the treatment (Fig 4.2, 4.3 and 4.4). In regards to the treatments 
without VN, the decline in metabolic activity may have been due to a reduction in 
cell number and / or reduced mitochondrial enzyme activity. An increase in 
metabolic activity may similarly be due to an increase in cell number or 
mitochondrial enzymatic activity. Bearing these limitations in mind, only TGF-β1 
together with VN at either 52 ng/well or 174 ng/well were able to stimulate 
metabolic activity after 72 hr that was significantly higher than the 10% FCS control 
(p<0.05 or p<0.01 respectively)(Fig 4.4a). This observation suggests that TGF-β1 has 
a direct stimulatory effect on hMSC metabolic activity, via its down stream 
signalling effectors, or indirectly by stimulating synthesis and expression of IGFBP-
3 and IGF-I as described previously (Kveiborg et al. 2001b).  
 
The possibility that the enhanced metabolic activity measured for hMSCs exposed to 
TGF-β1 is a response to endogenously produced IGFBP-3 and IGF-I is intriguing 
because the response of hMSCs exposed to the exogenously added IGFBP-3 and 
IGF-I was equivalent to 10% FCS while the response to TGF-β1 at either 
concentration of VN (52 ng/well or 174ng/well) were significantly higher than the 
response to 10% FCS (p<0.05 or p<0.01 respectively) (Fig 4.3 and 4.4). However, 
the exogenous IGFBP-3 used in this study was a mutated isoform (N109D) produced 
in E.coli and is non-glycosylated (~35 kDa) (Upstate, Waltham, MA, USA) whereas 
 146 
hMSCs exposed to TGF-β1 produce 38 kDa and 42 kDa isoforms of IGFBP-3 which 
likely represent partially and fully glycosylated isoforms (Kveiborg et al. 2001b; 
Kveiborg et al. 2002). Thus the basis of the difference in response remains unclear, 
although, glycosylation status of IGFBP-3 or the level of expression of either 
IGFBP-3 or IGF-I may play a role in the level of response.  
 
Human lung fibroblasts have also been shown to increase BrdU incorporation in 
response to VN and TGF-β1 compared to TGF-β1 alone and this response was due to 
direct interaction of αvβ3 integrins and the TGF-β type II receptor 
(TGFβIIR)(Scaffidi et al. 2004). Specifically, TGF-β1 increased the cell surface 
expression of αvβ3 integrins, co-localisation and immunocomplex formation between 
the TGFβIIR and αvβ3 integrin, and up regulated cyclin D1 to result in a 
synergistically enhanced proliferation response to ligand occupancy of the αvβ3 
integrin and the TGFβIIR (Scaffidi et al. 2004). Taken together, these data support 
my finding that hMSC metabolic activity was synergistically enhanced after 72 hr in 
response to TGF-β1 and VN at 52 ng/well and was further enhanced by VN at 
174ng/well. Furthermore, these findings suggest that the observed increase in 
synergistic responses may be due to the combined effects of: 1) an increase in 
integrin binding sites and a concomitant increase in cell surface αvβ3 integrins (ie an 
ability to respond to the increase in VN) and 2) perhaps an autocrine/paracrine 
response to endogenously expressed IGFBP-3 and IGF-I. However, further 
investigation into the specific mechanisms underpinning this response is necessary in 
order to draw specific conclusions about the role of TGF-β1, VN, IGFBP-3 or IGF-I 
and their respective receptors in the observed responses.  
 
While measurement of metabolic activity can provide an indication of a culture’s 
response to a given treatment in real time it does not necessarily give an indication of 
the cumulative response to a given treatment. To this end I decided to measure the 
change in hMSC derived total protein over 72 hr by staining cultures with the 
cationic dye crystal violet. In contrast to the observed metabolic activity response, 
there was no decline in hMSC total protein, thus indicating that the observed decline 
in metabolic activity after 24 hr was probably not due to a decrease in cell number 
but is more likely due to a decrease in mitochondrial enzyme activity. A decrease in 
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cell number would be likely to correspond to a decrease in total protein levels (Figs 
4.5, 4.6 & 4.7). Again I found that the major contributing factor to increasing hMSC 
total protein in this system was the presence of VN. Although, in contrast to the 
metabolic activity response, the combination of VN (especially at 174 ng/well) 
together with either of the IGFBPs and IGF-I seemed to slightly enhance the total 
protein accumulation after 72 hr (Figs 4.5a & 4.6a) compared to VN alone or IGF-I 
in the presence of VN, although this increase was not significant. In addition, the 
increase in total protein between 48 hr and 72 hr for hMSCs exposed to IGFBP-3 or 
-5 and IGF-I in the presence of VN at 174 ng/well was equivalent to that of hMSCs 
exposed to 10% FCS.  
 
Jia and Heersche (2000) reported that IGF-I could stimulate osteoprogenitor cell 
proliferation. However, others have reported that IGF-I has no effect on hMSC 
proliferation or differentiation (Jia and Heersche 2000; Walsh et al. 2003). Andress 
and Birnbaum (1992) have previously shown that an osteoblast derived isoform of 
IGFBP-5 enhances IGF-I stimulated osteoblast mitogenesis while purified IGFBP-3 
dose dependently inhibited IGF-I stimulated osteoblast mitogenesis (Andress and 
Birnbaum 1992). The authors postulated that the inhibitory action of IGFBP-3 was 
due to sequestration of IGF-I by IGFBP-3 in solution phase, thereby inhibiting IGF-I 
association with the IGFIR. Of particular interest, IGF-I in the presence of the bone 
matrix protein, osteopontin, a ligand for αvβ3 integrin, was shown to stimulate 
porcine smooth muscle cell (pSMC) proliferation and was further enhanced to levels 
similar to that observed for 10% FCS by the addition of IGFBP-5 (Nam et al. 2002), 
thus corresponding with my findings in hMSCs. Further, the interaction between 
IGFBP-5 and VN has been shown to be critical for the enhancement of IGF-I 
mediated pSMC DNA synthesis (Nam et al. 2002). Indeed research in our laboratory 
has confirmed and expanded the concept of enhanced cellular response to complexes 
composed of select IGFBPs and IGF-I, including IGFBP-3 and -5, bound to VN 
(Kricker et al. 2003; Hyde et al. 2004; Hollier et al. 2005). These findings are 
supported by the results detailed in the previous chapter and the present study adds to 
the growing body of experimental evidence. 
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The measurement of total protein in hMSC cultures exposed to TGF-β1, together 
with VN at either 52 ng/well or 174 ng/well, do not reflect the results obtained from 
the metabolic activity assays in that the large increase in metabolic activity between 
48 hr and 72 hr was not accompanied by a similar increase in protein accumulation 
in the same time period (Fig 4.7a & b). It is possible that the high metabolic activity 
stimulated in hMSCs exposed to 174 ng/well VN and TGF-β1 may result in 
increased protein expression at some time after 72 hr and therefore would not be 
evident in the total protein measurement at this time. In order to test this hypothesis, 
a more complete study of the functional response of hMSCs to VN and TGF-β1, with 
measurements taken over a longer period, is required to more accurately track the 
changes in response to these 2 factors. Such a study might also incorporate an 
analysis of the expression of αvβ3 integrins, IGFBP-3, IGF-I and the IGFIR. 
Coincidental interrogation of the signalling pathways of these receptors will assist a 
fuller understanding of the mechanisms underlying the responses observed in this 
study. 
 
Interestingly, my morphological assessment revealed that hMSC cultures exposed to 
VN at 52ng/well in the presence of either IGF-I or TGF-β1 underwent contraction 
and / or aggregation in a time-dependent manner (Figs 4.8a, b & c). In the first 
instance this aggregation appeared to be a loss of cells from the culture, possibly 
through loss of cell adhesion or cell death. However, closer analysis revealed that 
despite the phenomenon occurring in the cultures exposed to IGF-I or TGF-β1, most 
obvious after 72 hr (Fig 4.8c.2, 4, 6 & 8), the total protein data suggested there was 
little or no change in total protein content between any of these treatments and the 
total protein content of hMSCs exposed to VN at 52 ng/well alone. This suggests 
there was not a significant decrease in cell number during this time. Furthermore, 
cultures which were exposed to either IGF-I or TGF-β1 in the presence of VN at 174 
ng/well appeared to be protected from this effect (Fig 4.9). While few studies have 
previously described this phenomena, Hurley et al, (1994) described the aggregation 
of mouse osteoblastic cells exposed to TGF-β1 (Hurley et al. 1994) and more 
recently Karsdal and co-workers (2001) found that MC3T3-E1 cells cultured in 
serum free media and exposed to TGF-β1 developed identical culture morphologies 
as I have described here for the hMSCs. In addition when the MC3T3-E1 cells were 
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cultured on a type I collagen substratum (tissue culture plates pre-coated with 30 
µg/mL of type I collagen) under similar conditions, the effect was greatly diminished 
(Karsdal et al. 2001). Of interest, focal adhesion kinase (FAK) expression was 
increased and phosphorylation / activation of ERK1/2 and p38 MAP kinases, but not 
Jun N-terminal Kinase (JNK) was also increased in response to TGF-β1 which may 
partly explain the increase in metabolic activity in hMSCs measured in my own 
study.  
 
Signalling pathway specific inhibitors in the Karsdal et al studies revealed that the 
p38 MAP kinase pathway but not the ERK1/2 or JNK pathways, were involved in 
the morphological response to TGF-β1 (Karsdal et al. 2001). This phenomenon may 
be further explained, in part, by the fact that TGF-β1 is also known to induce 
plasminogen activator inhibitor (PAI-1) expression (Boehm et al. 1999; Kutz et al. 
2001). PAI-1 has recently been shown to mediate cell detachment from VN substrata 
by initiating endocytosis of uPA-uPAR-αv integrin complexes via complex 
formation with the low density lipoprotein (LDL) receptor related protein (LRP) 
(Czekay et al. 2003). These observations sit well with my observations that the 
aggregation response was attenuated in the presence of higher VN concentration, a 
condition in which more integrin binding sites are occupied. This is further 
supported by the finding that by over expressing the number of αvβ3 integrins on the 
surface of CHO cells, PAI-I mediated cell detachment is drastically reduced (Czekay 
et al. 2003). The present study is the first to: 1) describe this phenomenon in hMSCs; 
and 2) demonstrate that by increasing the concentration of VN the observed response 
can be attenuated. While a similar response has been reported for osteoblasts 
exposed to parathyroid hormone, where they adopted a stellate morphology (Tram et 
al. 1993; Karsdal et al. 2001), I am unaware of any studies, other than the present 
study, which reports a similar response to IGF-I.  
 
The molecular mechanism mediating the IGF-I mediated response remains to be 
elucidated. I initially thought that the observed growth factor mediated aggregation 
effect may be due to secretion of proteases which in turn affect hMSC attachment to 
the substratum. In addition, IGFBP-3 and -5 are known substrates for a number of 
proteases secreted by mesenchymal cells, including osteoblasts and of these MMP-2 
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features predominantly (Fowlkes et al. 1995; Sternlicht and Werb 2001). Indeed I 
found that purified IGFBP-5 could be degraded by factors within hMSC conditioned 
media (Fig 4.13). However, I found that there was no correlation between the 
functional expression of either MMP-2 or -9, as determined by gelatin zymography, 
and the growth factor-induced hMSC culture phenotype. I observed that both MMP-
2 and MMP-9 were present in the hMSC conditioned media in their pro-form, 
indicating that neither IGF-I or TGF-β1, nor indeed any other treatment, had an effect 
on MMP-2 or -9 activation (Fig 4.11). Indeed, MMP-2 and -9 accumulate in the 
conditioned media over time (Fig 4.12). Similar results have been reported for 
MC3T3-E1 cells exposed to TGF-β1, where TGF-β1 was found to not affect the 
expression of MMP-2, yet induced MMP-13 expression (Karsdal et al. 2001). 
However, Karsdel et al did not clarify whether the secreted MMP-2 was the active or 
in-active pro-form.  
 
Given that hMSCs exposed to no treatment whatsoever (the –VN control) also 
expressed pro-MMP-2 and -9 I concluded that both of these proteases are 
constitutively expressed by hMSCs (Lane 2, Fig 11a.1 & b.1). It appears this is 
relatively common for a number of different cell types, especially for MMP-2 
(Sternlicht and Werb 2001). Interestingly, VN has been shown to induce MMP-2 
expression in melanoma cells (Bafetti et al. 1998) and both MMP-2 and -9 interact 
or cooperate with αvβ3 integrins to regulate cell migration and invasion (Brooks et 
al. 1996; Rolli et al. 2003). Others have further reported that over expression of 
TIMP-2, an MMP-2 inhibitor, resulted in reduced MMP-2 activity (as expected) and 
restored attachment and spreading of melanoma cells on a VN substratum in spite of 
also demonstrating that activated MMP-2 did not degrade the VN substrate (Ray and 
Stetler-Stevenson 1995). Indeed solution phase VN has been shown to not be 
susceptible to MMP-2 mediated proteolysis (Bafetti et al. 1998). I did not investigate 
the expression of TIMPs by hMSCs in this study. Further investigations of the fate of 
the proteins used in this study are required to more fully understand the dynamics of 
biologically active species within such serum free culture environments.  
 
In conclusion, the data presented in this chapter indicate that VN is a valuable matrix 
component that provides a significant initial stimulus for the serum-free culture of 
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hMSCs and that in the presence of other factors, such as TGF-β1, additional stimuli 
can be achieved. In addition the concentration of VN is an important factor in the 
maintenance of culture phenotype and integrity and further investigation into the 
effect of endogenously expressed proteases on the functionality of matrix 
components, growth factors or other constituents is warranted. Lastly, a detailed 
investigation of the mechanisms of TGF-β1 action on hMSC function in the serum-
free environment is required.  
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CHAPTER 5: 
MULTI-PROTEIN COMPLEXES 
DETERMINE SaOS-2 CELL FUNCTIONAL 
RESPONSES 
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5.1 INTRODUCTION 
Fibronectin (FN) is a 400-500 kDa, multifunctional plasma and ECM glycoprotein 
which typically exists as a homodimer of two 200-250 kDa disulfide linked subunits. 
The molecular weight (MW) of FN can vary depending on alternative splice 
variations (Tamkun et al. 1984), although FN derived from plasma commonly has a 
lower MW (~450 kDa) than ECM - derived FN (~500 kDa). Plasma FN is largely 
synthesised by hepatocytes in the liver and is present in plasma at ~300 µg/mL and is 
soluble at physiological pH. In contrast, ECM FN is not soluble at physiological pH 
(Yamada and Kennedy 1979). FN is also a component of mature bone ECM and has 
been shown to mediate a number of cellular functions in vitro including cell 
attachment, spreading, migration, proliferation and differentiation (Grzesik and 
Robey 1994; Degasne 1999; Garcia et al. 1999; Xu et al. 2004). These functional 
effects are dependent on the type of cells under investigation, the particular suite of 
integrins which they express and the substrate-mediated conformation of the FN 
molecules themselves (Garcia et al. 1999; Danen et al. 2002). Cell attachment to FN 
is mediated by a wide range of different integrins and significant among these are the 
RGD binding integrins α5β1 and αvβ3 (Ruoslahti and Pierschbacher 1987; Ruoslahti 
1988; Plow et al. 2000; Pankov and Yamada 2002). In addition to the RGD 
recognition sequence, FN has a number of other integrin binding sites which 
facilitate the binding of α2β1, α4β1 and α4β7 integrins (Plow et al. 2000). 
Furthermore, cell surface integrins, in particular the α5β1 integrin, mediate FN fibril 
assembly into the ECM via the ability of this integrin to support high levels of 
RhoA-GTPase activity (Danen et al. 2002). RhoA-GTPase is involved in regulation 
of cell-cell adhesion, as well as actin stress fibre and focal contact formation (Rottner 
et al. 1999).    
 
FN is capable of binding to a number of ECM proteins including, most notably, type 
I collagen (Col-I), especially in its denatured form, gelatin (Engvall and Ruoslahti 
1977; Ruoslahti 1988; Pankov and Yamada 2002). Other ECM components which 
are known to interact with FN include type IV collagen, fibrin, heparin and heparan / 
chondroitin / dermatan sulphate proteoglycans (Ruoslahti 1988; Romberger 1997). 
More recently FN has been shown to bind both IGFBP-3 and -5 (Gui and Murphy 
2001). This interaction between IGFBP-5 and FN has recently been shown to 
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negatively modulate IGF-I dependent action on mouse embryonic cell (MEC) 
migration by enhancing proteolytic degradation of IGFBP-5, although the identity of 
the particular protease, or proteases, involved in this event remain unresolved (Xu et 
al. 2004). Additionally, FN has been shown to prevent apoptosis in mature 
osteoblasts and this effect was further enhanced by the addition of TGF-β1 (Globus 
et al. 1998). The authors found that FN and TGF-β1 cooperated to regulate the 
survival of mature osteoblasts in vitro.  
 
Similar to VN, FN molecules also have a monolayer saturation limit when bound to 
tissue culture plastic which has been measured at 0.36 µg/cm2 (Pitt et al. 1989; 
Garcia et al. 1999). However, interrogation of high concentrations of pre-bound FN 
with monoclonal antibodies revealed that multilayering of the FN molecules was 
possibly occurring, although it was unclear whether this effect was due to steric 
hindrance of antibody binding to FN molecules (Underwood et al. 1993).  
 
FN shares many of the desirable properties of VN for tissue engineering 
applications, such as the ability to adhere to a variety of tissue culture and 
biomaterial surfaces, the ability to facilitate cell attachment to those surfaces (Steele 
et al. 1995; Carvalho et al. 1998; McFarland et al. 1999; Ogura et al. 2004; Sim et 
al. 2004; Deligianni et al. 2005; Lee et al. 2006), activation of integrin mediated 
signalling pathways (Carvalho et al. 1998; Krause et al. 2000) and the ability to bind 
IGFBP-5 (Gui and Murphy 2001; Xu et al. 2004). In view of this I hypothesised that 
pre-bound combinations of FN, IGFBP-5 and IGF-I could stimulate similar 
functional responses in SaOS-2 cells to those observed in the presence of VN, 
IGFBP-5 and IGF-I. Furthermore, VN, FN, IGFBP-5, IGF-I and TGF-β1 have each 
been linked to mesenchymal stem cell, and / or osteoblast differentiation processes 
(Dedhar 1989; Dedhar et al. 1989; Moursi et al. 1996; Moursi et al. 1997; Kim et al. 
2003; Sakaguchi et al. 2004; Salasznyk et al. 2004b), prompting me to evaluate the 
effect of specific combinations of these factors on osteoblast specific gene 
expression, namely cbfa-1, ALP and Col-1 genes.  
 
SaOS-2 cells express both αvβ3 and α5β1 integrins, the VN and FN receptors 
respectively (Koistinen et al. 1999; Livak and Schmittgen 2001; Postiglione et al. 
 156 
2003; Kilpadi et al. 2004). They also express the IGF-I and the type I, type II and III 
(betaglycan) TGF-β receptors (Takeuchi et al. 1995; Bilbe et al. 1996; Nasu et al. 
2000; Grey et al. 2003; MacEwen et al. 2004). Moreover, SaOS-2 cells, being an 
osteosarcoma cell line, are far easier to culture and do not require the long culture 
periods required for hMSCs or primary osteoblasts. Therefore, the studies in this 
chapter utilise SaOS-2 cells to evaluate: 1) osteoblastic responsiveness to various 
combinations of FN, IGFBP-5 and IGF-I or VN and FN; and 2) osteoblastic 
differentiation marker expression in cells exposed to select pre-bound combinations 
of VN, FN and growth factors, such as IGFBP-5, IGF-I, EGF and TGF-β1. 
 
5.2 EXPERIMENTAL PROCEDURES 
Full details of both the materials and methods used in the generation of the data 
presented in this chapter are described in chapter 2. The following are brief 
summaries of the materials and experimental procedures used for the generation of 
data presented in section 5.3.  
 
5.2.1 Materials 
For full details of the materials used in generating the data for this chapter please 
refer to section 2.1. Purified human VN (Promega), IGFBP-5 (Dr Sue Firth) and 
IGF-I (GroPep), were obtained as detailed in the previous chapters. Other proteins 
used in the generation of the data for this chapter included recombinant human TGF-
β1 and recombinant human bFGF (Chemicon Pty / Ltd), purified human FN (Sigma-
Aldrich), and recombinant human EGF (Invitrogen). Tissue culture reagents were as 
described in previous chapters and detailed in chapter 2.  
 
Other key reagents used to generate the data presented in this chapter include 
Fraction V RIA grade BSA (Calbiochem), First Strand (AMV) cDNA synthesis kit 
(Roche Diagnostics), CyQUANT® reagent (Molecular Probes / Invitrogen), 
Sigmacote®, Dexamethasone, Glycerol-2-phosphate and Tri-Reagent (Sigma-
Aldrich), L-Ascorbic acid 2-phosphate tri-sodium salt (Wako) and SYBR® green 
PCR master mix (Applied Biosystems).  
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5.2.2 Pre-binding of Proteins  
For full details of this method please refer to sections 2.3 and 2.4. SaOS-2 cell 
migration was assessed on pre-bound combinations of FN, IGFBP-5 and IGF-I. 
Briefly, the underside of Transwell™ tissue culture plate inserts (Costar) were 
coated with 1 mL of 6 µg/mL FN / sf-αMEM or sf-αMEM alone for 4 hr in a 
humidified 5% CO2/95% air atmosphere at 37°C followed by 2 washes with 1 mL of 
0.5% BSA / HBB. Duplicate 0.5 mL aliquots of IGFBP-5 (0.1 µg/mL) in 0.05% 
BSA / HBB / sf-αMEM, together with either 0.5 mL IGF-I (0.025 µg/mL) in 0.05% 
BSA / HBB / sf-αMEM or 0.5 ml  of 0.05% BSA / HBB / sf-αMEM, was added to 
wells with, or without, FN and incubated at 4°C overnight. Following incubation, the 
lower chambers were washed twice with 1 mL 0.05% BSA / HBB / sf-αMEM prior 
to the addition of 1 mL 0.05% BSA / HBB / sf-αMEM to the lower chamber of each 
Transwell™ and incubation until required.  
 
SaOS-2 proliferation was assessed on pre-bound combinations of VN, FN, IGFBP-5 
and IGF-I. Specifically, 52 µL of 1 µg/mL VN / sf-αMEM, 6 µg/mL FN / sf-αMEM 
or sf-αMEM alone was added to each well of a 96-well tissue culture plate and 
incubated for 2 hr in a humidified 5% CO2/95% air atmosphere at 37°C. Following 
removal of ±VN or FN / sf-αMEM solution, wells were washed with 0.5% BSA / 
HBB. Wells were then blocked with 1% BSA / HBB, incubated for 30 mins in the 
above conditions and each well was washed with 0.5% BSA / HBB followed by 
addition of 43.5 µL of IGFBP-5 (1.6 µg/mL) in 0.5% BSA / HBB either alone, or in 
combination with IGF-I (0.4 µg/mL), and with or without VN. The plates were 
incubated at 4°C overnight. 
 
SaOS-2 cell osteoblast marker expression was assessed on the following 
combinations of pre-bound proteins: VN alone; VN / IGFBP-5 / IGF-I; VN / TGF-
β1; and VN / FN / EGF. Specifically, 1.5 mL of VN / sf-αMEM (1 µg/mL) or FN / 
sf-αMEM (6 µg/mL) or VN / FN / sf-αMEM (1 µg/mL / 6 µg/mL) were added to 
individual wells of a 6-well tissue culture plate and incubated for 2 hr in a 
humidified 5% CO2/95% air atmosphere at 37°C. Following removal of VN / ± FN 
sf-αMEM solutions, wells were washed with 0.5% BSA / HBB and blocked with 1% 
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BSA / HBB for 30 mins in the above conditions, after which wells were washed 
again with 0.5% BSA / HBB. Specific wells then received 1.263 mL of IGFBP-5 / 
IGF-I / sf-αMEM (160 ng/mL IGFBP-5 / 40 ng/mL IGF-I), TGF-β1 / sf-αMEM 
(115.2 ng/mL), EGF / sf-αMEM (115.2 ng/mL) or sf-αMEM alone, and were then 
incubated at 4°C overnight. Growth factor solutions were then removed and each 
well was washed with sf-αMEM prior to the addition of 1.5 mL of sf-αMEM to 
treatment wells, or 10% FCS, or osteogenic supplemented media (+OS media) to 
control wells. 
 
5.2.3 Transwell™ Migration Assay 
For full details of this method please refer to section 2.6. Sub-confluent cultures of 
SaOS-2 cells were passaged 1:1 the day prior to assay and serum-starved for 4 hr 
before harvesting and seeding of 2 x 105 cells into the upper chamber of 12 µm pore 
Transwells™ which had been pre-coated with various combinations of FN, IGFBP-5 
and / or IGF-I. Following 5 hr incubation in a 5% CO2/95 % air atmosphere at 37°C. 
Un-migrated cells were removed from the upper surface of the Transwell™ 
membrane with a cotton bud. Migrated cells were fixed in formaldehyde and stained 
with crystal violet. The Transwell™ membranes were immersed in a beaker of 
running tap water to remove excess stain and were allowed to air dry prior to 
extraction of adsorbed crystal violet dye in 10% acetic acid. Sub-samples were 
transferred to a 96-well microtitre plate and the absorbance read at 595 nm. Results 
are from 2 (-FN treatments) or 3 (+FN treatments) separate experiments with 
treatments assessed in triplicate. The data are expressed as the mean absorbance, as a 
percentage above the +VN control, ± the standard error of the mean (SEM).  
 
5.2.4 Proliferation Assay 
For full details of this method please refer to section 2.8. Sub-confluent cultures of 
SaOS-2 cells were serum-starved for 4 hr prior to harvest and seeding of 5000 cells / 
well into black 96-well plates containing various pre-bound combinations of VN, 
IGFBP-5 and IGF-I. Cells were allowed to proliferate for 24 hr, 48 hr or 72 hr prior 
to removal of spent media and storage of the culture plates at -80°C until analysis. 
Cyquant™ reagent was added to each well and the fluorescence measured at 480 nm 
excitation and 520 nm emission. Fluorescence units were converted to cell number 
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by using cells kept from the time of seeding to construct a cell number standard 
curve as per the manufacturer’s instructions. Results are from 3 separate experiments 
performed in at least triplicate and are expressed as the mean cell number ± standard 
error of the means (SEM). 
 
5.2.5 Solution Phase Culture 
For full details of this method please refer to section 2.15. Sub-confluent cultures of 
SaOS-2 cells were washed twice with HBSS prior to harvest by trypsin / EDTA 
digestion and the addition of 1.44 x 105 cells/well in sf-αMEM into pre-prepared 6 
well tissue culture plates (as per section 2.15) and incubation in a humidified 5% 
CO2/95% air atmosphere at 37°C. Media was changed twice weekly using the 
protein concentrations detailed in section 2.15. Digital images were captured at 
various time-points through-out the culture period, as indicated in the figures and as 
detailed in section 2.12.    
 
5.2.6 Differentiation Assay 
For full details of this method please refer to section 2.16. Sub-confluent cultures of 
SaOS-2 cells were washed twice with HBSS prior to harvest by trysin / EDTA 
digestion and re-suspension in sf-αMEM. Cells were counted and seeded at 5 x 105 
cells per well in a total volume of 3 mL. Plates were incubated in a humidified 5% 
CO2/95% air atmosphere at 37°C for 48 hr, or 7 days with 1 media change (for the 7 
day plate) on day 4 using growth factor concentrations identical to those used at the 
time of seeding, described above. Digital photographs were taken to assess culture 
morphology prior to RNA extraction. 
 
5.2.7 Real Time PCR Analysis 
For full details of this method please refer to section 2.17. Monolayer cultures from 
differentiation assays at either 48 hr, or 7 days, were harvested with 1 mL Tri-
Reagent (Sigma-Aldrich) and stored at -80°C until required for RNA extraction (less 
than 1 month). Total RNA was then isolated by addition of 0.2 mL of chloroform, 
then mixed and centrifuged at 12,000 x g for 15 minutes at 4°C, prior to the transfer 
of the aqueous phase to fresh 2 mL Eppendorf tubes and addition of 0.5 mL of 100% 
isopropanol with gentle mixing. Samples were then subjected to further 
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centrifugation at 12,000 x g for 10 min at 4°C prior to removal of the supernatant 
and washing of the RNA pellets with 1 mL 75% ethanol. Samples were gently mixed 
and centrifuged at 7500 x g for 5 min at 4°C prior to removal of the supernatant and 
brief air drying of the RNA pellets. Each pellet was resuspended in 20 µL of DEPC- 
treated ddH20, transferred to fresh 0.5 mL Eppendorf tubes and immediately placed 
on ice. Total RNA concentration and quality of each sample was determined by UV 
spectrophotometry and were subsequently stored at -80°C until required for cDNA 
synthesis.  
 
cDNA synthesis was performed on each total RNA sample using First Strand cDNA 
synthesis kit (AMV) according to the manufacturers instructions. Briefly, 0.5 µg of 
total RNA was reacted with 10 mM Tris, 50 mM KCl, 5 mM MgCL2, 1 mM dNTPs, 
3.2 µg of random hexamer oligonucleotide primers, 50 units ‘Protector’ RNase 
inhibitor (Roche), 20 units AMV reverse transcriptase and ddH20 in a final volume 
of 20 µL. Reaction tubes were gently mixed, pulse centrifuged and incubated at 
25°C for 10 min, 42°C for 60 min, 99°C for 5 min and finally 4°C o / n. The 
resulting cDNA samples were stored at -80°C until required for real time-PCR 
analysis.  
 
Each cDNA sample was diluted 1:5 with TE buffer prior to the addition of 2.0 µL  of 
diluted cDNA template to triplicate PCR reaction mixtures containing 10 µL of 
SYBR® green PCR master mix, 5 pmol of forward primer, 5 pmol of reverse primer 
and ddH20 to a final volume of 20 µL per well. PCR microplates loaded with the 
PCR reaction mixtures were pulse-centrifuged, placed into an ABI Prism 7000 real 
time-PCR machine and subjected to 50°C for 2 min, 95.0°C for 10 min, then 40 
cycles of 95.0°C for 15 sec and 60.0°C for 1 min, followed by a dissociation stage of 
95.0°C for 15 sec, 60°C for 20 sec and 95°C for 15 sec. Raw data were exported to 
Microsoft Excel, transformed and analysed using the 2-∆∆CT method (User Bulletin # 
2 for ABI Prism® 7000 Sequence Detection System and Livak and Schmittgen 
(Livak and Schmittgen 2001)). cDNA prepared as above from cells just prior to 
seeding (unseeded cells) was utilised as a time 0 control to which all treatments were 
compared. Results are expressed as mean fold change compared to the time zero (T0) 
(un-seeded) cell control ± SEM from triplicate PCR reactions for each of 3 
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individual differentiation experiments. PCR primers for cbfa-1, ALP and COL-1 are 
presented in table 2.1.  
 
5.3 RESULTS 
5.3.1 Effect of pre-bound FN, IGFBP-5 and IGF-I on SaOS-2 cell migration. 
In this series of experiments I wished to evaluate the migratory response of SaOS-2 
cells exposed to the matrix protein FN, another ECM glycoprotein present in bone 
which has been shown to both interact with IGFBP-5 and modulate IGFBP-5 / IGF-I 
mediated cell responses (Xu et al. 2004). Here, I directly compared the response of 
SaOS-2 cells exposed to pre-bound combinations of FN ± IGFBP-5 ± IGF-I with 
results obtained for the VN-based treatments detailed in chapter 3 (Figure 5.1). FN 
was added in stoichiometrically equivalent amounts compared to that utilised for the 
previous VN studies, while the IGFBP-5 and IGF-I concentrations were kept 
equivalent. I observed that SaOS-2 cell migration was significantly enhanced in 
response to FN alone (147.7 ± 13.1% (n=9) of the +VN treatment) compared to the 
response to VN alone (100.0 ± 9.2% (n=9)) (p<0.05) (Figure 5.1).  This migration 
was further enhanced in the additional presence of IGF-I (191.4 ± 14.4% (n=9) of the 
+VN treatment) compared to the migration response to VN alone (p<0.01), FN alone 
(p<0.05) and the corresponding VN / IGF-I treatment (126.8 ± 10.0% (n=9) of the 
+VN treatment) (p<0.01). This last result suggests that some IGF-I was retained on 
the Transwell™ membrane surface thus mediating increased SaOS-2 cell migration 
through the membrane (Fig 5.1). While, SaOS-2 cell migration in response to FN / 
IGFBP-5 (156.6 ± 15.3% (n=9) of the +VN treatment) was significantly higher than 
that measured for VN alone (p<0.01), and VN / IGFBP-5 (p<0.01) it was not 
different to that of FN alone. As was the case for the migration response to VN / 
IGFBP-5 / IGF-I, the FN / IGFBP-5 / IGF-I treatment (244.2 ± 17.3% (n=9) of the 
+VN treatment) produced a synergistic SaOS-2 cell migration response, and this was 
significantly higher than the response to VN alone (p<0.01), FN alone (p<0.01), FN / 
IGFBP-5 (p<0.01), FN / IGF-I (p<0.05) and VN / IGFBP-5 / IGF-I (p<0.05). As 
detailed in chapter 3 there was little or no migration of SaOS-2 cells in the absence 
of VN or FN (n=6) (Figure 5.1). Taken together, these data indicate that FN can 
induce enhanced SaOS-2 cell migration through 12 µm pore Transwell™ 
membranes, and that, as was the case for VN, the presence of IGFBP-5 and IGF-I 
 162 
synergistically enhanced the migration response. The VN results from figure 3.1 
have been included in light grey in figure 5.1 for comparative purposes.   
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Figure  5.1. Effect of pre-bound FN, IGFBP-5 and IGF-I on SaOS-2 cell 
migration. SaOS-2 cells (2 x 105 cells/Transwell™) were incubated in serum free-
αMEM and allowed to migrate for 5 hr on pre-bound combinations of IGFBP-5 (50 
ng/well) and IGF-I (12.5 ng/well) in the presence or absence of pre-bound FN (6 
µg/well). Following incubation, un-migrated cells were removed from the upper 
surface of the Transwell™ by cleaning with a cotton bud. Migrated cells were then 
fixed in formaldehyde for 20 min and subsequently stained with crystal violet for 20 
min. Excess stain was removed by immersion of the inserts in a reservoir of 
circulating tap water and air dried prior to extraction of crystal violet in 0.5 mL of 
10% acetic acid. Triplicate 100 µL sub-samples were then transferred to individual 
wells of a 96-well micro-titre plate and the absorbance read at 595 nm. Results were 
corrected using data from plate blanks (10% acetic acid alone) and are expressed as 
the corrected absorbance relative to the VN only control (100%) (horizontal red line) 
± standard error of the means (SEM). Significant difference to the VN only control is 
indicated by α (p<0.05) or β (p<0.01) and was determined by post-hoc t-test. 
Significant difference between the FN only treatment and other FN groups is given 
by λ (p<0.05) or ψ (p<0.01) or select groups (where linked by line) is indicated by # 
(p<0.05) or * (p<0.01). 
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5.3.2 Effect of various doses of pre-bound FN on SaOS-2 cell proliferation. 
In order to determine if FN alone could stimulate SaOS-2 cell proliferation in serum-
free conditions a series of dose-response, time course assays were conducted (Figure 
5.2). As was observed for the dose-dependent response of SaOS-2 cells to various 
concentrations of VN, detailed in chapter 3, there was no increase in cell number 
after 24 hr of serum-free culture in any treatment (n=6) above the number of cells 
seeded (5000 cells/well) (Figure 5.2a). After 48 hr, however, cell number in the 10% 
FCS control had increased to 6999 ± 212 cells (n=15), which was significantly 
higher than any other treatment (p<0.01) (Figure 5.2b). SaOS-2 cell number was 
generally maintained by tissue culture surfaces coated with FN, but was observed to 
be significantly decreased in the absence of FN  (-FN control) (3606 ± 278 cells 
(n=15)), compared to SaOS-2 cells exposed to wells coated with FN at 48 µg/mL 
(5327 ± 432 cells (n=6)), 24 µg/mL (5049 ± 262 cells (n=15)), 12 µg/mL (5107 ± 
314 cells (n=15)), 6 µg/mL (4685 ± 261 cells (n=15)), or 3 µg/mL (4701 ± 272 cells 
(n=15)) (p<0.01) and 1.5 µg/mL (4631 ± 287 cells  (n=15)) (p<0.05) (Figure 5.2b). 
However, SaOS-2 cell number was not significantly different to the –FN control 
after 48 hr, when exposed to wells treated with either 0.75 µg/mL (n=9) or 0.375 
µg/mL (n=9) FN. In addition, cell number in the 0.375 µg/mL treatment was 
significantly lower than cell numbers measured in wells treated with FN at 12 
µg/mL, or above (p<0.05) (Figure 5.2b). This trend remained essentially unchanged 
after 72 hr with only the 10% FCS control (8442 ± 231 cells (n=12)) exhibiting an 
increased cell number, while numbers in the –FN control decreased further (2767 ± 
193 cells (n=12)) (Figure5.2c). SaOS-2 cell population in cultures exposed to wells 
treated with 48 µg/mL (5454 ± 253 cells (n=6)), 24 µg/mL (5089 ± 199 cells 
(n=12)), 12 µg/mL (5193 ± 162 cells (n=12)), 6 µg/mL (4735 ± 109 cells (n=12)), or 
3 µg/mL (4570 ± 178 cells (n=12)), 1.5 µg/mL (4438 ± 153 cells (n=12)) and 0.75 
µgmL (4037 ± 240 cells (n=6)) remained significantly higher than the –FN control 
(p<0.05). Cell number was observed to decrease further in cultures exposed to wells 
coated with 0.375 µg/mL of FN (2945 ± 186 cells (n=6)), to levels similar to the –FN 
control. There was no significant difference between the results obtained for the 
treatments containing greater than 12 µg/mL of FN, although, cell numbers were 
significantly lower compared to the 12 µg/mL treatment in the 0.375 µg/mL, 0.75 
µg/mL and 1.5 µg/mL treatments (p<0.01) and the 3 µg/mL and 6 µg/mL treatments 
(p<0.05) (Figure 5.2c). Taken together, these data demonstrate that pre-bound FN 
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does not stimulate SaOS-2 cell proliferation, but rather, may dose-dependently 
rescue SaOS-2 cell survival in serum-free conditions. 
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Figure 5.2. Effect of various doses of pre-bound FN on SaOS-2 cell 
proliferation.  SaOS-2 cells (5000 cells/well) were incubated in serum free-αMEM 
and allowed to proliferate for a) 24 hr, b) 48 hr and c) 72 hr in wells pre-coated with 
50 µL solutions of FN at various concentrations as indicated. Cells seeded into wells 
without VN, or in 10% FCS, were employed as controls. Following incubation, 
media was aspirated and the tissue culture plates were stored at -80°C. CyQUANT® 
reagent was then added to each well as per the manufacturer’s instructions and the 
fluorescence measured at 480 nm excitation 520 nm emission. Results were 
corrected using data from plate blanks (CyQUANT® reagent only) and cell number 
calculated from a standard curve and expressed as mean cell number ± standard error 
of the means (SEM). Statistical significance was determined by post-hoc t-test. 
Significance between treatments and the –FN control is indicated by α (p<0.05), or β 
(p<0.01). Significant difference to the 12 µg/mL treatment or select groups (where 
linked by line) is indicated by λ (p<0.05), or ψ (p<0.01). Significant difference to all 
other groups is indicated by * (p<0.01). Horizontal red line indicates initial number 
of cells seeded per well. 
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5.3.3 Effect of various doses of pre-bound FN and VN on SaOS-2 cell 
proliferation.  
Given that FN, like VN, is a significant constituent of serum (Yamada and Olden 
1978) and is also present in bone matrix (Grzesik and Robey 1994), a series of FN 
dose response assays in the presence of 1 µg/mL of VN were performed to determine 
if the combined presence of both FN and VN could modulate a proliferative response 
in SaOS-2 cells, compared to either component in isolation. Similar to the results 
obtained for the individual components alone (Figures 3.3 and 5.2), after 24 hr no 
significant increase in cell number, over the initial cell seeding of 5000 cells/well 
was observed (n=6 for all treatments at 24 hr)(Figure 5.3a). There was no significant 
difference in cell number between the VN only control (5396 ± 392 cells) and the 
FN treatments at 1.5 µg/mL (4891 ± 259 cells), 3 µg/mL (4508 ± 175 cells), 6 µg/mL 
(4476 ± 296 cells) and the 10% FCS control (4831 ± 337 cells). There were, 
however, significantly fewer cells than the VN only control in wells where cells were 
cultured in wells coated with VN and 12 µg/mL (4181 ± 222 cells), 24 µg/mL (4407 
± 204 cells) or 48 µg/mL (4300 ± 205 cells) of FN (p<0.05)(Figure 5.3a).  After 48 
hr no significant difference in cell number was observed between any of the FN 
containing treatments and the VN only control (4831 ± 288 cells (n=15)) (Figure 
5.3b). There were significantly fewer cells in wells coated with FN at 0.75 µg/mL 
(4158 ± 333 cells (n=9)) compared to wells coated with either 24 µg/mL (5155 ± 288 
cells (n=15)) or 48 µg/mL (5183 ± 310 cells (n=6)) of FN (p<0.05). However, cell 
numbers in wells coated with FN at 0.375 µg/mL (4721 ± 230 cells (n=9)), 1.5 
µg/mL  (5052 ± 346 cells (n=15)), 3 µg/mL (4820 ± 324 cells (n=15)), 6 µg/mL 
(4575 ± 299 cells (n=15)) or 12 µg/mL (5006 ± 367 cells (n=15)) were not different 
to the 24, or 48 µg/mL treatments (Figure 5.3b). The cell population of the 10% FCS 
control (6999 ± 212 cells (n=15)) increased (as detailed in the previous section 
(section 5.3.2)) to a level significantly higher than all other treatments (p<0.01) 
(Figure 5.3b). Interestingly, after 72 hr cell numbers had increased in both the 10% 
FCS control (8442 ± 231 cells (n=12)) (as detailed in section 5.3.2) and in wells 
coated with FN at 48 µg/mL (6449 ± 179 cells (n=6)). The result obtained for the 48 
µg/mL of FN treatment was significantly higher than both the VN only control (4802 
± 389 cells (n=12)) and all other FN containing wells (p<0.01), while the 10% FCS 
response was higher than all treatments (p<0.01) (Figure 5.3c). There was no 
difference in cell number between any of the FN containing treatments and the VN 
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only control (n FN 0.375 µg/mL, 0.75 µg/mL =9; n FN1.5 µg/mL, 3.0 µg/mL, 6.0 µg/mL, 12.0 µg/mL, 24.0 µg/mL 
=12). Taken together these data indicate that the addition of FN and VN together do 
not substantially modify the proliferative response of SaOS-2 cells over a 72 hr 
period compared to either of the components alone, with perhaps the exception of the 
high dose (48 µg/mL) of FN.  
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Figure 5.3. Effect of various doses of pre-bound FN and VN on SaOS-2 cell 
proliferation.  SaOS-2 cells (5000 cells/well) were incubated in serum free-αMEM 
and allowed to proliferate for a) 24 hr, b) 48 hr and c) 72 hr in wells pre-coated with 
50 µL solutions of 1 µg/mL VN with FN at various concentrations as indicated. 
Cells seeded into wells coated with VN alone or in 10% FCS were employed as 
controls. Following incubation, media was aspirated and the tissue culture plates 
were stored at -80°C. CyQUANT® reagent was then added to each well as per the 
manufacturer’s instructions and the fluorescence measured at 480 nm excitation and 
520 nm emission. Results were corrected using data from plate blanks (CyQUANT® 
reagent only) and cell number calculated from a standard curve and expressed as 
mean cell number ± standard error of the means (SEM). Statistical significance was 
determined by post-hoc t-test. Significant difference to the +VN control or select 
groups (where linked by line) is indicated by α (p<0.05) or β (p<0.01). Significant 
difference to all other groups is indicated by * (p<0.01). Horizontal red line indicates 
initial number of cells seeded per well. 
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5.3.4 Effect of pre-bound FN, IGFBP-5 and IGF-I on SaOS-2 cell proliferation. 
IGFBP-5 is known to bind to FN and this interaction has also been shown to 
modulate IGF-I mediated cell activity (Xu et al. 2004). Following the results of 
SaOS-2 cell migration studies, detailed in section 5.3.1, which demonstrated that 
SaOS-2 cell migration is synergistically enhanced in the presence of pre-bound FN, 
IGFBP-5 and IGF-I, I hypothesized that similarly pre-bound combinations of FN, 
IGFBP-5 and IGF-I could stimulate enhanced cell proliferation over the individual 
components alone. To test this hypothesis a series of proliferation assays in tissue 
culture plates coated with various combinations of FN (6 µg/mL), IGFBP-5 (1.6 
µg/mL) and IGF-I (0.4 µg/mL) were performed. I observed that after 24 hr there had 
not been any increase in cell number in the VN only control (4927 ± 154 cells 
(n=18)) over the initial cell seeding density of 5000 cells/well. Furthermore, there 
was no significant difference in cell number between the VN only control and the –
FN control (4427 ± 300 cells (n=17)), IGF-I only (4340 ± 326 cells (n=17)) or the 
IGFBP-5 / IGF-I (5037 ± 241 cells (n=17)) treatments. However, there were 
significantly fewer cells in the IGFBP-5 only treatment (3789 ± 246 cells (n=17)) 
compared to the VN only control (p<0.01) (Figure 5.4a). Conversely, cell numbers 
had increased above the initial cell seeding density in the 10% FCS control (6064 ± 
143 cells), FN only (6011 ± 355 cells (n=18)), FN / IGF-I (6342 ± 359 cells (n=18)) 
and the FN / IGFBP-5 (6427 ± 401 cells (n=18)) treatments and were found to be 
significantly higher than the VN only control (p<0.01), as was the FN / IGFBP-5 / 
IGF-I (6170 ± 469 cells (n=18)) treatment, although only slightly less so (p<0.05) 
(Figure 5.4a). After 48 hr, cell numbers in the –FN (3327 ± 159 cells (n=18)), IGF-I 
only (4354 ± 232 cells (n=18)), IGFBP-5 only (3414 ± 127 cells (n=18)) and the 
IGFBP-5 / IGF-I treatments had significantly fewer cells than the VN only control 
(5589 ± 174 cells (n=18)) (p<0.01). This was mainly due to a slight increase in cell 
number in the VN only control in contrast to the general decrease in cell number in 
the treatments without FN. Cell numbers on the other hand increased in wells which 
had been pre-coated with FN alone (6395 ± 209 cells (n=18)), FN / IGF-I (7737 ± 
416 cells (n=18)), FN / IGFBP-5 (7006 ± 261 cells (n=18)), FN / IGFBP-5 / IGF-I 
(7193 ± 419 cells (n=18)) or exposed to 10% FCS (8163 ± 148 cells (n=18)). All of 
these treatments led to cell numbers which were significantly greater than the VN 
only control (p<0.01). Furthermore, the 10% FCS control samples contained 
significantly more cells than wells coated with FN only (p<0.01), FN / IGFBP-5 
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(p<0.01), or FN / IGFBP-5 / IGF-I (p<0.05), but not FN / IGF-I (Figure 5.4b). After 
72 hr, cell numbers in the VN only control (5382 ± 297 cells (n=18)) had not 
changed from that measured after 48 hr, while cell numbers in the –FN control (2574 
± 135 cells (n=18)), IGF-I only (2969 ± 120 cells (n=18)), IGFBP-5 (2601 ± 94 cells 
(n=18)) and IGFBP-5 / IGF-I (3232 ± 124 cells (n=18)) had decreased further 
compared to the VN only control (p<0.01). In addition, cells exposed to wells coated 
with FN only (4720 ± 224 cells (n=18)), FN / IGF-I (5354 ± 243 cells (n=18)), FN / 
IGFBP-5 (5386 ± 211 cells (n=18)) and FN / IGFBP-5 / IGF-I (6133 ± 274 cells 
(n=18)) decreased in number to levels equivalent to that of the VN only control. 
Intriguingly, SaOS-2 populations in wells coated with FN / IGFBP-5 remained 
significantly greater in cell numbers in the FN only control (p<0.05), while, cell 
numbers in wells coated with FN / IGFBP-5 / IGF-I remained higher than the cell 
number measured in wells coated with FN alone (p<0.01), or FN / IGF-I or FN / 
IGFBP-5 (p<0.05). The only treatment that lead to an increase in cell number 
between 48 hr and 72 hr, however, was the 10% FCS control (8917 ± 143 cells 
(n=18)) which had a higher cell number than any other treatment (p<0.01) (Figure 
5.4c). Taken together, these data support the findings reported in section 5.3.2 that 
FN alone can support cell survival over 72 hr, but does not support a sustained 
proliferative response over the same time frame. Furthermore, these data suggest that 
pre-binding of IGFBP-5 and IGF-I together with FN can reduce the rate of decline in 
cell number compared to FN alone, or in combination with either IGFBP-5, or IGF-I, 
over 72 hr. 
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Figure 5.4. Effect of pre-bound FN, IGFBP-5 and IGF-I on SaOS-2 cell 
proliferation.  SaOS-2 cells (5000 cells/well) were incubated in serum-free-αMEM 
and allowed to proliferate for a) 24 hr, b) 48 hr and c) 72 hr in wells pre-coated with 
solutions of IGFBP-5 (69.5 ng/well) and/or IGF-I (17.4 ng/well) in the presence or 
absence of pre-bound FN (6 µg/mL). Cells seeded into wells without FN or in 10% 
FCS were employed as controls. Following incubation, media was aspirated and the 
tissue culture plates were stored at -80°C. CyQUANT® reagent was then added to 
each well, as per manufacturer’s instructions, and the fluorescence measured at 480 
nm excitation 520 nm emission. Results were corrected using data from plate blanks 
(CyQUANT® reagent only), cell number calculated from a cell number standard 
curve and expressed as mean cell number ± standard error of the means (SEM). 
Statistical significance was determined by post-hoc t-test. Significant difference to 
the +VN control or select groups (where linked by line) is indicated by α (p<0.05) or 
β (p<0.01). Significant difference to the 10% FCS control is indicated by # (p<0.05) 
or * (p<0.01). Significant difference to the +FN control is indicated by λ (p<0.05) or 
ψ (p<0.01). Horizontal red line indicates initial number of cells seeded per well.  
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5.3.5 Effect of solution phase VN and FN with or without EGF or bFGF on 
SaOS-2 cell culture morphology. 
In order to determine if solution phase VN and FN could sustain SaOS-2 cell 
cultures over longer periods of time than 72 hr, I propagated SaOS-2 cells in the 
presence of VN and FN with, or without, the addition of EGF, or bFGF, or both, and 
examined culture morphology. After 12 days of continuous culture with re-feeding 
twice weekly, SaOS-2 cells maintained in the presence of VN generally appeared 
irregular in shape with small cytoplasms, were poorly spread and some cells 
exhibited blebbing. In addition, there were an obvious number of dead and floating 
rounded cells. Those cells which did appear to be well attached to the culture surface 
were clustered tightly into small groups (Figure 5.5a). In contrast, SaOS-2 cells 
cultured in the presence of FN, while also small and irregularly shaped with a 
number of  dead and apoptotic cells present, were more numerous and more evenly 
distributed over the culture surface than those exposed to VN alone (Figure 5.5b). 
Interestingly, the addition of the VN and FN together resulted in a more elongated 
cell morphology and more attached cells than either of the components in isolation 
(Figure 5.5c). Similarly, cells cultured in the presence of VN, FN and EGF had 
greatly improved cell and culture morphology with many more attached and well 
spread cells of a generally elongated morphology. In addition, there were fewer 
dead, or floating, cells present compared to cultures exposed to VN, or FN alone, or 
in combination. Cells cultured in the presence of VN and FN continued to exhibit a 
number of cells with apoptotic morphology (Figure 5.5d). SaOS-2 cells cultured in 
the presence of VN, FN and bFGF, were in general very small, cuboidal-shaped cells 
with very little cytoplasm. There also appeared to be fewer attached cells compared 
to the VN, FN, EGF treatment (Figure 5.5e). When SaOS-2 cells were exposed to all 
four components, ie. VN, FN, EGF and bFGF, cell morphology assumed a more 
heterogeneous phenotype. Some cells adopted the more elongated shape evident in 
the VN, FN, EGF treatment, while others were smaller and more cuboidal in shape, 
similar to those in the VN, FN, bFGF treatment (Figure 5.5f). In comparison, SaOS-
2 cells cultured in 10% FCS in a parallel study were confluent, small and had a 
generally cuboidal morphology, typical of SaOS-2 cells cultured for 10 – 14 days 
(Fig 5.5g – h). These data indicated that neither VN, nor FN, in isolation, could 
sustain SaOS-2 cell viability. However, when used in combination, and with the 
addition of EGF, SaOS-2 cell cultures generally appeared healthier with more 
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homogeneous cell morphologies than the other treatments after 12 days of culture, 
but did not attain the extent of growth observed when SaOS-2 cells were cultured in 
the presence of 10% FCS. 
 
 
 
 
 
 
Figure 5.5. Effect of solution phase VN and FN with or without EGF or bFGF 
on SaOS-2 cell culture morphology.  
Sub-confluent cultures of SaOS-2 cells were harvested using trypsin / EDTA 
digestion prior to the addition of 1.44 x 105 cells/well into pre-prepared 6-well tissue 
culture plates containing solutions of VN / sf-αMEM (1 µg/mL), FN / sf-αMEM (6 
µg/mL) or VN / FN / sf-αMEM (1 µg/mL / 6 µg/mL). Cells were added to 
individual wells of a 6 well tissue culture plate together with either EGF (5 ng/mL), 
or bFGF (5 ng/mL), as indicated. The plates were incubated in a humidified 5% 
CO2/95% air atmosphere at 37 °C for up to 12 days. Spent culture media was 
changed twice weekly using protein concentrations detailed above and in section 
2.15. Digital images of each culture were taken at X100 magnification on day 12 (or 
days 10 and 14 for 10% FCS cultures) as indicated. Bar = 200µm. 
(Note: 10% FCS images were reproduced with permission of K, Shrobback, Tissue 
Repair and Regeneration Program, Institute of Health and Biomedical Innovation, 
Queensland University of Technology).  
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Figure 5.5 
a) VN b) FN
c) VN/FN d) VN/FN/EGF
e) VN/FN/bFGF f) VN/FN/EGF/bFGF
x100
g) 10% FCS (day 10) h) 10% FCS (day 14)
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5.3.6 Effect of VN, VN / IGFBP-5 / IGF-I, VN / TGF-β1 or VN / FN / EGF on 
SaOS-2 cell morphology, compared to osteoblastic differentiation media. 
Osteoblasts often change their morphology during osteoblastic cell differentiation 
(Aubin 1998). Therefore, I monitored the change in cell morphology of SaOS-2 cells 
exposed to VN alone, VN / IGFBP-5 / IGF-I, VN / TGF-β1, or VN / FN / EGF, over 
7 days compared to SaOS-2 cells exposed to 10% FCS, or 10% FCS supplemented 
with known osteogenic agents (+OS media), as part of a broader study into the effect 
of these treatments on osteoblast marker expression. SaOS-2 cells were seeded at 
high density into 6 well plates which had been pre-prepared with the matrix proteins 
and growth factors. After 48 hr SaOS-2 cell cultures exposed to 10% FCS, or +OS 
media were 100% confluent and these cells had adopted a small cobblestone like 
morphology, indicative of osteoblast-like differentiation, although some cells 
exhibited mitotic indices (Figure 5.6a.5 & 6). In contrast SaOS-2 cell cultures 
exposed to VN alone, VN / IGFBP-5 / IGF-I, or VN / TGF-β1, were not confluent 
and cell morphology was both irregular and heterogeneous. In addition, a few cells 
exhibited apoptotic-like morphologies as assessed by visualisation of cell membrane 
blebbing, while a few others had visible mitotic indices (Figure 5.6a.1-3). 
Interestingly, the VN / FN / EGF treatment induced the elongated, fibroblast like 
morphology which was evident in the solution phase cultures detailed above in 
section 5.3.5 and Figure 5.5d. Furthermore, SaOS-2 cell cultures exposed to this 
treatment were confluent and had few cells with apoptotic type morphologies, but 
also very few visible mitotic indices (Figure 5.6a.4).  After 7 days SaOS-2 cell 
cultures exposed to VN alone, and VN / TGF-β1, had visibly decreased in cell 
number, although the morphologies of cells exposed to these treatments remained 
largely unchanged from that described above after 48 hr, albeit with fewer cells 
(Figure 5.6b.1 & 3). Similarly, SaOS-2 cell cultures exposed to the VN / FN / EGF 
treatment were still confluent, while the cells themselves remained relatively 
elongated (Figure 5.6b.4). Of particular interest, however, SaOS-2 cell cultures 
exposed to the VN / IGFBP-5 / IGF-I treatment appeared almost confluent and the 
cell morphology had changed from irregular shaped, as described above, to a more 
cobblestone type morphology similar to that of cells exposed to the 10% FCS 
treatment (Figure 5.6b.2 & 5). The +OS media induced similar cell morphology and 
density to the 10% FCS treatment but also induced the formation of bright refractory 
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bodies (Figure 5.6b.6). I have previously identified these refractory bodies in this 
cell line to be calcium deposits by Von Kossa staining (data not shown). 
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Figure 5.6a Effect of VN, VN / IGFBP-5 / IGF-I, VN / TGF-β1 or VN / FN / EGF 
on SaOS-2 cell morphology after 48 hr. Sub-confluent cultures of SaOS-2 cells 
were harvested with trypsin / EDTA digestion prior to the addition of 5 x 105 
cells/well in pre-prepared 6 well tissue culture plates coated with solutions of VN / 
sf-αMEM (1 µg/mL), VN / FN / sf-αMEM (1 µg/mL / 6 µg/mL) IGFBP-5 / IGF-I / 
sf-αMEM (160 ng/mL / 40 ng/mL), TGF-β1 / sf-αMEM (115.2 ng/mL), or EGF / sf-
αMEM (115.2 ng/mL) in combinations as indicated above and as detailed in section 
5.2.2 and 2.16. Plates were incubated in a humidified 5% CO2/95% air atmosphere at 
37°C for 48 hr. SaOS-2 cells cultured in the presence of 10% FCS, or osteogenic 
supplemented media (+OS media), were utilised as controls. Digital images were 
taken at X200 magnification to assess culture morphology prior to total RNA 
extraction. Bar = 100 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 183 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6a 
 
 
 
 
 
 
 
a.1. VN a.2. VN/IGFBP-5/IGF-I
a.3. VN/TGF-ß1 a.4. VN/FN/EGF
a.5. 10% FCS a.6. +OS
x200
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Figure 5.6b Effect of VN, VN / IGFBP-5 / IGF-I, VN / TGF-β1 or VN / FN / 
EGF on SaOS-2 cell morphology after 7 days. Sub-confluent cultures of SaOS-2 
cells were harvested with trypsin / EDTA digestion prior to the addition of 5 x 105 
cells/well in pre-prepared 6 well tissue culture plates coated with solutions of VN / 
sf-αMEM (1 µg/mL), VN / FN / sf-αMEM (1 µg/mL / 6 µg/mL) IGFBP-5 / IGF-I / 
sf-αMEM (160 ng/mL / 40 ng/mL), TGF-β1 / sf-αMEM (115.2 ng/mL), or EGF / sf-
αMEM (115.2 ng/mL) in combinations as indicated above and as detailed in section 
5.2.2 and 2.16. Plates were incubated in a humidified 5% CO2/95% air atmosphere at 
37°C for 7 days with a single media change on day 4 using growth factor 
concentrations as described above. SaOS-2 cells cultured in the presence of 10% 
FCS, or osteogenic supplemented media (+OS media), were utilised as controls. 
Digital images were taken at X200 magnification to assess culture morphology prior 
to total RNA extraction. Bar = 100 µm. 
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Figure 5.6b 
 
 
 
 
 
b.1. VN b.2. VN/IGFBP-5/IGF-I
b.3. VN/TGF-ß1 b.4. VN/FN/EGF
b.5. 10% FCS b.6. +OS
x200
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5.3.7 Effect of VN, VN / IGFBP-5 / IGF-I, VN / TGF-β1 or VN / FN / EGF on 
osteoblast differentiation marker expression in SaOS-2 cells. 
VN has been shown to induce type I collagen expression in human mesenchymal 
stem cells (Salasznyk et al. 2004b). In addition, IGF-I has been implicated in bone 
formation processes in vivo and in vitro (Mohan and Baylink 1991; 1993; 1996; 
Long et al. 1998; Mohan and Baylink 1999; Jia and Heersche 2000; Yakar et al. 
2002) while, IGFBP-5 over expression in vitro has been associated with the 
attenuation of various osteoblast differentiation markers (Durant et al. 2004). In view 
of this and the reasons outlined above in sections 5.3.5 and 5.3.6, I assessed 
osteoblast differentiation marker expression in SaOS-2 cells in the presence of VN 
alone, VN / IGFBP-5 / IGF-I, VN / TGF-β1 or VN / FN / EGF. I found that after 48 
hr there had been no change in cbfa-1 mRNA transcript expression compared to the 
time zero (T0) control in any of the treatments, with the exception of the 10% FCS 
control which induced a 4.11 ± 1.11 fold increase in cbfa-1 expression compared to 
the T0 control (p0.05) (n=3 for all treatments) (Figure 5.7a). ALP transcript 
expression was increased by 3.99 ± 0.65 fold (VN / IGFBP-5 / IGF-I), 2.99 ± 0.42 
fold (VN / TGF-β1) or 3.00 ± 0.36 fold (VN / FN / EGF) compared to the T0 control 
(p<0.01). Similarly both the 10% FCS control and the +OS media induced a 5.35 ± 
1.27 fold and 2.50 ± 0.48 fold increase in SaOS-2 cell ALP mRNA expression 
respectively (p<0.05). However, ALP expression in response to VN only (2.4 ± 0.61 
fold) was not significantly different to the T0 control (Figure 5.7b). While Col-I 
expression was not significantly changed by any treatment compared to the T0 
control (1.00 ± 0.07 fold change), there was a significantly higher relative expression 
level of Col-I transcripts in the VN / FN / EGF treatment (1.41 ± 0.16 fold increase 
above the T0 control) and the +OS treatment (0.82 ± 0.14 fold of the T0 control) 
(p<0.05) (Figure 5.7c). 
 
In a parallel series of experiments, the cells were cultured for 7 days with media 
changes for each treatment occurring on day 4, prior to RNA extraction, subsequent 
cDNA synthesis and real-time PCR. After 7 days of culture no significant difference 
in cbfa-1 mRNA transcript expression was observed between any of the individual 
treatments and the T0 control. Nor were any differences observed between any of the 
treatments, including either the 10% FCS control or the +OS treatment (n=3 for all 
treatments) (Figure 5.8a). Conversely, after 7 days of culture ALP transcript 
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expression in the VN only (0.81 ± 0.23 fold of the T0 control), VN / TGF-β1 (1.00 ± 
0.09 fold of the T0 control) and the VN / FN / EGF (0.97 ± 0.01 fold of the T0 
control) were decreased to levels equivalent to the T0 control. While, the ALP 
transcript levels in the VN / IGFBP-5 / IGF-I (2.35 ± 0.43 fold of the T0 control), 
10% FCS control (4.06 ± 1.29 fold of the T0 control) and the +OS treatment (2.15 ± 
0.37 fold of the T0 control) were relatively lower at 7 days compared to the same 
treatments at 48 hr, ALP transcript levels in the VN / IGFBP-5 / IGF-I and the +OS 
treatment remained significantly higher than ALP levels in the T0 control (p<0.05). 
While the mean relative level of ALP transcript in cells exposed to the 10% FCS 
control was higher than all other treatments, there was no statistical difference 
between this treatment and ALP transcript levels in the T0 control. This was likely 
due to the large error associated with this treatment (Figure 5.8b). Surprisingly, Col-I 
transcript levels were lower in all treatments after 7 days compared to the same 
treatments after 48 hr, although Col-I transcript levels in cells exposed to VN only 
(0.70 ± 0.2 fold of the T0 control), VN / FN / EGF (0.98 ± 0.13 fold of the T0 
control) and the 10% FCS control (0.54 ± 0.18 fold of the T0 control) remained 
statistically equivalent to the T0 control. In addition, the relative level of Col-I 
transcripts in cells exposed to VN / IGFBP-5 / IGF-I (0.52 ± 0.09 fold of the T0 
control), VN / TGF-β1 (0.60 ± 0.06 fold of the T0 control) and the +OS treatment 
(0.31 ± 0.04 fold of the T0 control) was significantly lower than the level of Col-I 
transcripts in the T0 control (1.00 ± 0.07 fold of the T0 control) (p<0.01). 
Furthermore, relative Col-I transcript levels in cells exposed to VN / IGFBP-5 / IGF-
I and VN / TGF-β1 were significantly lower than in cells exposed to VN / FN / EGF 
(p<0.05), as were Col-I transcript levels in cells exposed to the +OS treatment 
(p<0.01) (Figure 5.8c). Taken together these data suggest that neither VN alone, VN 
/ IGFBP-5 / IGF-I, VN / TGF-β1 or VN / FN / EGF had any effect on cbfa-1 mRNA 
expression after 48 hr or 7 days. However, the VN / IGFBP-5 / IGF-I treatment was 
able to increase ALP mRNA transcription in the absence of serum in the short term 
and maintained a higher level of ALP transcription after 7 days of culture compared 
to any of the other serum-free treatments. Somewhat surprisingly, the +OS treatment 
appeared to have down regulated Col-I expression after 48 hr, while the VN only, 
VN / IGFBP-5 / IGF-I, VN / TGF-β1 and VN / FN / EGF treatments did not 
significantly affect Col-I transcript levels at 48 hr. The relatively low levels of Col-I 
mRNA transcripts measured in cells exposed to VN only, VN / IGFBP-5 / IGF-I 
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Figure 5.7.  Effect of VN, VN / IGFBP-5 / IGF-I, VN / TGF-β1 or VN / FN / EGF 
on osteoblast differentiation marker expression in SaOS-2 cells after 48 hr. Sub-
confluent cultures of SaOS-2 cells were harvested using trypsin / EDTA digestion 
prior to the addition of 5 x 105 cells/well in pre-prepared 6 well tissue culture plates 
coated with solutions of VN / sf-αMEM (1 µg/mL), VN / FN / sf-αMEM (1 µg 
VN/mL / 6 µg FN/mL), IGFBP-5 / IGF-I / sf-αMEM (160 ng BP-5/mL / 40 ng IGF-
I/mL), TGF-β1 / sf-αMEM (115.2 ng/mL), or EGF / sf-αMEM (115.2 ng/mL) in 
combinations as indicated above and as detailed in section 5.2.2 and 2.16. SaOS-2 
cells cultured in the presence of 10% FCS or osteogenic supplemented media (+OS 
media) were utilised as controls. Plates were incubated in a humidified 5% CO2/95% 
air atmosphere at 37°C for 48 hr prior to total RNA extraction and subsequent cDNA 
synthesis. Sample cDNA was subjected to real-time PCR using PCR primers for a) 
cbfa-1, b) ALP or c) COL-1 α1chain. Results were normalized against 18s mRNA 
expression and are presented as mean fold change from time 0 (T0) control (cDNA 
derived from un-seeded cells and indicated by horizontal red line) ± standard error of 
the means (SEM) from triplicate PCR reactions for each of 3 individual 
differentiation experiments. Significant differences between individual treatments 
and the T0 control, or between treatments linked by line, was determined by post-hoc 
t-test and is indicated by α (p<0.05) or β (p<0.01). 
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Figure 5.8.  Effect of VN, VN / IGFBP-5 / IGF-I, VN / TGF-β1 or VN / FN / EGF 
on osteoblast differentiation marker expression in SaOS-2 cells after 7 days. 
Sub-confluent cultures of SaOS-2 cells were harvested using trypsin / EDTA 
digestion prior to the addition of 5 x 105 cells/well in pre-prepared 6 well tissue 
culture plates coated with solutions of VN / sf-αMEM (1 µg/mL), VN / FN / sf-
αMEM (1 µg VN/mL / 6 µg FN/mL) IGFBP-5 / IGF-I / sf-αMEM (160 ng BP-5/mL 
/ 40 ng IGF-I/mL), TGF-β1 / sf-αMEM (115.2 ng/mL), or EGF / sf-αMEM (115.2 
ng/mL) in combinations as indicated above and as detailed in section 5.2.2 and 2.16. 
SaOS-2 cells cultured in the presence of 10% FCS, or osteogenic supplemented 
media (+OS media) were utilised as controls. Plates were incubated in a humidified 
5% CO2/95% air atmosphere at 37°C for 7 days with a single media change at day 4, 
prior to total RNA extraction and subsequent cDNA synthesis. Sample cDNA was 
subjected to real time PCR using PCR primers for a) cbfa-1, b) ALP or c) COL-1 α1 
chain. Results were normalized against 18s mRNA expression and are presented as 
mean fold change from time zero (T0) control (cDNA derived from unseeded cells 
and indicated by horizontal red line) ± SEM from triplicate PCR reactions for each 
of 3 individual differentiation experiments. Significant differences between 
individual treatments and the T0 control, or between treatments linked by line, were 
determined by post-hoc t-test and is indicated by α (p<0.05) or β (p<0.01). 
Significant difference between the VN / IGFBP-5 / IGF-I treatment and all other 
serum-free VN containing treatments is given by ψ (p<0.05).    
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Figure 5.8 
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and VN / TGF-β1 after 7 days, suggest that either these treatments down regulate 
Col-I expression over this time or that there is a relatively high transcript number in 
the SaOS-2 cells at T0 immediately prior to seeding. Thus these findings suggest that 
the VN only, VN / IGFBP-5 / IGF-I and VN / TGF-β1 had no effect on Col-I 
transcription, and the low transcript number measured in cells exposed to these 
treatments may be the result of a reduction in transcript number due to the absence of 
an appropriate stimulus. Interestingly, the VN / FN / EGF treatment seemed to 
maintain Col-I transcription at basal levels equivalent to that in the T0 control.  
 
5.4 DISCUSSION 
In Chapter 3 I reported that the pre-bound combination of VN, IGFBP-5 and IGF-I 
can stimulate enhanced cell migration, metabolic activity and cell proliferation in 
osteoblast-like SaOS-2 cells. Each of these proteins are present in bone matrix and 
play important roles in bone development and remodelling (Bautista et al. 1990; 
Bautista et al. 1991; Seiffert 1996; Kumagai et al. 1998; Schvartz et al. 1999). 
Another important constituent of both bone matrix and blood plasma (like VN) is the 
~450-500 kDa glycoprotein FN (Yamada and Olden 1978; Yamada and Kennedy 
1979; Grzesik and Robey 1994). Like VN, FN also has an RGD integrin binding 
motif and can therefore facilitate cell adhesion to various culture surfaces (Steele et 
al. 1995; Carvalho et al. 1998; Degasne 1999; McFarland et al. 1999). Although, it 
is thought that it is the presence of VN in FCS which facilitates the adhesion of cells 
to the culture surface in standard in vitro tissue culture settings (Underwood and 
Bennett 1989).  
 
VN molecules attached to tissue culture substrates have an estimated monolayer 
saturation limit of 0.21 µg/cm2 (Pitt et al. 1989). Similarly, monolayers of FN 
molecules bound to tissue culture plastic in a ‘side on’ arrangement (as opposed to 
‘end on’) have a saturation limit of 0.36 µg/cm2 (Pitt et al. 1989). However, 
interrogation of tissue culture surfaces which have been exposed to high 
concentrations of VN or FN with monoclonal antibodies, has revealed that these 
molecules may undergo ‘multilayering’ (Underwood et al. 1993). VN and FN share 
many desirable properties important for applications in tissue engineering, such as 
the ability to adhere to a variety of tissue culture and biomaterial surfaces, the ability 
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to facilitate cell adhesion to those surfaces (Pitt et al. 1987; Pitt et al. 1989; Degasne 
1999; Ku et al. 2005), activate integrin mediated signalling pathways (Carvalho et 
al. 1998; Krause et al. 2000) and are able to bind IGFBP-5 (Gui and Murphy 2001; 
Xu et al. 2004). Thus, I hypothesised that pre-bound combinations of FN, IGFBP-5 
and IGF-I could stimulate similar functional responses in SaOS-2 cells as was 
observed for VN, IGFBP-5 and IGF-I. 
 
The study reported in this chapter has shown that when FN, IGFBP-5 and IGF-I are 
pre-bound to polycarbonate Transwell™ membranes, the osteoblast-like cell line 
SaOS-2 exhibits enhanced cell migration in serum-free conditions compared to either 
FN alone or similar treatments incorporating VN. In addition, I have shown that FN 
pre-bound to tissue culture plastic in the presence, or absence, of pre-bound VN 
dose- dependently influences SaOS-2 cell survival over 72 hr and that the pre-bound 
combination of FN, IGFBP-5 and IGF-I can enhance SaOS-2 cell survival compared 
to FN alone, but not compared to VN alone. Specifically, I have demonstrated that 
SaOS-2 cell migration across 12 µm pore polycarbonate Transwell™ membranes 
coated with FN is significantly enhanced by approximately 46% compared to 
membranes exposed to stoichiometrically equivalent amounts of VN, regardless of 
the presence or absence of additional growth factors (Figure 5.1).  
 
Similar results have been described previously for polymorphonuclear cell migration 
in response to FN alone and VN alone (Everitt et al. 1996). Thus Everitt et al. (1996) 
reported an approximate 50% increase in cell migration on FN coated filters 
compared to blank or VN-coated filters and that this enhanced response was 
mediated by α5β1 integrins. I also observed that the relative difference between the 
various FN based treatments were similar to responses observed for the VN based 
treatments detailed in chapter 3 and figure 3.1, with the exception that the FN, IGF-I 
treatment simulated significantly more cell migration than the FN only treatment 
(Figure 5.1). Significant, however, was the finding that pre-bound combinations of 
FN, IGFBP-5 and IGF-I could synergistically enhance SaOS-2 cell migration across 
the Transwell™ membranes, similar to the results obtained for VN coated 
Transwell™ membranes described in chapter 3. This result contradicts the findings 
of Xu and co-workers who used a similar migration assay system to the one used in 
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this study, and recently reported that IGFBP-5 binds to FN and that this interaction 
negatively regulates the potentiating effect of IGFBP-5 on IGF-I-mediated mouse 
embryonic cell (MEC) migration (Xu et al. 2004). The authors found that IGFBP-5, 
while bound to FN, could still bind IGF-I in a trimeric complex, similar to the 
findings of others in respect to IGFBP-5 / IGF-I complex formation with other ECM 
proteins such as VN, osteopontin and thrombospondin (Nam et al. 2000; Nam et al. 
2002; Kricker et al. 2003). While Kricker et al. (2003) and Nam et al. (2000, 2003) 
found that complex formation between IGFBP-5 and IGF-I with VN, osteopontin or 
thrombospondin further stimulated the potentiating effects of IGFBP-5 on IGF-I 
mediated cell function, Xu and co-workers reported that the presence of FN 
abolished the potentiating effect of IGFBP-5 on IGF-I mediated MEC migration 
(Nam et al. 2000; Nam et al. 2002; Kricker et al. 2003; Xu et al. 2004). They also 
demonstrated that this may be due to the expression of IGFBP-5 degrading proteases 
by MECs in response to exposure to FN. Specifically, they conclude that these 
enzymes degrade the IGFBP-5 that is bound to FN, thus abolishing its ability to 
modulate IGF-I mediated effects on cell migration. However, Xu et al. 2004 added 
IGFBP-5 in solution to MECs in the top of Boyden chambers and IGF-I in solution 
to the bottom well with FN either coated onto the underside of the upper chamber or 
added in solution together with the MECs and IGFBP-5 with or without protease 
inhibitors in to the upper chamber (Xu et al. 2004). Thus an alternative explanation 
of their data may be that upon exposure to FN, MECs express IGFBP-5 proteases 
which degrade IGFBP-5 and / or IGFBP-5 / IGF-I complexes in solution, thus 
abolishing the ability of IGFBP-5 to efficiently localise IGF-I to the cell surface and 
positively modulate MEC migration. 
 
In the present study, I pre-bound FN, IGFBP-5 and IGF-I to the lower chamber and 
underside of Transwell™ membranes prior to the seeding of SaOS-2 cells into the 
upper chamber in serum-free media. Thus any IGFBP-5 / IGF-I complexes present 
were bound to either the FN or potentially, non-specifically to the underside of the 
lower chamber and membrane face and were not in solution. It has been postulated 
by others that ECM bound IGFBP-5 is protected from proteolytic degradation which 
facilitates its positive effects on IGF-mediated cell function (Jones et al. 1993; Arai 
et al. 1994; Conover 1995). It is concluded that pre-bound combinations of FN, 
IGFBP-5 and IGF-I enhance cell migration in SaOS-2 cells. I acknowledge that it is 
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possible that the response observed in the two individual studies is specific to the 
particular types of cells used and in particular, to differences in the integrins present 
on the cell surface of these 2 cell types. However, I would hypothesise that 
application of the migration assay conditions employed by Xu and co-workers, but 
employing SaOS-2 cells, would yield similar results to those reported by Xu et al. 
2004 for the MECs. That is, the manner in which the combination of matrix protein 
and growth factors are presented to the cells is critical to the proper elucidation of 
the mechanisms underlying cell functions. These findings clearly have further 
general implications for the use of FN-based ECM / GF coatings on biomaterials. 
This aspect will be discussed more thoroughly in the next chapter. 
 
Osteoblast cell survival is highly dependent on attachment to a surface, a 
phenomenon known as anchorage-dependence (Hynes 1987; Ruoslahti and Reed 
1994). This regulation of cell survival is mediated in part by integrin receptor 
initiated intracellular signalling pathways such as the anti-apoptotic FAK, PI 3-
kinase, AKT pathway and the pro-apoptotic Bcl-2, caspase activation pathway 
(Howe et al. 1998; Giancotti and Ruoslahti 1999; Grigoriou et al. 2005). For 
example, Zhao and co-workers (2005) demonstrated that the β3 subunit of 
unoccupied αvβ3 integrins transmitted a “death” signal by association and activation 
of the pro-apoptotic protease caspase-8 in osteoclasts (Zhao et al. 2005). Various 
integrins are capable of binding to FN (Ruoslahti 1988; Pankov and Yamada 2002) 
and SaOS-2 cells are known to express both α5β1 and αvβ3 integrins (Koistinen et al. 
1999; Postiglione et al. 2003; Kilpadi et al. 2004), receptors for FN and VN 
respectively. In the present study I found that pre-bound FN alone could sustain the 
SaOS-2 cell population in a dose-dependent manner for 72 hr but could not facilitate 
cell proliferation over the same time period (Figure 5.2). Maximal SaOS-2 cell 
survival was achieved by coating the tissue culture surface with FN concentrations of 
6-12 µg/mL (Figure 5.2c). Interestingly, this functional response to pre-bound FN 
correlates well with the observation of Underwood and co-workers (1993) that BHK 
cell adhesion was maximal at the monolayer saturation limit of FN to tissue culture 
polystyrene (0.36 µg/cm2) which correlates to coating the culture surface with an 
approximate 10 µg/mL of FN solution (Underwood et al. 1993; Garcia et al. 1999). 
Thus this suggests that: 1) the survival of 5000 SaOS-2 cells required the FN surface 
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treatment to be at, or above, the saturation limit for FN on tissue culture polystyrene; 
and 2) FN coatings that are below the monolayer saturation limit (6-12 µg/mL) 
cannot sustain the initial number of cells seeded. Whether this is because pre-bound 
FN at concentrations below the saturation limit does not provide sufficient cell 
attachment sites to retain all cells or because a rapid reduction in the number of cell 
attachment sites occurs due to proteolytic degradation of FN molecules, remains 
unclear.  
 
Since both FN and VN are significant constituents of serum I wished to examine the 
effect that pre-binding both FN and VN to the tissue culture surface had on cell 
proliferation. Unexpectedly, I found that the lower concentrations of FN seemed to 
inhibit SaOS-2 cell survival in the presence of VN, while at the highest concentration 
of FN, SaOS-2 cell number was significantly increased above that found with VN 
alone after 72 hr (p<0.01). This suggests that the cells had proliferated in response to 
this particular treatment (Figure 5.3c). This response is reminiscent of a threshold 
effect whereby high concentrations of cell attachment sites are required to initiate the 
proliferative response. This hypothesis is supported by the studies which show that 
both FN and VN can bind to tissue culture plastic in much greater amounts than their 
respective monolayer saturation limits (0.36 µg/cm2 and 0.21 µg/cm2 
respectively)(Pitt et al. 1987; Pitt et al. 1989). However, to achieve this density, FN 
molecules change orientation from ‘side-on’ to ‘end-on’, or undergo multilayering 
with a concomitant change in conformation. VN molecules tend to multilayer at 
higher concentrations without apparent changes in conformation (Underwood et al. 
1993). Therefore it is possible that in the present study more integrin binding sites 
were available at the highest dose of FN, thus facilitating a proliferative response. 
Changes in FN conformation in response to differences in culture surface properties, 
or the presence of type I collagen, can modulate between specific integrin-mediated 
cell functions, such as proliferation and differentiation of myogenic cells (Garcia et 
al. 1999). Garcia et al. (1999) concluded that this effect was due to conformation 
dependent differences in the level of α5β1 integrin binding to FN. Thus treatment of 
tissue culture surfaces with multiple matrix proteins can affect the conformation of 
those proteins and therefore the specific suite of integrins able to bind, thus 
modulating subsequent cell function. Clearly, further studies are required to 
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characterise the conformational nature of, in particular, simple combinations of ECM 
protein coatings on tissue culture polystyrene in order to more fully understand the 
particular functional consequences of matrix / culture surface interactions and thus 
desirable surface properties for future biomaterial constructs.  
 
As discussed above, IGFBP-5 has previously been shown to interact with FN and 
this study and others have shown that the combination of FN, IGFBP-5 and IGF-I 
can positively and / or negatively modulate cellular responses such as cell migration 
(Jones et al. 1993; Mohan et al. 1995; Xu et al. 2004). This in turn, has important 
implications for the design of advanced biomaterial / ECM constructs. Thus, I also 
wished to examine whether pre-bound IGFBP-5 and IGF-I in the presence of pre-
bound FN would have a potentiating effect on cell proliferation, another important 
possible design feature of advanced tissue engineered constructs. I found that after 
72 hr pre-bound FN, IGFBP-5 and IGF-I could sustain significantly higher SaOS-2 
cell numbers than FN alone, but was not able to enhance the response of SaOS-2 
cells cultured in the presence of pre-bound VN, IGFBP-5 and IGF-I (compare Fig 
3.6 and Fig 5.4). In fact, cell number in all serum-free treatments declined after 
peaking at 48 hr. However the decline in cell number was smaller in the presence of 
FN, IGFBP-5 and IGF-I compared to the other FN treatments. This result, together 
with the results detailed in chapter 3, suggest that either: 1) SaOS-2 cells are 
interacting with FN and VN via different mechanisms; or 2) there are fewer binding 
sites available for engagement of IGFBP-5 / IGF-I complexes and thus limited 
receptor engagement and mitogenic signaling. Further studies are required to 
determine the amount of IGFBP-5 and IGF-I that is capable of being retained by 
both FN and VN, or combinations thereof, immobilised on tissue culture plastic. As 
pointed out above, determination of how much, if any, IGFBP / IGF-I binds to tissue 
culture polystyrene from serum under standard culture conditions would be of 
significant interest.  
 
In a related study in which I examined responses to solution phase FN and VN, with 
or without EGF or bFGF (known to bind to VN and induce functional responses in 
other cell lines (Schoppet et al. 2002; Hollier et al. 2005), preliminary morphological 
data suggested that the combination of VN, FN and EGF could sustain SaOS-2 cell 
viability for extended periods of time (12 days)(Figure 5.5d). I therefore decided to 
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include this treatment in a pre-bound format in subsequent experiments evaluating 
the effect of select treatments on morphology and osteoblast marker expression in 
SaOS-2 cells. Other specific serum-free treatments which had yielded interesting or 
intriguing results throughout this study were selected for evaluation of their effect on 
SaOS-2 cell morphology and select osteoblast marker expression. These treatments 
were: VN alone (as a base line treatment); VN / IGFBP-5 / IGF-I (due to the 
enhanced proliferation and metabolic activity it induced in SaOS-2 cells and reported 
in chapter 3); VN / TGF-β1 (due to the enhanced response it induced in hMSC 
metabolic activity, as detailed in chapter 4, and for the reported effects both proteins 
have on osteogenic differentiation (Salasznyk et al. 2004a; Salasznyk et al. 2004b); 
and VN / FN / EGF (for the intriguing effect this combination had on SaOS-2 cell 
morphology and apparent survival, as detailed above). 
 
Osteoblast in vitro morphology typically changes during osteogenic differentiation 
from a spread / polygonal, or fibroblastic morphology, to a compacted and 
cobblestone / cuboidal morphology (Aubin 1998). I therefore compared the 
morphology of SaOS-2 cells exposed to pre-bound VN alone; VN / IGFBP-5 / IGF-
I; VN / TGF-β1; or VN / FN / EGF with SaOS-2 cells cultured in 10% FCS or 10% 
FCS supplemented with osteogenic factors (OS media) over 7 days. The osteogenic 
supplements were utilised to drive the differentiation process and marker expression. 
SaOS-2 cells cultured in this environment represent a model of rapidly 
differentiating cells whereas, SaOS-2 cells cultured in the presence of 10% FCS 
undergo terminal differentiation over a longer time period and as such represent a 
model of more slowly differentiating cells (data not shown). After 7 days of culture 
SaOS-2 cells exposed to pre-bound VN, IGFBP-5 and IGF-I adopted a more 
cobblestone / cuboidal morphology similar to that observed for SaOS-2 cells 
cultured in 10% FCS or OS media (Figure 5.6b). Dexamethasone, a glucocorticoid 
constituent of OS media is known to induce osteogenic differentiation in hMSCs 
including a morphological transformation from fibroblastic to cuboidal (Cheng et al. 
1994). Thus, the morphology of SaOS-2 cells exposed to VN / IGFBP-5 / IGF-I, 
10% FCS and OS media is consistent with the process of osteoblast differentiation. 
The key difference, however, between these results is that cells exposed to VN / 
IGFBP-5 / IGF-I did not proliferate to the same extent as cells exposed to 10% FCS 
and they began to adopt a more cobblestone appearance while sub-confluent. This 
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suggests, that VN, IGFBP-5 and IGF-I may facilitate SaOS-2 cell differentiation 
processes and that other factors, which are present in FCS, are required to drive the 
proliferative response.  
 
These conclusions were further supported by the finding that VN / IGFBP-5 / IGF-I 
also facilitated the increase (Figure 5.7b) and maintenance of ALP gene expression 
over 7 days compared to the T0 control (unseeded SaOS-2 cells) whereas other 
serum-free, VN containing, treatments did not sustain the initial increase in ALP 
expression above the T0 control (Figure 5.8b). In a parallel study also performed in 
our laboratory, the VN / IGFBP-5 / IGF-I treatment induced a consistent increase in 
ALP activity over 14 days (Figure 5.9).  
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Figure 5.9. Effect of VN, alone or in combination with IGFBP-5 / IGF-I or 
TGF-β1, on ALP activity per 105 SaOS-2 cells. Alkaline phosphatase activity is 
expressed as nmol of p-nitrophenol produced per minute per 105 cells ± SEM. 
Statistical significance was determined using Student’s t-test (p<0.05 or p<0.01). 
Significant difference (p<0.05) to control groups at the same time point are indicated 
by α (10% FCS), β (10%+OS), or γ (sf-αMEM). (Reproduced with permission of K, 
Shrobback, Tissue Repair and Regeneration Program, Institute of Health and 
Biomedical Innovation, Queensland University of Technology).  
 
Since SaOS-2 cells are known to express high levels of ALP (Murray et al. 1987) it 
is possible that the initial increase in ALP transcription and the accumulation of ALP 
activity induced by VN, IGFBP-5 and IGF-I may represent facilitation of a more 
‘normal’ phenotype rather than a differentiation response. The apparent 
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disengagement of ALP gene transcription (Figure 5.7b and 5.8b) and enzymatic 
activity (Figure 5.9) over extended time may be an artefact of the ALP bioassay. The 
ALP assay data is a measure of the accumulated enzyme in the system, whereas the 
real-time PCR data more closely reflects the status of gene transcription at the time 
of RNA extraction (a “snap-shot”). Alternatively, these data may also reflect 
discordance between transcriptional and post translational regulatory mechanisms. 
Indeed, expression of the ALP gene has been shown to be regulated very early post 
transcripionally by the presence of destabilising intronic sequences (Kiledjian and 
Kadesch 1991). Furthermore, its functional activity is regulated by inorganic 
phosphate sources (Farley et al. 1994; Orimo and Shimada 2006), while regulation 
of its release by SaOS-2 cells is Ca2+ and growth factor dependent (Anh et al. 1998). 
Clearly further studies are required to fully elucidate the mechanisms of action of 
VN / IGFBP-5 / IGF-I on ALP expression in SaOS-2 cells and the effects of the 
addition of the components in solution following the initiation of cellular responses 
on the pre-bound format. From a tissue engineering point of view this would be 
important because it is conceivable that for some in vitro tissue engineered 
constructs, media changes would be required and thus knowledge of how cellular 
mechanisms are modulated by the provision of various signals in solution will be an 
important design consideration for such constructs. 
 
The parallel study by Shrobback et al mentioned above, also revealed that SaOS-2 
cells exposed to either VN alone; VN / IGFBP-5 / IGF-I; or VN / TGF-β1 
incorporated increasing levels of [3H]-Proline, as a percentage of total protein 
synthesis over time, compared to SaOS-2 cells exposed to 10% FCS alone (Figure 
5.10). [3H]-Proline incorporation is a commonly used functional bio-assay for de 
novo collagen synthesis in bone cells  (McCarthy et al. 1989; Layman and Ardoin 
1998) and hence these data seem to suggest either that the presence of VN could 
facilitate the incorporation of L-proline into accumulated protein or, that the 
presence of unknown / unidentified factors within FCS suppress the increased 
incorporation of L-proline. Indeed, the elevated levels of target gene expression 
(cbfa-1, and ALP) in the 10% FCS treatment compared to the other treatments may 
reflect the combined effect of high metabolic activity induced by factors within FCS, 
coupled with a contact-mediated differentiation response. 
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Figure 5.10. Effect of VN, alone or in combination with IGFBP-5 / IGF-I or 
TGF-β1, on the ratio of [3H]-Pro and [3H]-Leu in newly synthesised proteins in 
SaOS-2 cells. Results are expressed as the mean ratio of [3H]-Pro to [3H]-Leu in 
newly synthesised protein ± SEM. Statistical significance was determined using 
Student’s t-test (p<0.05 or p<0.01). Significant difference (p<0.05) to control groups 
at the same time point are indicated by α (10% FCS), β (10%+OS) or γ (sf-αMEM). 
(Reproduced with permission of K Shrobback, Tissue Repair and Regeneration 
Program, Institute of Health and Biomedical Innovation, Queensland University of 
Technology).  
 
While VN has been associated with induction of osteogenic differentiation processes 
in hMSCs, such as type I collagen expression (Salasznyk et al. 2004b), others have 
observed that over-expression of αvβ3 integrins promotes cell proliferation with 
decreased expression of a number of key markers of osteogenic differentiation 
(Cheng et al. 2001). However, integrin (including αvβ3 integrin) interaction with the 
ECM is essential to facilitate osteoblast-mediated matrix mineralisation (Schneider 
et al. 2001). Indeed, the expression of the osteoblast differentiation marker 
osteopontin (OPN) has been shown to be up-regulated in cells over expressing αvβ3 
integrins (Cheng et al. 2001) while others report that OPN gene expression is not 
altered by osteoblast attachment to the αvβ3 integrin ligands OPN or VN (Carvalho 
et al. 1998). Similarly, IGF-I has been shown to increase L-proline uptake and type I 
collagen synthesis in SaOS-2 cells (Kudo et al. 1996) and has been shown to be 
involved in the suppression of apoptosis and maintenance of  the differentiated 
phenotype of more mature osteoblasts (Walsh et al. 2003). IGF-I is further reported 
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to mediate survival and proliferative responses in SaOS-2 cells via PI3-Kinase and 
p42 / 44 MAPK pathways (Grey et al. 2003) and similarly IGFBP-5 is associated 
with both osteoblast mitogenesis and bone formation (for a recent review of the role 
of IGFBP-5 in bone the reader is referred to (Govoni et al. 2005)). Thus the overall 
combined effects of VN, IGFBP-5 and IGF-I in a pre-bound format in serum-free 
media on osteoblast function remain unclear and warrant further investigation.  
 
One of the most intriguing findings in the present study was that within 48 hr SaOS-
2 cell cultures exposed to VN / FN / EGF were confluent and adopted an elongated 
or fibroblast-like morphology and maintained this until day 7 (Figure 5.6a.4 and 
5.6b.4). Apart from an initial increase in ALP expression after 48 hr, the cbfa-1, ALP 
and Col-I transcript levels had returned to (ALP), or were maintained (cbfa-1 and 
Col-I), at levels equivalent to T0 after 7 days (Figure 5.7 and 5.8). Taken together, 
these data suggest that the VN, FN and EGF treatment induced a quiescent state on 
the cells. Hence, while transcription levels of cbfa-1, ALP and Col-1 had returned to 
T0 levels, the cultures displayed few mitotic indices compared to cultures exposed to 
FCS (Figure 5.6a and b). Furthermore, as mentioned above, this treatment could also 
sustain the cells in a similar morphological state for up to 12 days of culture (Figure 
5.5). This conclusion is supported by studies which have shown that EGF, via the 
EGF receptor (EGFR), inhibits osteogenic differentiation processes such as collagen 
synthesis and ALP activity (Kumegawa et al. 1983; Chien et al. 2000). For example, 
transcription of the osteoblast marker osteocalcin (OC) has been shown to be 
negatively regulated by Fos and Jun heterodimers binding to the AP-1 site within the 
vitamin D response element the of the OC gene promoter, inhibiting both vitamin D 
mediated and basal OC gene transcription (Owen et al. 1990). EGF is known to up-
regulate Fos and Jun production (Marks et al. 1996; Wan et al. 2001), thus providing 
a mechanism for EGF- and EGFR-mediated down regulation of osteoblast 
differentiation and marker expression (Chien et al. 2000). Interestingly, FN has been 
associated with the development of the osteoblast phenotype, especially on a pre-
bound type I collagen culture surface (Stephansson et al. 2002). In addition, the α5β1 
integrin / FN interaction was found to be critical for rat calvarial osteoblast 
differentiation in vitro, and perturbation of this interaction by function blocking 
antibodies down-regulated ALP and OC gene expression (Moursi et al. 1996; 
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Moursi et al. 1997). Although the same authors demonstrated that FN can act as a 
survival factor for more mature osteoblasts (Globus et al. 1998), the mechanism(s) 
controlling, or contributing to the apparent quiescence of SaOS-2 cell exposed to VN 
/ FN / EGF remain unclear. It is important to examine if the apparent quiescence is 
reversible, and if the cells could be further induced to express a more differentiated 
phenotype by, for example, removal of the EGF and replacement with a known 
osteogenic factor such as bone morphogenetic protein 2 or 7. This level of control 
over cell phenotype in serum-free culture conditions will have application in the field 
of bone tissue engineering for the development of cell / biomaterial constructs.  
 
In conclusion, the data presented in this chapter suggest that FN together with 
IGFBP-5 and IGF-I (in serum-free conditions) can stimulate enhanced SaOS-2 cell 
migration, but not proliferation, over and above the levels attained for VN / IGFBP-5 
/ IGF-I reported in chapter 3. Furthermore, pre-bound FN alone in serum-free 
conditions could facilitate SaOS-2 cell survival over 72 hr in a dose-dependent 
manner, while at high concentrations and in the presence of pre-bound VN, SaOS-2 
cell numbers are increased. In addition, I have also shown that VN / IGFBP-5 / IGF-I 
in serum-free conditions can facilitate an increase in ALP expression and activity 
and adoption of a more differentiated morphology by SaOS-2 cells. Furthermore, the 
VN / FN / EGF serum-free treatment seemed to induce quiescence in SaOS-2 cells 
while maintaining cbfa-1, ALP and Col-1 mRNA levels similar to those present at 
the time of seeding. While it is obvious that further investigations into the 
mechanisms underlying these results are required, it is clear that these treatments 
represent a basic starting platform of a defined ECM / growth factor, serum-free 
culture system that might hold potential in controlling cell phenotype for tissue 
engineering applications.    
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CHAPTER 6: 
GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 206 
6.1 DISCUSSION 
The field of bone tissue engineering has continued to expand over the 19 years when the 
formal definition of the term ‘tissue engineering’ was first developed at a meeting of 
representatives of the biotechnology and engineering community in Lake Tahoe, 
California in February 1988. The broad definition of the term ‘tissue engineering’ is the 
use of living cells, together with either natural or synthetic extra cellular components in 
vitro, for the development of implantable parts or devices for the restoration or 
replacement of tissue or organ function (Patrick et al. 1998). There have been several 
seminal advances critical for the advancement of the field of tissue engineering, one of 
which was the discovery and isolation of so-called mesenchymal stem cells from bone 
marrow (Friedenstein et al. 1970; Friedenstein et al. 1987; Caplan 1991; Friedenstein et 
al. 1992). This discovery has provided a source of cells which have a proven ability to 
differentiate into multiple lineages and affect tissue repair in both animal models and 
humans (Bruder et al. 1998a; Bruder et al. 1998b; Pittenger 1999; Caplan and Bruder 
2001; Grayson et al. 2004; Otto and Rao 2004; Warren et al. 2004). Other more recent 
advances include the discovery that members of the IGF family of growth factors could 
interact directly with the ECM protein VN and that this enhances functional responses in 
porcine smooth muscle cells and MCF-7 breast cancer cells (Upton et al. 1999; Nam et 
al. 2002; Kricker et al. 2003). Inspired by these early findings members of our research 
team quickly realised that the adhesive properties of VN, coupled with the ability to 
associate with a growth factor, could be used as a delivery mechanism to immobilise the 
growth factor at the culture surface where it could be accessed to enhance various 
cellular responses. In particular, it was postulated that this may more accurately reflect 
the environment that cells encounter in vivo. Numerous studies have since demonstrated 
that select pre-bound combinations of VN ± IGF-II and VN ± the 6 IGFBPs ± IGF-I are 
able to mediate various functional responses in MCF-7 cells and HaCAT keratinocytes 
(Noble et al. 2003; Hyde et al. 2004). Since these initial observations, other growth 
factors have also been shown to also interact with VN; these include EGF, bFGF and 
TGF-β1 (Schoppet et al. 2002). In addition, when these growth factors are presented to 
cells in vitro, in association with VN, cellular responses are greater than responses to the 
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individual components (Schoppet et al. 2002; Hollier et al. 2005), suggesting 
interactions between distinct receptor induced signaling pathways.  
 
Vitronectin and members of the IGF family of growth factors and TGF-β1 are important 
components of bone tissue (Bautista et al. 1990; Bautista et al. 1991; Seiffert 1996) and 
VN is the principal protein to adsorb to tissue culture plastic from serum containing 
media (Bale et al. 1989; Pitt et al. 1989; Steele et al. 1995). The broad aim of this PhD 
project was to characterise the functional responses of human osteoblasts and human 
mesenchymal stem cells to pre-bound combinations of VN, IGFBP-5 and IGF-I under 
serum-free conditions, with a view to expanding the study to include other biological 
factors important to musculoskeletal repair such as FN, TGF-β1 and EGF. Therefore, 
this thesis has principally focussed on functional analyses such as cell migration, 
metabolic activity, proliferation, total protein assays and morphological analysis.  
 
Overall, the hypothesis proposed in chapter 1 that: ‘Specific combinations of the ECM 
protein VN and members of the IGF family of growth factors, such as IGFBP-3 or -5 
and IGF-I can support cell attachment, migration, proliferation and / or differentiation of 
human osteoblast like cells (SaOS-2) and hMSCs in culture in the absence of animal 
derived culture media additives is supported by a number of key findings reported in this 
thesis. Experimental observations reported in chapter 3 specifically demonstrates SaOS-
2 cell migration is significantly enhanced in the presence of VN together with IGFBP-5 
and IGF-I. In addition, VN / IGFBP-5 / IGF-I enhanced SaOS-2 cell metabolic activity 
after 48 hr and manifests as enhanced proliferation after 72 hr. These findings are 
important because osteoblast adhesion to, migration and colonisation of 3 dimensional 
biomaterial scaffolds are desirable in bone tissue engineering contexts (Anselme 2000). 
Thus, these findings indicate that pre-bound VN / IGFBP-5 / IGF-I may have potential 
as a bioactive coating for tissue engineered biomaterial constructs. This conclusion is 
further supported by the fact that (as mentioned above) VN is a matrix component of 
bone (Seiffert 1996) and IGFBP-5 and IGF-I are highly expressed in bone tissue 
(Bautista et al. 1990; Bautista et al. 1991). Indeed, others have investigated VN for its 
value as a potential bioactive coating for 3 dimensional biomaterial constructs for tissue 
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engineering applications (Fabrizius-Homan and Cooper 1991; Degasne 1999; Webster 
et al. 2001; Lacouture et al. 2002; Ku et al. 2005; Schleicher et al. 2005). 
 
A pertinent observation also reported in chapter 3 was that metabolic activity assayed 
after 48 hr permitted the increased SaOS-2 cell numbers measured after 72 hr of culture 
on VN / IGFBP-5 / IGF-I. In contrast, other treatments were unable to sustain SaOS-2 
metabolic activity resulting in fewer cells in the same period of culture. Importantly, 
since there is a clear discrepancy between the 48 hr metabolic activity data and cell 
number observed at the same time point, these data clearly demonstrate that the use of 
assays based on metabolic activity are far from ideal measures of proliferation. 
Significantly however, these data also show that by understanding the limitations of 
such assays one may apply such data to build a more complete picture of the functional 
response to given treatments / surfaces etc. This is especially true in relation to bona fide 
cell proliferation which would logically require an increase in cellular metabolic activity 
prior to an increase in cell number. Future studies should incorporate functional analyses 
of metabolic activity, total protein synthesis and cell number over time as a matter of 
course in order to construct a more complete picture of the functional effects of these 
and other combinations of proteins within in vitro settings. Moreover, such approaches 
would avoid the common misinterpretation or over-interpretation of experimental data.  
 
A prolific body of evidence has been generated on the isolation, characterisation, 
propagation and therapeutic potential of so-called human mesenchymal stem cells 
(hMSCs) (Haynesworth et al. 1992; Bruder et al. 1994; Caplan 1994; Wakitani et al. 
1994; Jaiswal et al. 1997; Caplan et al. 1998; Johnstone et al. 1998; Solchaga et al. 
2001). Indeed, hMSCs cultured in vitro and seeded onto various types of biomaterial 
scaffold materials have a demonstrated ability to repair large segmental bone defects in 
animal models and by implication suggest that this technology has an equivalent 
potential in human patients (Bruder et al. 1994; Bruder et al. 1998a; Bruder et al. 1998b; 
Turgeman et al. 2001). A major obstacle to the clinical use of ex vivo expanded hMSCs 
is that current culture methods require the use of animal-derived media supplements 
such as foetal calf serum (FCS). Regulatory authorities such as the Food and Drug 
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Administration (FDA) in the USA or the Therapeutic Goods Administration (TGA) in 
Australia restrict the use of cell based therapeutics which have come into contact with 
animal derived substances due to the risk of pathological transfer of disease to patients 
(Federal Register). Bovine Spongiform Encephalitis (BSE) commonly known as ‘mad 
cow disease’ is an example of a pathogen which may be transferred to human recipients 
through cell based therapeutics exposed to contaminated FCS. Other animal derived 
media supplements such as anterior pituitary extract are also undesirable for therapeutic 
applications due to the “un-defined” nature of these products which often exhibit 
significant batch to batch variation. This is the primary reason behind the common 
practice of batch testing of specific lots / batches of FCS for optimal cell culture 
performance (Lennon et al. 1996). Thus, a key research focus of our team is to examine 
the efficacy of using various combinations of matrix proteins and growth factors to 
replace animal derived media supplements for the culture of therapeutically important 
cell and tissue grafts. Indeed our research team has demonstrated that primary human 
keratinocytes derived from adult skin can be established and expanded in serum-free 
conditions using combinations of VN, IGFBP-5, IGF-I and EGF (Dawson et al. 2006). 
Additionally, serum-free methodologies for the culture of primary limbal epithelial cells 
for treatment of a range of serious eye injuries has also been achieved (Ainscough et al. 
2006). However, both of these epithelial cell types still required the use of a mouse 
feeder layer to provide as yet unknown components of the in vitro environment. No such 
feeder layer is required for the establishment and serial propagation of hMSCs. 
Furthermore, the argument for developing a serum-free medium which incorporates VN 
is convincing since VN is the principal protein which is adsorbed on to tissue culture 
plastic from serum (McFarland et al. 1999) in standard culture conditions. Thus, I would 
hypothesise that VN should be a principal component in any rational serum replacement 
for the in vitro culture of cells, given that most experimental data derived from in vitro 
studies have included exposure of cells to serum.  
 
The difference in complexity between media containing 10% FCS and media containing 
VN, an IGFBP and IGF-I is clearly illustrated in figure 6.1.  
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Figure 6.1 Comparison of protein from media with 10% FCS and media with VN, 
IGFBP and IGF-I 
Proteins within DMEM culture media containing 10 % FCS (0.1µL) (lane 1) and media 
containing VN (75 kDa and 68 kDA), IGFBP-3 (32 kDa) and IGF-I (7.5 kDa not clearly 
identified on gel) (10µL) (lane 2) were separated by 10% SDS-PAGE under non 
reducing conditions and subsequently silver stained. (MW marker: lane M). 
(Reproduced with permission of L Cormack, Tissue Repair and Regeneration Program, 
Institute of Health and Biomedical Innovation, Queensland University of Technology). 
 
Thus, the ability of the VN, IGFBP-5 and IGF-I formulation to support functional 
responses in hMSCs was examined. Subsequently, the second aim of this project sought 
to characterise the initial functional response of hMSCs to various combinations of VN, 
IGFBP-3 or -5 and IGF-I, or VN and TGF-β1 in serum-free conditions.  
 
Several novel findings were made during the studies, reported in chapter 4. Initially, I 
attempted to establish bone marrow-derived fibroblastic cultures directly from the 
mononuclear cell fraction of whole bone marrow obtained from patients presenting for 
total joint replacement surgery, using pre-bound combinations of VN and IGFBP-3 or -5 
and IGF-I, or VN and TGF-β1. However, this approach failed to support adequate 
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fibroblastic cell attachment. Whereas, leaving the unbound fraction of VN and growth 
factors in solution did support fibroblastic cell attachment and maintenance over 3-4 
days of culture but unfortunately this approach did not sustain the cultures beyond this 
time point. To the best of my knowledge this is the only study which has described the 
discreet attachment of fibroblast like cells from the mononuclear cell fraction of whole 
bone marrow, rather than forming in colonies. It is, however, unclear whether or not 
these cells were hMSCs. Further studies are clearly required to test the colony formation 
capabilities and multi-lineage potential of these cells.  
 
Based on the above results I decided to characterise the functional response of hMSCs 
which had been established using classical methods and expanded in culture. Thus, I 
also reported in chapter 4 that solution phase VN in combination with TGF-β1, 
significantly enhanced hMSC metabolic activity in a dose-dependent manner, with 
responses being greater than those measured after 72 hr in the presence of 10 % FCS. 
This result indicated that TGF-β1: 1) has a direct stimulatory effect on hMSC metabolic 
activity via its down stream signalling effectors; or 2) stimulates metabolic activity 
indirectly by inducing the expression of other mitogens which act in an autocrine / 
paracrine fashion. This latter hypothesis is supported by the findings of Kveiborg and 
co-workers who showed that TGF-β1 induces the expression of IGFBP-3 and IGF-I in 
hMSCs (Kveiborg et al. 2001). This possibility is intriguing because the presence of 
exogenous IGFBP-3 and IGF-I did not result in an equivalent response to TGF-β1 at 
either concentration of VN tested (52 ng/well or 174 ng/well). However, in the study 
reported herein an E.coli derived IGFBP-3 mutant (N109D) which is non-glycosylated 
(~35 kDa) was utilised, whereas the 2 isoforms of IGFBP-3 produced by hMSCs 
exposed to TGF-β1 were partially (38 kDa) or fully glycosylated (42 kDa) isoforms 
(Kveiborg et al. 2002). The mechanisms underlying the variable response to VN, 
IGFBP-3 or-5 and IGF-I compared to VN and TGF-β1 remain unclear; however, it is 
possible that the expression level and / or post translational modifications of TGF-β1-
induced IGFBP-3 and IGF-I may be important and further studies are required to 
ascertain if this is indeed the case.  
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Interestingly, VN together with TGF-β1, has been reported to increase DNA synthesis in 
human lung fibroblasts (hLF) via a mechanism which involves the interaction of the 
TGF-β type II receptor (TGFβIIR) and αvβ3 integrins (Scaffidi et al. 2004). In this 
situation, ligand occupancy induced co-localisation and immuno-complex formation of 
both the αvβ3 integrin and the TGFβIIR, increased expression of the αvβ3 integrins on 
the cell surface and synergistically enhanced the hLF proliferative response via up 
regulation of cyclin D1 (Scaffidi et al. 2004). hMSCs are known to express αvβ3 
integrins (Conget and Minguell 1999) and are responsive to TGF-β1 (Kveiborg et al. 
2001). Taken together these mechanistic data support my functional findings that VN 
and TGF-β1 synergistically stimulate hMSC metabolic activity and this response is 
further enhanced with increasing the VN concentration. Moreover, this may be due to an 
increase in cell surface αvβ3 integrins mediating the response to the increase in VN, 
perhaps in combination with endogenously expressed IGFBP-3 and IGF-I which acts in 
an autocrine / paracrine manner, resulting in the observed synergistic response. 
Obviously, the specific mechanisms underpinning this response remain to be elucidated 
and further investigation of the underlying mechanism(s) is warranted.   
 
In contrast to the metabolic activity data detailed in chapter 4, which revealed a general 
decrease in metabolic activity between 24 hr and 48 hr assays of total protein revealed 
no such decrease, suggesting that the observed reduction in WST-1 metabolism was 
probably not the result of decreased cell numbers. However the increase in metabolic 
activity between 48 hr and 72 hr does not necessarily indicate an increase in cell number 
but may instead indicate an increase in extra-cellular protein production. Generally, VN, 
IGFBP-3 or -5 and IGF-I, or VN and TGF-β1, facilitated an increase in total protein 
equivalent to that of hMSCs exposed to 10% FCS over 72 hr. IGF-I has been positively 
(Jia and Heersche 2000) and negatively (Walsh et al. 2003) associated with 
osteoprogenitor cell proliferation. In addition, others have shown that IGFBP-5 
enhances IGF-I mediated mitogenesis in osteoblasts (Andress and Birnbaum 1992), 
while the growth of porcine smooth muscle cells cultured in the presence of the αvβ3 
integrin ligand, osteopontin, and IGF-I was found to be enhanced to levels similar to that 
of cells cultured in 10% FCS by the addition of IGFBP-5 (Nam et al. 2000). In further 
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support of my own observations, Nam and co-workers found that the potentiating effect 
of IGFBP-5 on IGF-I-mediated DNA synthesis was dependent on the binding 
interaction of IGFBP-5 to VN (Nam et al. 2002). Overall, these data tend to support the 
results presented in this thesis and related reports which have found that complexes 
composed of select IGFBPs together with IGF-I, including IGFBP-3 and -5, bound to 
VN can enhance the functional responses of various cell types (Kricker et al. 2003; 
Hyde et al. 2004; Hollier et al. 2005; Schleicher et al. 2005; Ainscough et al. 2006; 
Dawson et al. 2006).  
 
I also reported in chapter 4 that the presence of IGF-I or TGF-β1 and a relatively low 
concentration of VN, induced the aggregation of cells in the cultures, whereas a 
relatively high concentration of VN attenuated this aggregation phenomenon. 
Furthermore, total protein data suggests that the aggregation effect was not due to a 
decrease in cell number, since in the presence of the lower concentration of VN, hMSC 
total protein continued to increase over time, as did cell aggregation over time. If the 
aggregation effect was due to a reduction in cell number I would have expected to 
observe a decrease in total protein content over time or at least a plateau in protein 
accumulation.  
 
Studies performed using the mouse osteoblast cell line (MC3T3-E1 cells) exposed to 
TGF-β1 have described similar morphological changes, and reported that in the presence 
of pre-bound type I collagen these changes were abrogated (Hurley et al. 1994; Karsdal 
et al. 2001). Moreover TGF-β1 was found to increase activation of the ERK1/2 and p38 
MAP kinase signalling pathways; however, only the p38 MAP kinase pathway was 
implicated in the morphological changes (Karsdal et al. 2001). Interestingly, TGF-β1 is 
known to induce plasminogen activator inhibitor (PAI-1) expression (Boehm et al. 
1999; Kutz et al. 2001) which can mediate cell detachment from VN by initiating 
endocytosis of uPA-uPAR-αv integrin complexes. Indeed, PAI-I mediated CHO cell 
detachment can be drastically reduced by over-expression of αvβ3 integrins on the cell 
surface (Czekay et al. 2003). In addition, Tram and co-workers have previously 
described a similar response to parathyroid hormone in osteoblasts (Tram et al. 1993), 
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thus supporting the observation that higher concentrations of VN can attenuate the 
aggregation response in hMSCs. This is the first study to describe this type of response 
in either hMSCs or to IGF-I, and to report that the response can be dose-dependently 
attenuated by VN. However, the specific mechanisms of the observed aggregation 
response to both TGF-β1 and IGF-I in hMSCs remains to be elucidated.  
 
My initial thoughts regarding the growth factor mediated hMSC aggregation 
phenomenon was that this may have been due to secreted protease activity, indeed pro-
MMP-2 and pro-MMP-9 was found to be present in the conditioned media of hMSCs 
(including hMSCs cultured in serum-free media alone) regardless of treatment. This 
indicated that 1) hMSCs constitutively express MMP-2 and MMP-9 in vitro and 2) none 
of the treatments had any affect on the functional expression of MMP-2 or MMP-9 by 
hMSCs. Thus, there was no correlation with the presence of either of these MMPs in the 
hMSC conditioned media and the aggregation affects of either IGF-I or TGF-β1. In 
addition, it appears that the constitutive expression of MMP-2 is relatively common in a 
number of cell types (Sternlicht and Werb 2001). However, the IGFBPs used in this 
study are known substrates for each of these MMPs (Fowlkes et al. 1995; Sternlicht and 
Werb 2001) and I also reported in chapter 4 that as yet unidentified factors within the 
hMSC conditioned media could degrade purified IGFBP-5. Again the data is supported 
by the findings of others which showed MMP-2 and MMP-13 are present in the 
conditioned media of MC3T3 osteoblast cells and that the expression of MMP-13, but 
not MMP-2, had been induced by TGF-β1 (Karsdal et al. 2001).  Interestingly, Ray and 
Stetler-Stevenson (1995) showed that attachment and spreading of melanoma cells on 
VN could be restored by over expression of the MMP-2 inhibitor tissue inhibitor of 
metalloproteinase-2 (TIMP-2), despite showing that the VN substrate was not degraded 
by activated MMP-2 (Ray and Stetler-Stevenson 1995). The expression of, or putative 
role of, secreted MMP inhibitors on the functional response of hMSCs to VN ± IGFBP-
3 or -5 and IGF-I, or VN and TGF-β1 was not investigated during this study. However, 
the answers to this and other unknowns, such as the fate of the exogenously added 
proteins, are vital to understand the relationship between such therapeutically important 
cells and artificial environments, especially from a tissue engineering context.  
 215 
In summary, the findings presented in chapter 4 suggest that VN is a valuable matrix 
component for the initial stimulus of hMSCs metabolic activity and protein sysnthesis in 
serum-free culture. Moreover, the addition of growth factors such as TGF-β1 can 
enhance the response, although culture integrity may depend on the concentration of VN 
or some other matrix protein. In addition, further investigation is required to determine 
the effect of endogenously expressed proteases on the function of added matrix 
components, growth factors or other constituents, as well as the specific mechanisms of 
action of these exogenous factors on cell function. 
 
Like VN, the matrix protein FN is a major matrix component of blood plasma (Yamada 
and Kennedy 1979), is an important matrix component within bone tissue (Grzesik and 
Robey 1994; Moursi et al. 1996), facilitates cell adhesion to various surfaces via 
integrin receptors (Moursi et al. 1997; Carvalho et al. 1998; Danen and Yamada 2001; 
Danen et al. 2002; Stephansson et al. 2002) and has been shown to bind IGFBP-3 and -5 
(Gui and Murphy 2001). In addition, the binding interaction between FN and IGFBP-5 
has been shown to modulate IGF-I mediated mouse embryonic cell migration (Xu et al. 
2004). For these reasons, and my observations that VN, IGFBP-5 and IGF-I could 
modulate enhanced migration and proliferative responses in SaOS-2 cells (as reported in 
chapter 3), I hypothesised that FN / IGFBP-5 / IGF-I may support similar activities in 
SaOS-2 cells. In chapter 5, I report that FN / IGFBP-5 / IGF-I synergistically enhanced 
SaOS-2 cell migration through 12 µm pore Transwell™ membranes. In addition, the 
trend between the various combinations of FN ± IGFBP-5 ± IGF-I was similar to that 
reported for treatments which incorporated VN, although the level of the response was 
on average 46% greater in treatments incorporating FN compared to the same treatment 
using VN. This was despite using coating solutions in which FN and VN were at 
stoichiometrically equivalent concentrations. Based on these data, I conclude that pre-
bound FN / IGFBP-5 / IGF-I stimulates SaOS-2 cell migration. Moreover, I hypothesise 
that the manner in which the combination of matrix protein and growth factors are 
presented to the cells is critical to elucidating the mechanisms underlying functional cell 
responses. Importantly, these findings have implications for applications with FN coated 
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biomaterial constructs, for the induction of cell migration responses into, or onto, the 
material surfaces.  
 
I also reported in chapter 5 that (in serum-free conditions) FN alone dose dependently 
facilitated SaOS-2 cell survival, but not proliferation, and that maximal cell survival was 
observed at around the monolayer saturation limit of 10 µg/mL (Underwood et al. 1993; 
Garcia et al. 1999). Furthermore, I reported that pre-binding of both VN and various 
concentrations of FN to the culture surface induced a dose dependent effect on SaOS-2 
cell survival. In addition, this seemed to induce a threshold effect, with SaOS-2 cell 
proliferation occurring at the highest concentration of FN in the presence of culture 
surface-saturating levels of VN. Pitt and co-workers have previously reported that multi-
layering of FN occurs at high concentrations due to re-orientation of molecular 
interactions with the adsorbing surface, whereas VN does not re-orientate but does 
undergo multi-layering (Pitt et al. 1987; Pitt et al. 1989; Underwood et al. 1993). 
Therefore, I hypothesise that in the present study there were more integrin binding sites 
available in the presence of VN and the highest dose of FN, thus facilitating a 
proliferative response. Of course this hypothesis remains to be tested. The finding that 
standard tissue culture surfaces preferentially bind VN from complex solutions such as 
serum (Underwood and Bennett 1989) is of interest because subsequent studies have 
also demonstrated that ECM molecules such as FN and VN undergo concentration 
dependent conformational changes or multilayering which may in turn affect the 
biological activity of such coatings (Underwood et al. 1993). McFarland et al. (1999) 
determined the amounts of VN and FN bound to tissue culture polystyrene (TCP) 
surfaces following exposure to culture medium containing FCS. Using 125Iodine labelled 
VN (125I-VN) or FN  (125I-FN) the authors found that the maximal surface density of FN 
attained in the presence of 10% FCS which had been depleted of both VN and FN was 
13 ng / cm2. Conversely, VN surface density in the presence of FCS was dependent on 
VN concentration not FCS concentration with 50 µg/mL of VN in a 30% FCS solution 
resulting in 50 ng/cm2 of bound VN. This indicated, as mentioned above, that VN 
preferentially adsorbs to TCP in the presence of FCS. Furthermore, McFarland and co-
workers (1999) also found that the coating concentration of purified 125I-VN in PBS was 
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linearly correlated with the surface density of adsorbed VN with 2 µg/mL of VN 
resulting in 103 ng/cm2 of bound VN. Taken together these data clearly indicate that 
although VN preferentially adsorbs to the TCP surface less VN can adsorb to TCP when 
in the presence of FCS compared to when in a simple salt solution. This therefore 
suggests that factors within FCS may impede or slow the adsorption of VN to TCP. 
 
In chapter 3 I reported that pre-bound VN / IGFBP-5 / IGF-I could synergistically 
enhance SaOS-2 cell proliferation over 72 hr of culture whereas in chapter 5 I showed 
that pre-bound FN / IGFBP-5 / IGF-I could stimulate enhanced SaOS-2 cell migration in 
a similar manner to VN. I therefore hypothesised that pre-bound FN / IGFBP-5 / IGF-I 
could also stimulate SaOS-2 cell proliferative responses. I subsequently showed that 
pre-bound FN / IGFBP-5 / IGF-I failed to stimulate SaOS-2 cell proliferation to the 
levels attained for pre-bound VN / IGFBP-5 / IGF-I. This suggests that either, SaOS-2 
cells in this system interact with FN and VN, via different mechanisms (ie different 
integrins) or that FN is unable to retain the same level of IGFBP-5 / IGF-I complex 
formation as VN and thus delivers less mitogenic signal to the cells. It would therefore 
be interesting to determine the amount of IGFBP-5 and IGF-I that can be retained by FN 
or VN, or various combinations thereof, when bound to tissue culture plastic. Similarly, 
determining the concentration of IGFBP / IGF-I complex retained at the culture surface 
under standard culture conditions in the presence of 10% FCS would also be of 
significant interest in order to better understand the intimate microenvironment of cell 
culture conditions in vitro. Moreover, elucidation of the functional concentration of 
these complexes retained on biomaterial surfaces following exposure to whole human 
blood (in vivo) or serum (in vitro) would help determine if adsorption of other molecular 
species from these complex body fluids could mask the biological activity of the pre-
bound complex’s studied in this project. Initially, these studies may take the form of 
epitope mapping investigations similar to those of Underwood et al. (1993) or 
Underwood and Bennett (1989).    
 
As discussed in chapter 5, I reported an interesting preliminary result from a related 
study in which the effect of serum-free solution phase combinations of VN, FN, bFGF 
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and EGF on SaOS-2 cell culture expansion were examined. This related study showed 
that VN / FN / EGF could sustain SaOS-2 cell culture for up to 12 days and the culture 
appeared generally healthy. Therefore, I decided to include this treatment in a pre-bound 
format in further studies in order to determine if this format could also elicit functional 
responses which may be valuable in a tissue engineering context. These studies were 
aimed at the investigation of the expression levels of select osteoblast markers in 
response to VN alone, VN / IGFBP-5 / IGF-I, VN / TGF-β1 and as mentioned VN / FN / 
EGF. I report in this thesis that after 7 days VN / IGFBP-5 / IGF-I in serum-free 
conditions induced a change in SaOS-2 cell morphology from a well spread, or 
polygonal morphology, to a more cobblestone or cuboidal appearance. This type of 
morphological change is often associated with osteoblast differentiation processes 
(Aubin 1998). Interestingly, the change in SaOS-2 cell morphology in response to VN / 
IGFBP-5 / IGF-I occurred while the culture was sub-confluent, compared to similar 
changes observed in cultures exposed to 10% FCS which had reached confluence prior 
to a substantial change in cell morphology.  This result raised the possibility that VN / 
IGFBP-5 / IGF-I could stimulate SaOS-2 cells to undergo further differentiation. This 
was supported by the finding that VN / IGFBP-5 / IGF-I supported the expression and 
maintenance of ALP gene expression over 7 days and that, in a parallel study performed 
in our laboratory, resulted in a steady increase in ALP activity over 14 days. However, 
the ability of VN / IGFBP-5 / IGF-I to facilitate ALP expression may simply represent 
‘normal’ SaOS-2 cell function, rather than a specific differentiation response. SaOS-2 
cells are known to express high levels of ALP (Murray et al. 1987).  
 
Also of interest was the finding that VN / FN / EGF induced an elongated or fibroblast-
like phenotype in confluent cultures of SaOS-2 cells, with few mitotic indices evident 
after 48 hr and this being maintained until 7 days. In addition, cbfa-1, ALP and Col-I 
transcript levels in SaOS-2 cells exposed to VN / FN / EGF returned to, or were 
maintained, at levels equivalent to that determined for un-seeded cells (T0) after 7 days. 
Taken together these data suggest that this treatment may have induced these cells into 
quiescence. This interpretation is supported by my earlier observation that this treatment 
could support SaOS-2 cells in serum-free culture for up to 12 days, and further by the 
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findings of others demonstrating EGF / EGFR inhibits osteoblast differentiation 
processes (Kumegawa et al. 1983; Chien et al. 2000) and that FN acts as a survival 
factor for more mature osteoblasts (Globus et al. 1998). While the specific mechanisms 
involved in inducing the observed ‘quiescent’ state by VN / FN / EGF are at this point 
unknown, the possibility of reversing this state using other combinations of growth 
factors, such as BMPs, is intriguing and deserves further investigation. The ability to 
exert control over cell phenotype and function in vitro under serum-free conditions will 
have significant implications for the design and development of biomaterial constructs 
in the field of bone tissue engineering. 
 
In conclusion, the data presented in this thesis have confirmed, developed and expanded 
the findings of others that ECM proteins and growth factors act co-operatively to 
mediate various epithelial cell functions. Specifically, the data in this thesis extends this 
concept to include cells of mesenchymal origin, namely osteoblasts and hMSCs. To the 
best of my knowledge, this thesis presents the first evidence of functional responses in 
osteoblasts to completely pre-bound VN / IGFBP / IGF-I complexes under serum-free 
conditions and, as such, contributes to not only the work already performed within our 
research team but also to the field of bone tissue engineering. This thesis does not 
attempt to infer in vivo biological consequences of the interactions between the matrix 
proteins and growth factors used in this study; rather it has sought to characterise the 
functional response of bone forming cells to an artificially constructed ECM under 
artificial conditions. The initial work performed by other, former members of our 
laboratory (Hyde 2005; Kricker 2005) focussed on the structural and functional aspects 
of complexes of VN and various IGF family members in various epithelial cell types in 
vitro. These studies formed the foundation upon which many subsequent studies, 
including projects involving the serum-free culture of epithelial cell types for corneal 
replacement, wound healing of burns and diabetic ulcers and the serum-free culture of 
embryonic stem cells have been pursued. The project reported herein, being the first of 
its kind in bone-forming cells, has generated substantial data that will form the basis of a 
number of future studies, especially into the serum-free culture of therapeutically 
important cells such as hMSCs. In addition the data will inform experiments directed at 
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examining ECM / growth factor control over bone cell functions in tissue engineered 
constructs. Thus, it is my belief that the treatments developed and studied within this 
thesis represent a basic form of an ECM / growth factor, serum-free culture system 
which might be applied to control cell phenotype and function for future tissue 
engineering applications.    
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CHAPTER 7: 
APPENDIX 
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BUFFER RECIPES 
7.1 FUNCTIONAL ASSAYS 
HEPES Binding Buffer (HBB) pH 7.6 
0.1 M HEPES 
0.12 M NaCl 
5 mM KCl 
1.2 mM MgSO4.7H2O 
8 mM D-Glucose 
 
7.2 GELATIN ZYMOGRAPHY 
5X Loading Buffer pH 6.8 
0.05% Bromophenol blue 
50% Glycerol 
10% SDS 
0.5 M Tris base 
 
Running Buffer pH 6.8 
25 mM Tris base 
246 mM Glycine 
0.1% SDS 
 
Incubation Buffer pH 7.6 
50mM Tris base 
10mM CaCl2 
50mM NaCl 
 
Coomasie Blue Stain  
0.25% Coomasie Blue 
45% Methanol 
10% Acetic acid 
 223 
 
Destain 
40% Methanol 
10% Acetic acid 
 
Gelatin Zymograms  
(for 4 Gels)    4% Stacking Gel   10% Resolving Gel 
ddH20     5.4 mL    7.8 mL 
1.5 M Tris  pH 8.8   -    5.0 mL 
0.5 M Tris  pH 6.8   2.5 mL    - 
Porcine gelatin 10mg/mL  1 mL    2 mL 
10% SDS    100 µL   200 µL 
40% Bis/Acrylamide   1 mL    5 mL 
10% APS    50 µL    100 µL 
TEMED    5 µL    10 µL 
 
7.3 SDS-PAGE AND WESTERN BLOT 
Running Buffer pH 8.3 
25 mM Tris base 
200 mM Glycine 
0.1% SDS  
 
Transfer Buffer  
25 mM Tris base 
40 mM Glycine 
10% Methanol 
 
Tris Buffered Saline with Tween (TBST) 
10 mM Tris base 
140 mM NaCl 
 1% Tween 20 
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